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EXECUTIVE SUMMARY

Mommer, Rachel. J. Stroke Reduction in Elderly Patients with Atrial Fibrillation
Through Utilization of an Anticoagulation Toolkit in the Primary Care Setting.
Unpublished Doctor of Nursing Practice capstone project, University of Northern
Colorado, 2017.
Patients, especially those older than 65-years-old, do not receive adequate
assessment or management of atrial fibrillation, resulting in higher ischemic stroke rates
and worse outcomes related to strokes. Oral anticoagulation is recommended indefinitely
for patients with atrial fibrillation and a moderate to high risk of stroke; yet this
population is not receiving oral anticoagulation consistently. Factors such as
overexaggerated bleeding risk in the elderly, the lack of head-to-head studies comparing
anticoagulants, cost, patient compliance, safety, lab monitoring, and reversal agents
convolute the process of prescribing anticoagulation for atrial fibrillation. Variations
exist with assessing bleeding risk and stroke risk for every patient through reliable tools
such as HAS-BLED and CHA2DS2-VASc scores, respectively, and translating these
scores into practice. Due to these inconsistencies and the lack of a comprehensive,
universal guideline for assessment and management of atrial fibrillation, this topic was
selected for a capstone project.
A retrospective chart review was completed on 100 patients to assess the current
practice of diagnosing atrial fibrillation and treating with anticoagulation in the primary
care setting. Through utilization of two rounds of the Delphi method, expert opinion, and
iii

the recommendations of national and international guidelines, an evidence-based
anticoagulation toolkit was created and modified to guide primary care providers on
improving diagnosis of atrial fibrillation and enhanced initiation and maintenance of oral
anticoagulation to reduce the incidence of stroke in elderly patients with atrial fibrillation.
The Anticoagulation for Atrial Fibrillation Toolkit is a four-step, simplified guideline to
guide providers on improved diagnosis and treatment of AF; it is supported by four
algorithms: CHA2DS-VASc score, HAS-BLED score, comparison of anticoagulants, and
patient specific factors influencing selection of anticoagulant. Additionally, this toolkit
offers in one document a summary of additional information and resources for providers
to improve the overall management of atrial fibrillation. The chart reviews demonstrated
gaps between evidence and practice, predominantly a lack of utilization of CHA2DS2VASc and HAS-BLED scores to assess for stroke and bleeding risk, respectively, in
patients with atrial fibrillation, poor continued monitoring of AF in the primary care
setting, a disconnect between the treatment plan and providers, and the absence of
consistently diagnosing an irregular pulse as AF through an EKG.
Round 1 of the Delphi survey assessed providers’ comfort level and expertise
with prescribing anticoagulants and diagnosing and managing AF and Round 2 evaluated
the anticoagulation toolkit and how its incorporation could influence practice. Results
from Round 1 were utilized to revise the evidence-based anticoagulation toolkit; data
analysis concluded 70% consensus was achieved on at least 6 of the 10 questions. Even
without 70% consensus, the researcher incorporated provider expertise, suggestions, and
requests into the anticoagulation toolkit. In Round 2, data analysis of greater than 70%
consensus suggested the Anticoagulation for Atrial Fibrillation Toolkit was evidenceiv

based, user-friendly, promoted safety and efficacy of anticoagulation, and could
positively impact practice; however, the toolkit was too extensive and lengthy.
A thorough evaluation concluded this capstone project successfully addressed the
following problem statement: In adult patients with atrial fibrillation older than 65 years
old and a moderate to high risk of stroke, how effective is an anticoagulation toolkit in
guiding primary care providers on (a) diagnosing atrial fibrillation and (b) initiating and
maintaining oral anticoagulation safely, to reduce the incidence of ischemic stroke? The
comprehensive literature review not only provided extensive background information on
atrial fibrillation and anticoagulation but also highlighted key references to first compare
evidence to practice (analyze patient chart reviews) and then utilize these identified gaps
to translate evidence into practice (create the anticoagulation toolkit). Furthermore, the
PARIHS framework and RE-AIM model evaluated the ability to effectively facilitate the
results from this research project into practice. Additionally, this capstone project met all
five criteria of the EC as PIE model, concluding this was a successful Doctor of Nursing
Practice capstone project. A future extension of this project suggests evaluation of
patient outcomes with AF, predominantly stroke incidence, subsequent to implementation
of this toolkit in the primary care setting.
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CHAPTER I

PROBLEM STATEMENT

Background and Significance of Project
Background
Atrial fibrillation (AF) is the most frequent cardiac arrhythmia, affecting
approximately 2.7 to 6.1 million people in the United States (Centers for Disease Control
and Prevention [CDC], 2015). The American Heart Association (AHA) in 2015 released
the alarming estimate of the incidence of this disease increasing to 5.6 to 12 million
people by the year 2050, influenced by the large aging population and its expanding
cardiovascular risk factors and comorbidities (Desai, El-Chami, Leon, & Merchant,
2017). Atrial fibrillation is present in 0.5% of Americans less than 40 years old, 5% of
the population older than age 65, and 10% in persons 80 years of age or older (Desai et
al., 2017). Likewise, the American College of Cardiology (ACC; Doherty et al., 2017)
predicted AF prevalence in 18% of the population older than 85 years old. One in four
patients age 40 or older will develop atrial fibrillation with an estimated 16 million
Americans diagnosed with AF by 2050 (You et al., 2012). Internationally, stroke caused
by AF is most prevalent within the United States and Europe and least prevalent within
Latin America, revealing a higher incidence in persons older than 75 years old and
female. Globally, AF is predominantly diagnosed through a health history or captured on
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an electrocardiogram with few patients receiving cardiac monitoring post stroke to assess
for AF (Perera et al., 2016).
Negative Outcomes of Atrial
Fibrillation
Negative outcomes with AF are related to a decrease in cardiac output, resulting
in the symptoms experienced in patients as well as the formation of thrombi in the atria
and atrial appendages. Thrombi substantially increase the risk of strokes and
embolization in the periphery (Kumar, 2016b). Atrial fibrillation results in 750,000
hospitalizations annually and 130,000 deaths in the United States with death rates
increasing exponentially for the past 20 years. In Colorado alone, as many as 77.12 per
1,000 people ages 65 and older were hospitalized from 2007 to 2012 related to AF (CDC,
2015). Overall costs for this chronic disease are greater than $6 billion annually in the
United States with healthcare costs attributed solely to atrial fibrillation costing an extra
$8,705 per patient annually (CDC, 2015). According to the cost of clot model (Janssen,
2014d), in a hypothetical situation of 1,000 patients with AF at a high risk of stroke,
increasing prescription of anticoagulation by 10% would decrease the cost of strokes by
$258,554 and increase the cost of extracranial bleeds by $1,732 and intracranial bleeds by
$21,157, overall reducing healthcare costs by $235,666.
Stroke risk. The stroke rate increases four to five times with AF as well as the
severity of stroke complications as AF is the predominant cause of 15-20% of ischemic
strokes (CDC, 2015). Of significance, patients are unaware of the devastating effects of
AF; only 50% believe they are at risk for a stroke with AF with 43% voicing concerns of
developing heart disease as the predominant negative outcome of AF rather the 8% with
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stroke. Approximately 86% of patients feel they can explain the definition a stroke but
only 61% correctly comprehend the disease implications (AHA, n.d.).
Women diagnosed with atrial fibrillation have a two-fold increased risk of
mortality compared to a 1.5-fold increased risk in men, predominantly as a cause of
stroke, sudden cardiac death, or heart failure. Furthermore, left ventricular dysfunction is
present in 20-30% of patients with atrial fibrillation. Atrial fibrillation is a contributing
factor to 20-30% of ischemic strokes. Quality of life is diminished with AF even when
cardiovascular components are removed as these patients suffer from increased
depression, brain white matter lesions, cognitive decline, and vascular dementia
compared to patients without AF. Resulting from the aforementioned complications with
AF, 10-40% of these patients are hospitalized annually. This diagnosis is financially
devastating for the economy, contributing to 1% of total healthcare costs within the
United Kingdom and $6.0-26.0 billion dollars in the United States in 2008 alone
(Kirchhof et al., 2016). Atrial fibrillation is correlated with a five-fold enhanced risk of
ischemic stroke with a 5% risk of stroke even in patients who are properly anticoagulated
(You et al, 2012).
Recommendations. To reduce unnecessary healthcare costs and hospitalizations
as well as improve quality of life, atrial fibrillation treatment focuses on stroke risk
minimization and symptom management. Guidelines and clinical recommendations for
atrial fibrillation treatment are vast; yet the elderly population is not adequately included
in research studies. The primary cause of thromboembolic stroke is atrial fibrillation,
demonstrating escalating prevalence and worse outcomes in correlation with increasing
age. In fact, the stroke risk with AF is heightened five-fold and is the culprit of 25% of

4
strokes in the older population (Desai et al., 2017). The mortality rate is doubled with the
combination of ischemic strokes and atrial fibrillation and the neurological sequelae tend
to be more severe. The American College of Cardiology and American Heart Associated
have recommended atrial fibrillation patients with a CHA2DS2-VASc of 1 be treated
prophylactically with anticoagulation to prevent ischemic strokes; a systematic review of
evidence concluded all patients 65 years of age and older should be treated with
anticoagulation to prevent strokes regardless of risk factors (Desai et al., 2017).
Patients might require hospitalization for new onset atrial fibrillation, treatment
for heart failure or hypotension after rate or rhythm control, starting antiarrhythmic drugs,
symptomatic atrial fibrillation, or management of concurrent medical issues resulting in
arrhythmia such as infection, chronic obstructive pulmonary disease exacerbation,
hypertension, thyroid storm, or pulmonary embolism (Kumar, 2016b).
Classification of Recommendations and
Levels of Evidence
The American Heart Association (AHA) and American Stroke Association (ASA;
2016) evaluated the certainty of evidence-based recommendations upon the following
taxonomies: Level A evidence is obtained from numerous meta-analyses and randomized
clinical trials; Level B evidence is obtained from nonrandomized studies or one
randomized study; and Level C evidence is based upon expert opinion, case studies, or
standards of care. The treatment effect size is classified by the following: the benefits of
Class I evidence greatly outweigh the risks and treatment is recommended; the benefits of
Class IIa evidence outweigh the risks and with reason treatment should be implemented;
the benefits of Class IIb evidence outweigh the risks and treatment may be implemented;
and the harms of Class III (harm) or Class III (no benefit) evidence outweigh the benefits
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and treatment is not recommended. These classifications and recommendations of
evidence are illustrated in Figure 1 (January et al., 2014). These same criteria to evaluate
evidence are utilized by the European Society of Cardiology (ESC; Kirchhof et al., 2016)
and the Heart Rhythm Society (HRS; January et al., 2014). The American College of
Chest Physicians (CHEST) evaluates the quality of evidence as follows: Grade A
(strong), Grade B (moderate), and Grade C (low). The evidence quality is incorporated
into the overall recommendation for the evidence: Grade 1 (strong) and Grade 2 (weak;
Kearon, et al., 2016). The CHEST criteria to measure the quality of evidence is depicted
in Table 1.
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A recommendation with Level of Evidence B or C does not imply that the
recommendation is weak. Many important clinical questions addressed in the guidelines
do not lend themselves to clinical trials. Although randomized trials are unavailable,
there may be a very clear clinical consensus that a particular test or therapy is useful or
effective.
*Data available from clinical trials or registries about the usefulness/efﬁcacy in different
subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial
infarction, history of heart failure, and prior aspirin use.
†For comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A
and B only), studies that support the use of comparator verbs should involve direct
comparisons of the treatments or strategies being evaluated

Figure 1. Classification of recommendations and levels of evidence.
Adapted from January et al. (2014, p. 2249). Copyright 2014 by the American Heart
Association Inc., the American College of Cardiology Foundation, and the Heart Rhythm
Society.
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Table 1
American College of Chest Physicians Guideline Classifications for Evaluating the
Strength and Quality of Evidence
Classification

Strength of Evidence

Grade 1

Strong

Grade 2

Weak
Quality of Evidence

Grade A

High

Grade B

Moderate

Grade C

Low

Note. Adapted from Kearon et al. (2016). Copyright 2016 by The American College of
Chest Physicians.

Epidemiology
In 2010, an estimated 20.9 million men and 12.6 million women had atrial
fibrillation with higher rates evident in developed countries. Increasing incidence and
prevalence of atrial fibrillation are attributed to improved diagnosis of the disease as well
as rises in both the aging population and the following risk factors: heart failure, coronary
artery disease, hypertension, diabetes mellitus, chronic kidney disease, obesity, and
valvular heart disease. In Europe, the incidence of AF is one in four adults with an
estimated 120,000-215,000 new diagnoses by the year 2030 (Kirchhof et. al., 2016).
In the Framingham Heart Study of 5,209 subjects, a 10-year follow-up
demonstrated the mortality rate was higher in both men and women age 55- to 74-yearsold with atrial fibrillation (Kumar, 2016b). The incidence of AF is 9% in the elderly
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above 65-years-old compared to 2% in people less than 65-years-old. Atrial fibrillation is
more prevalent in older women of European heritage (CDC, 2015); however,
independent of age, the disease is generally more common in men (Kumar, 2016b). The
risk of death from AF in women is comparable to men; yet women exhibit more risk
factors to stroke than men (especially increasing age) regardless of anticoagulation status.
Furthermore, women tend to be more symptomatic with AF and utilize less rhythm
control treatment. Men and women both display similar bleeding risks from
anticoagulation (Class IIa, Level of Evidence B; Kirchhof et al., 2016).
Risk Factors
Other than increasing age and sex, risk factors for AF include obesity, heart
failure, diabetes, chronic kidney disease, hyperthyroidism, alcohol abuse, and left
ventricular hypertrophy. Additionally, hypertension is a prevalent factor in the etiology
of 14 to 22% of atrial fibrillation patients (CDC, 2015) with coronary heart disease as
another predominant contributing factor to disease onset (Ganz & Spragg, 2016). The
strongest predictive factor of an ischemic stroke is a prior stroke or transient ischemic
attack (TIA) in addition to increasing age (65 years of age or older), diabetes mellitus,
sex (women), and hypertension. One-third of patients with AF have concurrent coronary
artery disease (You et al., 2012). Abnormal laboratory results increasing an AF patient’s
risk of stroke include labile international normalized ratio (INR) levels, low time in
therapeutic range (TTR) while on warfarin, anemia, prior hemorrhage, alcoholism,
chronic kidney disease, elevated N-terminal pro-B-type natriuretic peptide, and high
troponin T or I (Kirchhof et al., 2016). Post coronary artery bypass graft or cardiac valve
surgery also increase AF risk (Kumar, 2016b).
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Clinical Manifestations
Atrial fibrillation can be asymptomatic, “silent” (Kirchhof et al., 2016), or can
present with the following clinical manifestations: heart palpitations, dizziness, fatigue,
shortness of breath (dyspnea), irregular heart rate, weakness, presyncope, chest pain
(CDC, 2015; Kumar, 2016b), difficulty sleeping, or psychosocial distress (Kirchhof et al.,
2016). Approximately 30% of AF patients present without symptoms; yet this population
demonstrates a higher CHA2DS2-VASc score and thus a higher risk of stroke. Of
significance, over 20% of people with silent AF are not diagnosed until after their first
stroke (Shahid, Shantsila, & Lip, 2016).
Classifications of Atrial Fibrillation
Atrial fibrillation can be paroxysmal (terminating in less than seven days
spontaneously or with electrical cardioversion or medications); persistent (episodes
lasting longer than seven days including those terminated through cardioversion); or
long-standing persistent (episodes lasting up to one year, often indefinitely despite
rhythm control; Kirchhof et al., 2016; Olshansky & Arora, 2016; Spragg & Kumar,
2017). Non-valvular atrial fibrillation (NVAF) includes patients with moderate to severe
mitral stenosis and/or a prosthetic heart valve (Guimaraes, Kaatz, & Lopes, 2015). Longstanding persistent AF is synonymous with permanent AF according to other sources
(You et al., 2012) or can be classified as long-standing persistent if the arrhythmia is
controlled with a rhythm control strategy (Kirchhof et al., 2016). With paroxysmal AF,
the risk of stroke is smaller than with persistent or permanent AF (patients are typically
younger with less risk factors); yet the risk is enhanced with the conversion of AF back to
normal sinus rhythm (cardioversion; You et al., 2012).
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As a result of the heightened risk of stroke regardless of the classification of atrial
fibrillation, the same prevention strategies utilizing anticoagulation are recommended,
especially since only 1 of 12 paroxysmal AF occurrences are symptomatic (You et al.,
2012). In a patient with AF risk factors, the risk of stroke is comparable with a duration
of AF greater than one year, independent of the type of AF. Other data suggest patients
with permanent AF have a heightened risk of stroke and mortality (4.2%) compared to
paroxysmal AF (2.1%) and persistent AF (3.0%; Shahid et al., 2016).
Severity of Atrial Fibrillation Scale
The Severity of Atrial Fibrillation scale (SAF), adopted from the Canadian
Cardiovascular Society Severity of Atrial Fibrillation Scale (CCS-SAF), accurately
assesses patient symptoms, association of symptoms with atrial fibrillation, and the
patient’s functionality (quality of life) by assigning the patient a score of 0 (asymptomatic
Afib) to 4 (severe Afib; American College of Cardiology, 2012). The CCS-SAF has
proven validity in quantifying quality of life related to a diagnosis of AF (Dorian et al.,
2006, 2009). The SAF can be found within the Anticoagulation for Atrial Fibrillation
Toolkit in Appendix A. Approximately 25-40% of atrial fibrillation patients display mild
symptoms or are asymptomatic while 15-30% display severe symptoms. The ESC also
has a similar scale named Modified European Heart Rhythm Association (EHRA)
symptom scale to assess for AF symptom severity (Class I, Level of Evidence C;
Kirchhof et al., 2016).
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Genetics
Background
Research has suggested early-onset AF is heritable with one-third of these
patients exhibiting one or more of 14 genetic variants, better known as single nucleotide
polymorphisms (SNPs), which increase the risk of disease. The most well-known genetic
variant is the Pitx2 (paired-like homeodomain transcription factor 2) on chromosome
4q25, increasing the risk of AF seven-fold. Carrying these genetic variants in the genome
has also been associated with an augmented risk of ischemic stroke. Theories on how
these genetic variants influence the onset of AF include atrial remodeling, penetration of
genetic defects, and transforming the action potential of the atrial cells (Shehab, Sperling,
Kegler, & Budnitz, 2010).
Clinical Pharmacogenetics Implementation
Consortium
As warfarin has a narrow therapeutic index and a vast inter-patient dosing
variability to achieve a therapeutic INR, four genetic variants have been identified that
contribute to 50% of the variability in warfarin dosing: CYP2C9, VKORC1, CYP4F2,
and CYP2C cluster (rs12777823). In 2016 The Clinical Pharmacogenetics
Implementation Consortium (CPIC), part of the National Institute of Health’s
Pharmacogenomics Research Network, examined peer-reviewed genetic and medication
guidelines and updated the 2011 guideline on pharmacogenetics-guided warfarin dosing
(Johnson et al., 2017). Literature discovered negative sequelae from incorrect warfarin
dosages was one of the most common adverse drug effects reported to the Food and Drug
Administration (FDA; Johnson et. al., 2017), not to mention the cause of acute
hemorrhage in 2.5 per 1,000 emergency room visits (Shehab et al., 2010). Based upon

12
this systematic review of data, CPIC recommended pharmacogenetic warfarin dosing
through an algorithm focusing on VKORC1 and CYP2C9 alleles and started loading
doses of warfarin based on genetic calculations and ancestry (Johnson et al., 2017).
The mechanism of action of warfarin is inhibition of the vitamin K epoxide
reductase complex; when administered, warfarin is a racemic mixture composed of Swarfarin (more potent) and R-warfarin (less potent). Gene CYP2C9 is an enzyme within
the cytochrome P450 family and metabolizes S-warfarin. The normal allele, CYP2C9*1,
results in normal metabolism of S-warfarin. In patients with alleles CYP2C9*2 and
CYP2C9*3, the metabolism of S-warfarin is decreased; thus, these patients display an
increased risk of bleeding while on warfarin and should be prescribed a lower dose.
Alleles CYP2C9*5, *6, *8, and *11 are more common in African Americans and are
more prominent in the general population, also influencing the dosing variability of
warfarin (Johnson et al., 2017). The VKORC1 allele encodes the vitamin K epoxide
reductase protein, inducing the change from vitamin-K epoxidase to vitamin K. The
genetic variant VKORC1 c-1639G>A is responsible for warfarin sensitivity and suggests
a lower dose of warfarin is needed compared to the variant 1639G/G. The VKORC1
genetic variant influences the dosing of warfarin amongst those of Asian, Caucasian, and
African American ancestry (Johnson et al., 2017).
Benefits and Risks of Pharmacogenetic
Testing for Warfarin
Benefits of pharmacogenetic warfarin testing include reaching a stable INR within
a shorter time frame and more consistently, which could potentially decrease the risk of
hemorrhage from inappropriate warfarin dosing and the risk of thromboembolism. Risks
of this genetic testing include calculation of the wrong dose of warfarin based upon these
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recommendations and calculating the incorrect genotype, which is a permanent
component of the patient’s medical record, especially if not following recommendations
specific to ancestry. The cost-benefit ratio of warfarin genetic testing is controversial as
stable international normalized ratios (INRs) can reduce costs related to INR testing itself
and decrease negative sequalae of poorly managed warfarin dosing; yet the majority of
insurance companies do not cover the costs of this testing. Furthermore, randomized
clinical trials of CYP2C9 and VKORC1 alleles have not demonstrated reliable results and
do not support the definitive benefits of genetic warfarin testing (Johnson et al., 2017).
Consensus of Major Organization
According to the CDC (2016a), routine pharmacogenomic screening of genetic
variants CYP2C9 and VKORC1 to prevent myocardial infarctions, venous thrombosis,
pulmonary embolism, or thromboembolic events related to AF or valve replacements is
ranked a Tier 2. More specifically, to obtain a Tier 2 recommendation, an FDA label
indicates genetic biomarkers. The clinical practice guideline supports the use of this
genetic test but does not include a systematic review; refuting evidence is available but
the use of this test is still encouraged. Conversely, only a systematic review recommends
the use of this genetic test or discovers inadequate evidence but still suggests use of this
test. For a Tier 2, the clinical practice guideline addresses individualized medication
dosing for the patient yet does not indicate specific genetic testing (CDC, 2016b).
The Centers for Medicaid and Medicare Services (CMS; 2009) covered this test
for eligible patients based upon evidence. More specifically, for CMS to cover
pharmacogenetic testing for warfarin, the patient must meet the following criteria: (a) no
prior genetic testing of markers CYP2C9 and VKORC1 alleles, (b) the patient has been
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administered less than five days of warfarin, and (c) the patient is currently participating
in a prospective, randomized, controlled clinical study for warfarin response and patient
outcomes. Unless the aforementioned measures are met, CMS does not routinely
recommend screening Medicare patients for pharmacogenomic testing for warfarin. In
the presence of familial AF with multiple generations involved, genetic counseling and
testing is an option (Class IIb, Level of Evidence C; January et al., 2014).
A systematic literature review of genetic variants for warfarin, specifically
VKORC1 and CYP2C9, concluded all patients with a bleeding event while on warfarin
should be tested within two weeks for VKORC1, CYP2C9*2 and CYP2C9*3 alleles
including the pediatric population. Additional recommendations for pharmacogenomic
testing while on warfarin include difficulties obtaining therapeutic INRs or adverse drug
events while on warfarin. Evidence endorsed utilization of a specific pharmacogenetic
dosing algorithm to accurately analyze the genotypes (Shaw et al., 2015). According to
the ESC, genetic testing for warfarin is not recommended as evidence has failed to
demonstrate an influence on time in therapeutic regimen or decreased bleeding risk
(Class III, Level B; Kirchhof et al., 2016).
Pathophysiology
With AF, the two upper heart chambers called atria beat irregularly, affecting the
blood flow down to the two ventricles (CDC, 2015). The rate of blood flow decreases
and allows blood to pool within the atria, enhancing the risk of thrombi (blood clots) and
thus stroke if a clot is expelled into the bloodstream and reaches the brain (AHA, n.d.).
Regarding the mechanism, a trigger, predominantly rapid firing from the pulmonary
veins, results in atrial fibrillation. Other triggers include reentry circuits, atrial stretch,
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inflammation, dilatation, fibrosis, repolarization abnormalities, autonomic imbalance, and
conduction disturbances. Early in the disease process, the atrium is fully functioning and
can spontaneously return to sinus rhythm more easily. Persistent AF occurs from cardiac
remodeling (electrical and structural) over time, inhibiting the ability of the fibrillation to
resolve spontaneously. Thus, paroxysmal AF often precedes persistent atrial fibrillation
(Olshansky & Arora, 2016). The complex and poorly understood mechanism of Afib is
summarized in Figure 2. Predominant mechanisms for ectopy and conduction
disturbances in the atria, which ultimately result in atrial fibrillation, include calcium
instability, ischemia, vascular remodeling, atrial fibrosis, hypocontractility, fatty
infiltration, and inflammation (Kirchhof et al., 2016).
Risk factors for AF such as hypertension and diabetes contribute to atrial
remodeling in the heart, ultimately resulting in fibrosis. This fibrosis contributes to
changes in atrial electrical conduction pathways to a reentry circuit, which further
potentiates the risk of arrhythmias such as atrial fibrillation. Research suggested
prevention of cardiac remodeling could minimize the onset of AF (Shahid et al., 2016).
The increased risk of blood clot or thrombus (prothrombotic) resulted not only from the
irregular rhythm associated with AF but also the remodeling in predominantly the left
atrial appendage. Even brief periods of AF could contribute to stroke as this irregular
rhythm harms the atrial heart muscle (myocardium), releasing inflammatory factors
within the endothelium that accumulate platelets at the site of injury and increase the risk
of thrombosis. Furthermore, with atrial remodeling, changes in the calcium balance
within cells influences the heart rate variability (autonomic tone) and thus precipitates AF
(Shahid et al., 2016).
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Figure 2. Mechanisms of atrial fibrillation. Adapted from Olshansky and Arora (2016).

History and Comparison of Anticoagulation
Derived in 1930, subcutaneous unfractionated heparin was the first anticoagulant
(Bayer HealthCare, 2010). Other than the route of administration through injection,
additional concerns with this anticoagulant included the risk of heparin-induced
thrombocytopenia (HIT) and osteopenia. In the 1940s, vitamin K antagonists warfarin
and acenocoumarol were released to the market (Bayer HealthCare, 2010). Prior to this
time, the natural form of warfarin, dicumarol, was noted to cause hemorrhages in cattle in
the 1920s and warfarin was used as rat poison in the 1950s (Williams, Riley, & Tidwell,
n.d.). In the 1980s, injectable low molecular weight heparins were created; this drug does
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not require the lab monitoring needed for unfractionated heparin and has a decreased risk
of HIT yet should be used cautiously in patients with renal insufficiency. The first oral
direct thrombin inhibitor, ximelagatran was released in Europe in the 1990s yet was
removed from the market due to liver impairment. In the 2000s, the first injectable factor
Xa inhibitor, fondaparinux, was released on the market. The next direct thrombin
inhibitor, dabigatran, was released in Europe in 2006 (Bayer HealthCare, 2010).
Rivaroxaban, the first oral direct factor Xa inhibitor, was released on the market in 2008
(Drugs.com, 2015b), followed by apixaban in 2012 (Drugs.com, 2016), and Edoxaban in
2015 (Daiichi Sankyo, 2015). A new factor Xa inhibitor, Betrixaban (Beyvxxa©), is
currently under study, demonstrating a longer half-life and reduced effects on renal
excretion and hepatic metabolism compared to other non-vitamin K oral anticoagulants
(NOACs) on the market (Hu, Vaidya, & Asirvatham, 2016). The first reversal drug for
dabigatran, idarucizumab, was released in 2015 (Boehringer Ingelheim, 2015b).
Currently, no specific reversal agents for the factor Xa inhibitors have been approved for
use; yet andexant alpha (a factor Xa inhibitor antidote) and ciraparantag (a universal
NOAC reversal agent) are currently in the development stages. The mechanism of how
the parenteral and oral anticoagulants alter the coagulation cascade is depicted in Figure
3.
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Figure 3. Coagulation cascade and the effects of oral anticoagulants.
Note. Vitamin K antagonists, such as warfarin, inhibit factors II, VII, IX, and X.
Dabigatran directly inhibits factor IIa (thrombin). Apixaban, betrixaban, edoxaban, and
rivaroxaban inhibit factor Xa. Abbreviation: TF, tissue factor. Adapted from Makaryus,
Halperin, and Lau (2013). Copyright 2013, Macmillan Publishers Limited.

Prevention of Stroke Through Anticoagulation
The consensus of guidelines for atrial fibrillation suggests patients with risk
factors for stroke should be given the opportunity to start oral anticoagulants for
thromboprophylaxis unless they are low risk or have other contraindications (Shahid et
al., 2016). Oral anticoagulation is recommended indefinitely to prevent
thromboembolism in patients with atrial fibrillation and a moderate to high risk of stroke
(Wigle, Hein, Bloomfield, Tubbe, & Doherty, 2013). Oral anticoagulation through
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vitamin K antagonists (VKAs) or NOACs has demonstrated a reduction in overall
mortality in patients with atrial fibrillation, predominantly strokes (Kirchhof et al., 2016).
By increasing anticoagulant prophylaxis in 10% of 1,000 high-risk patients with atrial
fibrillation, the stroke rate could be reduced by 8.4% as 33% of patients with low
bleeding risk and high stroke risk are not treated appropriately with anticoagulation
(Janssen Pharmaceuticals, 2014d). Newer studies are using the term direct oral
anticoagulants (DOACs; Samuelson, Cuker, Siegal, Crowther, & Garcia, 2017); thus,
DOAC and NOAC are used interchangeably in this paper.
Warfarin reduces stroke risk by two-thirds compared to aspirin or no
anticoagulation. Limitations of warfarin include the narrow therapeutic index, multiple
drug interactions, and frequent lab monitoring of INRs requiring dose adjustments. If
warfarin requires temporary interruption, bridging with unfractionated heparin or low
molecular weight heparin is initiated to decrease stroke risk in the interim (Class I, Level
of Evidence C; January et al., 2014). In comparison, the effects of NOACs are
predictable without necessitating lab monitoring. None of the NOACs (apixaban,
edoxaban, rivaroxaban, or dabigatran) thus far have demonstrated safety for use with
valvular AF (mitral stenosis) or artificial valves (Class III Harm, Level of Evidence B or
C; Kirchhof et al., 2016).
Ischemic stroke can be the initial manifestation of atrial fibrillation in patients,
occurring predominantly as an embolus from the left atrial appendage. In patients with
AF, ischemic stroke severity tends to be more severe including longer durations of
transient ischemic attacks (TIAs) because of larger emboli. Even with anticoagulant
prophylaxis, strokes of lesser severity can still occur in patients with AF. Chronic
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anticoagulation through warfarin or an NOAC (Dabigatran, Rivaroxaban, Apixaban or
Edoxaban) displays the best efficacy in the long-term prevention of stroke and recurrent
stroke in patients with nonvalvular atrial fibrillation (Manning, 2016). The annual risk of
stroke in patients with AF is ~1.5%, with a death rate of 3% even in anticoagulated
patients, attributed to either stroke, heart failure, or sudden cardiac death (Kirchhof et al.,
2016). Anticoagulants have demonstrated a 70% decreased risk of systemic embolism in
non-valvular AF patients; yet the risk of bleeding risk must be considered when
prescribing these medications (Manning, Singer, & Lip, 2016). However, without risk
factors, prophylaxis with anticoagulants or antiplatelets is contraindicated (Class III
Harm, Level of Evidence B; Kirchhof et al., 2016).
Assessing Stroke and Bleeding Risk
Stroke Risk
Evaluating for stroke risk with nonvalvular (nonrheumatic) AF is evaluated
through the CHADS2 or CHA2DS2VASc scoring tools. The CHADS2 tool is
recommended by the chest guidelines through validation of evidence and ease of use
(You et al., 2012). The CHA2DS2VASc tool is recommended by the ESC (Class I, Level
of Evidence A; Kirchhof et al., 2016); AHA/ACC/HRS (Class I, Level of Evidence B;
January et al., 2014); and the ASA (Meschia et al., 2014) to assess stroke risk and
necessity of anticoagulation with AF. The CHA2DS2VASc tool is recommended over the
CHADS2 to assess for stroke risk as the former highlights more risk factors and
demonstrates a better ability to predict patients with low, moderate, or high stroke risks.
More specifically, the CHADS2 does not always accurately predict if a patient is at low
stroke risk, thus increasing the incidence of thromboembolism in AF patients who do not
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receive anticoagulation. Risk stratifying patients with atrial fibrillation is essential as
only 70% of patients necessitating oral anticoagulation receive this treatment.
Furthermore, in high-risk patients with AF who suffered from a stroke, 29% were not
prescribed any anticoagulation, 31% were prescribed antiplatelets, and 39% were
prescribed warfarin, yet only 10% had therapeutic INR levels. Prescribing
anticoagulation adequately for AF patients is a predominant means to decrease stroke risk
in this population (Lane & Lip, 2012). Interpretation of CHADS2 and CHA2DS2VASc
scoring is explained within the Anticoagulation for Atrial Fibrillation Toolkit in
Appendix A.
CHADS2 or CHA2DS2VASc score of zero. Vitamin K antagonists (VKAs) have
been proven to decrease all-cause mortality with atrial fibrillation diagnoses except in
patients at low risk of stroke (CHADS2 score of 0) attributed to the increased risk of
intracranial bleeds from anticoagulation. Thus, treating patients with a CHADS2 score of
0 with aspirin for one year could decrease two nonfatal strokes in a population of 1,000
people with the caveat of three extracranial bleeds. More specifically, monotherapy with
aspirin could decrease the risk of stroke by 21% compared to no treatment; yet the risk of
bleeding increases by 50-60%. Treatment with a VKA could decrease the risk of stroke
by one-half compared to aspirin, yet increases the bleeding risk by 50% (2.5-fold
increased risk; You et al., 2012). In nonvalvular AF (NVAF) and a CHA2DS2VASc
score of 0, anticoagulation is not recommended (Class IIa, Level of Evidence C [January
et al., 2014; Manning et al., 2016]; Class IIa, Level of Evidence B--Meschia et al., 2014).
The American College of Chest Physicians (CHEST guidelines) made the same
recommendation of no treatment with a CHADS2 score of 0 (Grade 2B), proposing
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aspirin (Grade 2B) or aspirin with clopidogrel (Grade 2B) if the patient requested
anticoagulation for AF (You et al., 2012). In patients desiring an oral anticoagulant for a
CHA2DS2-VASc score of 0 but with a high risk of bleeding, apixaban and dabigatran are
suitable options. Consensus suggests aspirin is not recommended to prevent stroke in
patients with atrial fibrillation (Lane & Lip, 2012).
CHADS2 or CHA2DS2VASc score of one. The CHEST guidelines
recommended oral anticoagulation with a CHADS2 score of 1 (Grade 1B), proposing the
combination of aspirin and clopidogrel if the patient is unable to take oral anticoagulation
(Grade 2B; You et al., 2012). Dual treatment with aspirin and clopidogrel demonstrates
an increased risk of bleeding 1.5-2 times compared to warfarin (You et al., 2012). With a
CHA2DS2-VASc score of 1, dabigatran, rivaroxaban, and apixaban have demonstrated
superiority to warfarin with no increased bleeding risk (Lane & Lip, 2012). With
nonvalvular AF, a low risk for bleeding, and a CHA2DS2VASc score of 1, multiple
treatment options are appropriate depending on patient preference including no
anticoagulant, aspirin, or an oral anticoagulant (Class IIb, Level of Evidence C--January
et al., 2014; Class IIb, Level of Evidence C--Meschia et al., 2014). Anticoagulant
therapy for a CHA2DS2VASc score of 1 is generally prescribed based on clinical
judgment, with age 65-74 years old, hypertension, and diabetes as more significant risk
factors contributing to disease onset compared to female sex and vascular disease
(Manning et al., 2016).
CHADS2 or CHA2DS2VASc score of greater than or equal to two. With a
CHA2DS2VASc score ≥ 2, chronic anticoagulation is suggested to decrease the risk of
stroke (Grade 1a; Manning et al., 2016). Without other risk factors, sex alone is not a
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strong indicator of increased stroke risk, yet age greater than 65-years-old heightens the
influence of other risk factors such as sex and heart failure (You et al., 2012). With a
CHA2DS2-VASc score ≥ 2 (regardless of bleeding risk) and with elevated bleeding and
stroke risk, dabigatran, rivaroxaban, or apixaban have demonstrated superiority to
warfarin (Lane & Lip, 2012).
The AHA, ACC, and HRS (2014) proposed oral anticoagulation with a
CHA2DS2VASc score ≥ 2, history of prior stroke, or history of TIA and recommended
warfarin (Class I, Level of Evidence A), dabigatran, rivaroxaban, or apixaban as suitable
anticoagulants (Class I, Level of Evidence B--January et al., 2014; Class I, Level of
Evidence B--Meschia et al., 2014). Likewise, according to the CHEST guidelines (You
et al., 2012), a diagnosis of valvular AF, a low risk of bleeding, and a CHA2DS2VASc
score ≥ 2 warrants long term anticoagulation with warfarin with a therapeutic INR of 2.03.0 (Class I, Level of Evidence A). With a CHADS2 score of 2 or higher, the
combination of aspirin and clopidogrel is proposed if the patient is unable to take oral
anticoagulants (Grade 1B; You et al., 2012). Warfarin has displayed an annual reduction
in stroke, myocardial infarction, and systemic embolism (3.9%) compared to dual
antiplatelet therapy with aspirin and clopidogrel (5.6%). The bleeding risk increases
from 1.3% to 2.0% with monotherapy aspirin compared to dual antiplatelet therapy.
Based upon these findings, antiplatelet therapy is not suggested to reduce stroke risk in
patients with AF (Class III Harm, Level of Evidence A; Kirchhof et al., 2016).
Dabigatran 150 mg twice daily is preferred to dose-adjusted warfarin for AF, including
paroxysmal, with a CHADS2 score of 1 or 2 (Grade 2B); however, this drug is not
indicated with a creatinine clearance (CrCl) less than 30 mL/min (You et al., 2012). On
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the contrary, the ESC recommends oral anticoagulation for AF patients with a
CHA2DS2VASc score > 2 for men (Class I, Level of Evidence A) and > 3 for women
(Class I, Level of Evidence A) to prevent blood clots (Kirchhof et al., 2016).
Conclusions. Oral anticoagulants have proven superior in preventing stroke with
AF compared to antiplatelets such as aspirin (Manning et al., 2016); due to the
heightened bleeding risk, aspirin is not considered safe as monotherapy (Shahid et al.,
2016). Warfarin and NOACs have demonstrated similar stroke and bleeding risks in
nonvalvular AF; however, evidence suggests treatment with a NOAC (direct thrombin
inhibitor or factor Xa inhibitor) is superior (Manning et al., 2016). More specifically,
dabigatran, apixaban, edoxaban, and rivaroxaban have demonstrated non-inferiority to
warfarin in preventing stroke with AF yet demonstrate superiority in a reduction of
severe bleeding (a decrease in bleeding by 30-50%; Shahid et al., 2016). A comparison
of warfarin and NOACs is summarized within the Anticoagulation for Atrial Fibrillation
Toolkit in Appendix A. If a patient is unable to take an anticoagulant, dual antiplatelet
therapy consisting of aspirin 75-100 mg daily in addition to clopidogrel 75 mg daily is
recommended (Grade 2B; Manning et al., 2016). Due to increased bleeding risk, a
combination therapy of platelet inhibitors and oral anticoagulants is contraindicated post
stroke (Class III Harm, Level of Evidence B; Kirchhof et al., 2016). Based upon the
above evidence-based recommendations, the stroke risk of every patient with AF should
be assessed through the CHA2DS2-VASc score to determine if anticoagulation is the
appropriate treatment regimen for each individualized patient (Kumar, 2016b).
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Bleeding Risk
Overemphasizing bleeding risk is a predominant limiting factor in providers
prescribing oral anticoagulation, especially to the elderly. However, despite the risk of
bleeding and stroke both increasing with advanced age, aspirin becomes less effective
and oral anticoagulants become more effective in preventing ischemic stroke with
increasing age with a comparable bleeding profile between the two drugs (Lane & Lip,
2012). Factors increasing the risk of bleeding while on anticoagulation include
alcoholism (≥ 8 drinks weekly), poorly controlled hypertension (systolic blood pressure >
160 mmHg), prior history of bleeding, labile INRs with warfarin, concurrent use of
nonsteroidal anti-inflammatory drugs (NSAID)s or antiplatelet drugs, anemia, impaired
renal function, impaired liver function, prior stroke, falls, dementia, age > 65 years old,
genetics, malignancies, recent surgery, diabetes, recent myocardial infarction, and
interruptions of anticoagulation prior to a procedure (Doherty et al., 2017, Jaffar &
Bragg, 2003; Kirchhof et al., 2016). Cautious signs and symptoms suggesting bleeding
while on anticoagulation include bruising, fall to the head, severe headache of a long
duration, frequent nosebleeds, coughing up blood, coffee ground emesis, heavy bleeding
from the gums, swelling and pain in the abdomen, severe back pain, black or bloody
stools, bloody urine, heavy menstrual periods, and prolonged bleeding from lacerations
(Jaffar & Bragg, 2003).
Currently, data have been inadequate to add recommendations to guidelines on
assessing bleeding risk with anticoagulation through a validated tool, however, screening
for bleeding risk should still be calculated through hypertension, abnormal renal and liver
function, stroke, bleeding, labile international normalized ratio, elderly, drugs or alcohol
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(HAS-BLED); hepatic or renal disease, ethanol abuse, malignancy, older age, reduced platelet
count or function, re-bleeding, hypertension, anemia, genetic factors, excessive fall risk and
stroke (HEMORR2HAGES), or another evidence-based tool and incorporated into the

individualized treatment plan to help in the selection of anticoagulation (You et al.,
2012). Data have suggested HAS-BLED more accurately predicts major bleeding risk
compared to HEMORR2HAGES and is declared easier to use than other scales. The
AHA/ASA have endorsed the HAS-BLED score to assess for bleeding risk with
anticoagulation for AF (Meschia et al., 2014). A meta-analysis and systematic review of
HAS-BLED, HEMORR2HAGES and anticoagulation and risk factors in atrial fibrillation
(ATRIA) concluded HAS-BLED displays a better ability to predict severe bleeding risk
in patients with atrial fibrillation, has increased sensitivity, and is more user friendly
(Caldeira, Costa, Fernandes, Pinto, & Ferreira, 2014).
According to the bleeding risk scores, the annual risk of bleeding while on
anticoagulation increases with every positive risk factor with an overall bleeding risk of
1.5%. The scoring of these risk factors does not categorize the patient as low,
intermediate, or high risk for bleeding while on anticoagulation (Hwang, 2016b). The
purpose of bleeding scores is not to deter providers from prescribing anticoagulants but
rather to discover and adjust modifiable risk factors to reduce bleeding risk (Lane & Lip,
2012). The ESC recommends utilization of the HAS-BLED, ORBIT, or ABC bleeding
risk scale to reduce risk factors (Class IIa, Level B) yet advises against withholding oral
anticoagulation merely on the high risk of bleeding, as the patient’s individual bleeding
risk profile and reduction of risk factors should be incorporated into the risk-benefit ratio
(Kirchhof et al., 2016). If severe bleeding occurs while on anticoagulation, medications
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should be stopped until the etiology of the bleeding is discovered (Class I, Level of
Evidence C; Kirchhof et al., 2016). The hypertension, abnormal renal and liver function,
stroke, bleeding, labile INR, elderly, drugs or alcohol (HAS-BLED) scoring is illustrated
within the Anticoagulation for Atrial Fibrillation Toolkit in Appendix A.
Summary
Research has demonstrated CHA2DS2-VASc and HAS-BLED scores are a simple
and efficient means to assess whether anticoagulation is appropriate for a patient without
warranting further testing or lab work (Shahid et al., 2016). To prevent systemic
embolization and stroke, the CHA2DS2-VASc score is completed on patients to determine
if they meet criteria for long-term anticoagulation as shown in Appendix A. If the risk of
bleeding is less than the risk of stroke, all patients with AF are recommended to start
antithrombotic medications (Kumar, 2016b). More specifically a CHA2DS2-VASc score
≥ 2 suggests chronic anticoagulation and a score of 0 implies no anticoagulant therapy. A
score of 1 requires clinical judgement on whether to prescribe an anticoagulant,
considering factors such as age > 75 years and sex. According to CHADS2 scoring, the
absolute risks of stroke annually in patients not treated with anticoagulation are 0.8%
(score of 0), 2.2% (score of 1), 4.5% (score of 2), and 9.6% (score of 3-6; You et al.,
2012).
Direct Oral Anticoagulants Versus Warfarin
Comparison
Oral direct thrombin inhibitors or factor Xa inhibitors are recommended over
warfarin for NVAF (Grade 2B); however, research currently does not support selecting
one NOAC over the other (Manning et al., 2016). The baseline risk of extracranial
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bleeding per year is 0.5% in patients treated with warfarin. Randomized control trials
have demonstrated vitamin K antagonists such as warfarin decrease the risk of death by
one-fourth in patients with AF, in addition to the risk of nonfatal stroke by two-thirds,
when compared to patients with no anticoagulation (You et al., 2012). A meta-analysis
concluded morality rates decreased by 10%, stroke rates decreased by 19%
(predominantly hemorrhagic), and the risk of intracranial hemorrhage was reduced by
half with NOACs in comparison to warfarin, yet the rate of gastrointestinal bleeding
increased (You et al., 2012). The reduced bleeding risk was more prominent in patients
with labile INR values, yet the correlation of INR value and risk of intracranial
hemorrhage was unable to be confirmed. In general, warfarin is suitable for patients with
INRs within the therapeutic range 65% of the time who prefer lab monitoring, prefer
once day dosing, cost is an issue, chronic kidney disease, prosthetic heart valves, mitral
stenosis, or concurrent use of protease inhibitors or phenytoin contraindicated with
DOACs (Manning et al., 2016).
Oral anticoagulants have not been tested for safety and efficacy in patients with
kidney transplants. Dabigatran and rivaroxaban should be avoided with an estimated
glomerular filtration rate (eGFR) < 30 mL/min/1.732, apixaban with an eGFR < 25
mL/min/1.732, and edoxaban with an eGFR > 95 mL/min (Manning et al., 2016). In
patients with mild or moderate chronic kidney disease (CKD), NOACs demonstrated less
strokes, hemorrhages, and systemic embolisms compared to warfarin. However, only
warfarin has been safely utilized in patients with moderate or moderate-severe CKD.
Warfarin has displayed safety and efficacy in reducing stroke in dialysis patients
(Manning et al., 2016), while the pharmacokinetics and pharmacodynamics of dabigatran
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were not affected in patients with worsening renal impairment and chronic hemodialysis
(Dias et al., 2016).
Recommendations
The current 2014 recommendations of the AHA/ACC/HRS do not differentiate
between warfarin or DOACs for anticoagulation in AF. Since January 2016, CHEST
prefers oral anticoagulants rather than warfarin to treat atrial fibrillation and
thromboembolism without a cancer etiology (Samuelson et al., 2017). More specifically,
with venous thromboembolism without cancer, dabigatran, rivaroxaban, apixaban, or
exoxaban are recommended for long-term anticoagulation instead of warfarin (Grade
2B). In patients with venous thromboembolism and cancer, low-molecular weight
heparin is preferred instead of warfarin (Grade 2B) and any of the DOACs (Grade 2C;
Kearon et al., 2016). Warfarin has been used as an anticoagulant for over 60 years, yet
the drug contributes to 12.5% of hospitalizations for drug-drug interactions, 43% higher
costs for hemorrhages, and 33% of hospitalizations for adverse drug events in the elderly
(Janssen Pharmaceuticals, 2014c).
Research Studies
Currently, no head-to-head studies have been completed comparing the DOACs
(Shahid et al., 2016). Noseworthy et al. (2016) completed a retrospective analysis of
adult users of dabigatran, rivaroxaban, or apixaban from 2010-2015, assessing the safety
outcome of bleeding and the efficacy outcome of prevention of stroke and systemic
embolism in patients with NVAF. Results demonstrated no difference in the efficacy
outcome of preventing stroke or systemic embolism amongst the three drugs.
Rivaroxaban demonstrated an increased risk of major and intracranial bleeding compared
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to dabigatran and apixaban displayed a reduced risk of bleeding compared to both
dabigatran and rivaroxaban. The study concluded the efficacy of these anticoagulants is
comparable; yet the bleeding risk profiles differed with the highest risk of bleeding with
rivaroxaban and the lowest risk with apixaban (Noseworthy et al., 2016). These four
DOACs have demonstrated reductions in major bleeding and intracranial hemorrhage
compared to warfarin; however, dabigatran, rivaroxaban, and edoxaban (excluding
apixaban) demonstrated an increased risk of gastrointestinal bleeding compared to
warfarin. Attributed to their significant reduction in stroke and systemic embolism
reduction, the net clinical benefit of DOACs outweighed their bleeding risk. Unless the
patient has a mechanical heart valve, DOACs extend anticoagulation options other than
warfarin to a larger proportion of the population at risk for stroke (Shahid et al., 2016).
The AHA/ASA (2016) released an analogous study comparing the safety and efficacy of
apixaban, rivaroxaban, and dabigatran to warfarin with NVAF. This study concluded
apixaban has decreased stroke and bleeding risks compared to warfarin, dabigatran has
comparable stroke risk but lower bleeding risks compared to warfarin, and rivaroxaban
has comparable stroke and bleeding risks to warfarin in patients with nonvalvular atrial
fibrillation (Yao et al., 2016). The study by Noseworthy et al. appears to be a head-tohead of the three DOACs themselves; yet the study by the AHA/ASA is a comparison of
the DOACs individually with warfarin. In summary, all four DOACs compared to
warfarin demonstrate comparable efficacy (stable effectiveness independent of the time
in therapeutic range) and improved safety (decreased intercranial hemorrhages). In fact,
even with a therapeutic INR in the 2.0-3.0 range, two-thirds of intracranial bleeds still
occur (Guimaraes et al., 2015). A comparison of DOACs in general and warfarin is
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illustrated within the Anticoagulation for Atrial Fibrillation Toolkit located in Appendix
A.
Trends
The use of warfarin and the DOACs (apixaban, rivaroxaban, and dabigatran) was
reviewed in the outpatient setting from 2009 to 2014 through the IMS Health National
Disease and Therapeutic Index survey (cited in Barnes, Lucas, Alexander, & Goldberger,
2015). Results demonstrated more people are receiving outpatient visits for
anticoagulation, predominantly for initiation of DOACs for new onset AF (increase from
51.9% to 66.9%). Overall visits for anticoagulation increased from 2.05 quarterly to 2.83
quarterly. The use of DOACs for AF increased from 0.88 million to 1.72 million during
this five-year period, yet the prescription of warfarin and DOACs for AF was equivalent.
As far as individual NOACs for AF, rivaroxaban was prescribed most frequently
(47.9%), followed by apixaban (26.5%), and dabigatran (25.5%). This study concluded
NOACs were increasing in popularity for the AF population compared to warfarin
(Barnes et al., 2015).
Research is starting to compare the safety (thromboembolism) and efficacy
(bleeding) of specific dosing for DOACs versus warfarin as current dose adjustments for
DOACs are based primarily on renal function, age, body weight, and drug interactions
without a consensus suggesting the suitable consistent dose for patients. In a propensity
weighted, nationwide cohort study of patients with NVAF, apixaban 2.5 mg twice daily
demonstrated higher rates of ischemic stroke and systemic embolism compared to
warfarin; conversely, rivaroxaban 15 mg once daily and dabigatran 110 mg twice daily
displayed lower rates of thromboembolisms (Nielsen et al., 2017). Compared to

32
warfarin, bleeding rates were significantly decreased for dabigatran but not rivaroxaban
and apixaban (Nielsen et al., 2017).
Cost Comparison
As atrial fibrillation is associated with more severe strokes, anticoagulation to
prevent strokes is cost effective. In 2010, AF management cost $6.65 billion--44% was
attributed to hospitalizations for an AF diagnosis, 29% for AF as a comorbid condition
contributing to hospitalization, 23% for outpatient treatment, and 4% for medications;
improving medication management would save an estimated $1.3 billion per year
(Fendrick, 2010). Other costs to consider when selecting an anticoagulation include the
individual agent, lab monitoring, and treatment for hemorrhages. International
normalized ratio monitoring occurs every two to four weeks depending on the time in
therapeutic range and cost over $600 annually in 2014 for lab monitoring. In
comparison, warfarin cost $40-60 for a 30-day supply in 2014 compared to $350 each for
dabigatran, rivaroxaban, and apixaban (Fendrick, 2010).
The cost to treat adverse effects must be considered with oral anticoagulation:
hospitalization for a gastrointestinal bleeds costs approximately $24,000 while
hospitalization for an intracranial hemorrhage costs approximately $41,000. In general,
DOACs display a reduced risk of intracranial hemorrhage compared to warfarin; yet
dabigatran has the highest rate of gastrointestinal bleed. Conversely, adherence to a
treatment plan is important such as INR monitoring and heparin bridging with warfarin
and ingesting a DOAC once or twice daily as prescribed. As DOACs have a shorter halflife, missing one dose could increase the risk of thromboembolism compared to missing
four to five days of warfarin. The cost of the reversal agent should also be considered:
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Vitamin K, the reversal agent for warfarin, is the cheapest treatment for overdose and
bleeding compared to prothrombin complex concentrate or fresh frozen plasma (warfarin,
rivaroxaban, and apixaban) with the most expensive treatment as hemodialysis for
dabigatran (Crouse & Quigley, 2014).
A meta-analysis of NVAF patients concluded a risk reduction of 0.81 for stroke or
systemic embolism, 0.48 for intracranial hemorrhage, and 0.90 for overall mortality for
the DOACs compared to warfarin, suggesting cost savings for DOACs related to
increased prevention of complications. Resulting from these benefits, DOACs are the
preferred anticoagulants by the European Society of Cardiology and the Canadian
Cardiovascular Society (cited in Singh & Wijeysundera, 2015). The DOACs are
associated with increased costs but also higher quality adjusted life years (QALYs),
demonstrating cost effectiveness compared to warfarin (specifically to the DOACs,
dabigatran is most cost effective). However, warfarin is less costly when patients have
increased time in the therapeutic range (Singh & Wijeysundera, 2015).
Medicare Part D covers 94-99% the cost for apixaban, rivaroxaban, and
dabigatran as well as100% for warfarin but does not cover edoxaban (Medicare.gov,
n.d.). When comparing the average monthly price of the anticoagulants, warfarin costs
$11, rivaroxaban $371, apixaban $395, dabigatran $377, and edoxaban $326
(GoodRx.com, 2017). Manufacturers for all the DOACs offer drug savings cards and/or
a free monthly trial to help reduce the higher costs for the patient (Boehringer Ingelheim,
2016; Bristol-Myers Squibb, 2016; Daiichi Sankyo, 2017; Janssen Pharmaceuticals,
2016b).
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Dabigatran, rivaroxaban, and especially apixaban display higher QALYs,
demonstrating cost-effectiveness compared to warfarin; yet, this is influenced by the cost
of the individual anticoagulant agents (Harrington, Armstrong, Nolan, & Malone, 2014).
All four DOACS (apixaban, dabigatran, edoxaban, and rivaroxaban) demonstrated
decreased medical costs annually for events related to NVAF and thromboembolism
compared to warfarin (-$204 for dabigatran, -$140 for rivaroxaban, -$495 for apixaban,
and -$340 for edoxaban), which are estimated to continue rising within the next few
years; within these drugs, apixaban is the most cost effective (Amin, Bruno, Trocio, Lin,
& Lingohr-Smith, 2015). Patients with steady time in the therapeutic range display
improved outcomes; thus, the quality of life for warfarin is influenced by adherence to
INR monitoring and corresponding dose adjustments. Therefore, warfarin is more cost
effective than DOACs in atrial fibrillation patients demonstrating quality anticoagulation
(Janzic & Kos, 2013).
Screening and Diagnosis of Atrial Fibrillation
Evaluation of a patient with atrial fibrillation requires stringent monitoring and
follow up to prevent complications related to the disease itself as well as adverse effects
from the medications, predominantly bleeding risk. Diagnostics for this disease include
an exhaustive history and physical examination, a 12-lead electrocardiogram, and a
transthoracic echocardiogram. (Kumar, 2016b). Key components of the patient’s medical
history and examination include assessing for comorbid conditions, stroke risk,
symptoms associated with AF, the pattern of AF, and risk of thromboembolism or left
ventricular dysfunction (Class I, Level of Evidence C). A 12-lead EKG is necessary to
diagnose AF, determine the rate of the dysrhythmia, and assess for ischemia, conduction
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defects, and other signs of structural heart disease (Class I, Level of Evidence B;
Kirchhof et al., 2016). Once AF is diagnosed, a transesophageal echocardiography (TEE)
is recommended with all patients to drive the treatment plan and evaluate for structural
valve disease, atrial size, right heart function, and left ventricular size and function (Class
I, Level of Evidence C). Furthermore, a TEE is useful to assess for thrombi in the left
atrial appendage, suggesting earlier cardioversion or catheter ablation. Ambulatory
electrocardiogram (EKG) monitoring can be helpful to measure the effectiveness of rate
control treatments, correlate symptoms with ectopy, and discover paroxysmal AF
episodes (Kirchhof et al., 2016). Screening for atrial fibrillation is recommended by
checking a pulse or obtaining an electrocardiogram strip annually in patients 65 years of
age or older as this is the best means to detect silent atrial fibrillation in patients (Class I,
Level of Evidence B--Kirchhof et al., 2016; Class IIa, Level of Evidence B--Meschia et
al., 2014). In patients who have suffered from an ischemic stroke or a transient ischemic
attack, a rapid EKG followed by continuous EKG monitoring for 72 hours is
recommended to assess for atrial fibrillation (Class I, Level of Evidence B; Kirchhof et
al., 2016). Alcohol consumption, marijuana use, and cigarette smoking all increase the
risk of bleeding; thus, avoidance of these substances is urged while on any
anticoagulation (Society for Vascular Medicine, 2015). In summary, primary prevention
of stroke suggests screening for silent AF through a pulse check and electrocardiogram in
addition to 72 hours of cardiac monitoring in patients who have developed an ischemic
stroke or transient ischemic attack (Shahid et al., 2016).
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Shared Decision-Making Tool
The Society of Vascular Medicine (2015) created an online shared decisionmaking tool for patients and providers to aid in the selection of anticoagulants. The first
series of questions asked the patients to choose “yes” or “no” if any of the following
conditions exist: heart failure with an ejection fraction less than 40%; age 65-74 years
old; age 75 years old or greater; diabetes mellitus (treated with insulin or oral
medications); hypertension; previous stroke, thromboembolism or TIA; female sex; or
vascular disease (myocardial infarction, aortic plaque or peripheral vascular disease).
Other questions in this set included renal dysfunction (renal transplant, dialysis,
creatinine clearance greater than 2.25 mg/dL); liver dysfunction (cirrhosis or elevated
liver function tests); previous hemorrhagic stroke; previous major bleeding episode;
anemia; use of antiplatelets (including aspirin and nonsteroidal anti-inflammatories);
mechanical value replacement; or heavy alcohol use (greater than 16 beers or 10 glasses
of wine weekly). The next set of questions addressed the patient’s preference for
medications: choice of a medication developed in 1954 versus 2010 to prevent stroke,
choice of a medication with or without frequent blood draws and follow up with
healthcare providers, selection of a medication where the dose is dependent on blood
draws or standardized for everyone, and availability to afford a medication co-pay
costing greater than $10 per month. Based upon these results, the anticoagulant warfarin
or a DOAC (direct oral anticoagulant)--apixaban, rivaroxaban, dabigatran, or edoxaban-is provided to the patient with supporting rationale (Society of Vascular Medicine, 2015).
In addition, bleeding and stroke risks while on anticoagulation are calculated for
the patient and explained in depth (Society of Vascular Medicine, 2015). This tool
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highlights other factors for the patient to take into consideration when selecting an
anticoagulant such as interactions with foods or other medications, adverse drug effects,
cost, access to labs for INR monitoring, and potential compliance issues including
support systems and foreign languages. For warfarin and the DOACs, the website directs
the patient to a further question and answer section, answering topics of pregnancy, food
and medication interactions, consumption of alcohol and smoking, checking INRs while
on vacation, steps to take when a dose of the medication is missed, physical activity
while on anticoagulants, and stopping the anticoagulant prior to surgery or other invasive
procedures. The algorithm does not clarify whether the patient qualifies for
anticoagulation, no anticoagulation, or aspirin; the algorithm merely addresses the
appropriate anticoagulation based upon individualized patient preference and medical
history (Society for Vascular Medicine, 2015).
Lab Monitoring
Atrial Fibrillation
Routine monitoring of atrial fibrillation should occur annually--sooner in
symptomatic patients. This monitoring includes INRs for warfarin, CrCl for
antiarrhythmics and newer anticoagulants, documentation of any changes in the patient’s
medical history, EKG, labs assessing renal and hepatic function, and possible Holter
monitoring of cardiac rhythm (Kumar, 2016b). Analysis of thyroid stimulating hormone
and free T4 are also recommended for a new diagnosis in addition to a complete blood
count, a serum creatinine, a urinalysis for proteinuria, tests for diabetes mellitus (Kumar,
2016b), and serum electrolytes (Kirchhof et al., 2016). Natriuretic peptide values are
increased in AF; yet, evidence does not recommend these blood tests for screening
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purposes. However, troponin or natriuretic peptide can further assess bleeding and stroke
risk (Class IIb, Level of Evidence B). A complete blood count (CBC) should be obtained
every six months with all oral anticoagulants to assess for bleeding. Renal function for
all the NOACs should be obtained at least annually as well as hepatic function for
rivaroxaban and apixaban annually (January et al., 2014).
Warfarin
As warfarin is contraindicated during pregnancy, a urine human chorionic
gonadotropin (hCG) is recommended prior to initiating warfarin and as needed to assess
for pregnancy in women of child bearing age (University of Colorado Health North,
2015). The INR was created by the World Health Organization in 1982 to standardize
the prothrombin time (PT) to consistently and safely measure the effectiveness of
warfarin (Jaffar & Bragg, 2003). The anticoagulant effects of warfarin occur two to
seven days after starting the drug; thus, if rapid anticoagulation is needed, bridging with
heparin should occur for at least four days. The initial dose of warfarin is usually 5 mg
with an INR of 2 after four or five days; yet, lower doses should be used in the elderly
and those with a high risk of bleeding. Heparin can be stopped after the INR is
therapeutic for two days. The serum INR level should be checked daily until a
therapeutic range is achieved for two days, followed by blood work two to three times
weekly for one to two weeks, up to once per month with stable levels (Jaffar & Bragg,
2003; January et al., 2014; Wigle et al., 2013). More specifically, the AHA/ACA/HRS
(2014) recommended a minimum of weekly INR monitoring until a therapeutic INR was
achieved, then monthly lab draws (Class I, Level of Evidence A; January et al., 2014).
For atrial fibrillation, the targeted INR for warfarin is 2.0-3.0 (Manning, 2016). With
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dose adjustments, alcohol use, dietary or medication changes, labile INRs (January et al.,
2014), when transitioning between warfarin and another anticoagulant, or during
hospitalization (Hull & Garcia, 2016b), more frequent lab monitoring might be necessary.
If a dose of warfarin is missed, the effect on the INR appears two to five days later. With
labile INRs, factors such as patient compliance, medication changes, fluctuations in the
intake of vitamin K, and acute illness (diarrhea, fever, or vomiting) should be assessed
before altering the dose of warfarin (Jaffar & Bragg, 2003).
On average, it takes four months for a patient to reach a therapeutic INR with
25% failing to achieve therapeutic INRs, 30% displaying supratherapeutic or
subtherapeutic INRs, and a 10-fold increase in continuing therapy once stable INRs are
attained (Janssen Pharmaceuticals, 2014e). Surprisingly, only 55% of the time are AF
patients within their target therapeutic range while on warfarin (Janssen Pharmaceuticals,
2014e). Poor INR control results in an increased incidence of patients discontinuing
warfarin with one in four patients stopping warfarin within a year of treatment initiation.
With a lower CHADS2 score, patients are at a higher risk of stopping warfarin
prematurely with 50% of patients failing to adhere to their warfarin regimen (Janssen
Pharmaceuticals, 2014b). Furthermore, unstable INRs (< 2 or > 4) are present in 44% of
patients on warfarin (Janssen Pharmaceuticals, 2014c). The risk of thromboembolism
increases with an INR < 2 and the risk of bleeding increases with an INR > 4, especially
> 5 (Hirsh, Fuster, Ansell, & Halperin, 2003). If a patient has labile INRs, replacement
with a direct thrombin inhibitor or factor Xa inhibitor is an acceptable alternative (Class
I, Level of Evidence C; January et al., 2014).
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Direct Oral Anticoagulants
As DOACs are administered in fixed dose regimens, routine lab monitoring is not
required. However, situations warranting lab monitoring include an epidural, severe
bleeding, emergency surgery, or a stroke patient who may require thrombolysis.
Malabsorption, obesity, malnourishment, DOAC overdose, acute kidney injury, treatment
failure, or drug interactions may also necessitate lab testing for further investigation.
Specifically, a dilute thrombin time (dTT), thrombin time (TT) or ecarin-based assay
(also known as ecarin clotting time or ECT) are available for dabigatran anticoagulation
effects and anti-Xa assays with drug-specific calibrators for rivaroxaban, edoxaban, and
apixaban (Hu et al., 2016; Samuelson & Cuker, 2016; Samuelson et al., 2017). If these
specialized tests are not accessible, dabigatran levels can be measured through dTT or
aPTT (activated partial thromboplastin time) or INR for the factor Xa inhibitors
(rivaroxaban, edoxaban, and apixaban). The level of the DOAC within plasma is
influenced also by renal function, hepatic function, drug interactions, and the amount of
time elapsed since the last dose was administered (Samuelson & Cuker, 2016; Samuelson
et al., 2017).
Clinic Managed Versus Home Monitoring of
International Normalized Ratios
Introduction
International normalized ratio monitoring is managed within an outpatient
anticoagulation clinic, a provider within the community, or at home by the patient;
research suggested INR levels are best managed at an anticoagulation clinic or by the
patient (Hull & Garcia, 2016b). As the researcher was unable to discover a standardized
warfarin dosing guideline or nomogram and anticoagulation clinics usually follow their

41
own protocols for dosing anticoagulation based upon the target INR, an in-depth
discussion of warfarin dosing was not addressed within this paper. Of note, resources
such as warfarindosing.com can help providers determine the therapeutic dose of
warfarin based upon the two genes: cytochrome P450 2C9 (CYP2C9) and vitamin K
epoxide reductase (VKORC1; Washington University, 2016).
Clinic Managed International
Normalized Ratios
An example of a guideline for registered nurses and healthcare providers who
manage patients on anticoagulation includes indications and warnings for warfarin,
laboratory testing (for target INRs), patient education, initiation and maintenance of
warfarin therapy (including causes of abnormal INR levels), reversal agents for warfarin,
perioperative management and bridging, transitioning to DOACs, quality assessment,
nurse education, and how to manage non-compliant patients. In a hypothetical dosing
nomogram for initiating warfarin therapy, a dosage of 5-10 mg warfarin is initiated on
day one, adjusting the dose on days two to five for the target INR range of < 1.5 all the
way up to > 3 depending on the patient specific indication for anticoagulation. For
example, with a maintenance INR of 2.0-3.0 and if the INR is therapeutic, the serum INR
would be checked within 4 to 12 weeks depending on the stability of the INR levels
(University of Colorado Health North, 2015).
In the presence of subtherapeutic (low INR) and supratherapeutic INR (high
INR), a search for the cause of the poorly controlled INR is sought and the weekly
dosage levels of warfarin and frequency of INR monitoring are adjusted concurrently.
General recommendations include checking on new warfarin patients within the first
three to five days of initiating therapy and starting 5-10 mg for the first two days (3-5 mg
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with impaired liver function, malnutrition, heart failure, thyroid storm, drug interactions,
or elderly greater than 65 years old; University of Colorado Health North, 2015).
Compared to the 10-mg loading dose of warfarin, the 5-mg loading dose exerts less
anticoagulation effects and achieves a therapeutic INR quicker; it also has less risk of the
hypercoagulable state that can occur during the first 36 hours of starting warfarin
(Harrison et al., 1997; Wigle et al., 2013). Thus, to balance this anticoagulant and
antithrombotic balance, the 5-mg loading dose is recommended (Jaffar & Bragg, 2003).
Starting on day three, the maintenance dose of warfarin could be started, usually 5-mg
daily (University of Colorado Health North, 2015).
This hypercoagulable state when starting warfarin is the result of the decrease of
clotting factor VII and the concurrent decrease in proteins C and S, thus the importance
of bridging with heparin or low molecular weight heparin until the INR is therapeutic for
at least 24 hours (Jaffar & Bragg, 2003; Wigle et el., 2013). The consensus varies on the
percentage to adjust warfarin doses safely per week to achieve a therapeutic INR: 5% to
20% according to research studies (Jaffar & Bragg, 2003; Wigle, et al., 2013), 15% to
20% according to an anticoagulation clinic (University of Colorado Health North, 2015),
and 10% to 15% according to the RE-LY warfarin trial (Hull & Garcia, 2016b). With
continued maintenance of warfarin, past and current INR trends are considered as well as
adverse effects (especially bleeding) and drug interactions, targeting the warfarin therapy
to the individual patient. In patients who are willing and able, home INR monitoring is
preferred over monitoring within an anticoagulation clinic (University of Colorado
Health North, 2015).
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Home Monitoring of International
Normalized Ratios
Randomized control trials have concluded in comparison to clinic-managed INR
monitoring, home monitoring of INRs can decrease the risk of thromboembolic events by
42%. Patients treated with dabigatran 150 mg twice daily demonstrated a 35% decrease
in strokes compared to treatment with warfarin, suggesting home-monitoring of INRs is
as effective as a NOAC in patients adherent to their treatment plan with warfarin (You et
al., 2012). Other benefits include reduced costs (mileage reimbursement, appointment
cost, and lost wages), time savings by not requiring a clinic visit, improved convenience,
and increased patient preference. In fact, 76% of patients would rather pay more money
for point-of-care testing (POCT) at home than to travel to a monthly visit at an
anticoagulation clinic (Meyer et al., 2013). Cons of home monitoring include increased
costs of the devices and test strips needed for this monitoring (You et al., 2012). If cost is
not a concern, CHEST recommends home monitoring of INRs in patients who have been
thoroughly educated on how to use the devices and are willing to engage in selfmonitoring of INR levels (Ansell, 2013; Barcellona, Fenu, & Marongiu, 2016; Class IIB-Pozzi, Mitchell, Henaine, Safi, & Henaine, 2016). Interestingly, 80% of patients can
properly obtain a POCT INR level after education (Ansell, 2013).
Quality of Life
Quality of life assessments through the Duke Anticoagulation Satisfaction Scale
(DASS; Samsa et al., 2004) suggest improved satisfaction with general treatment, selfefficacy, distress, daily hassles, and strained social network with POCT INR testing,
displaying consistent results two years later (Pozzi et al., 2016). The DASS is a reliable
and validated 25-question scale assessing a patient’s satisfaction and dissatisfaction with
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an anticoagulation routine. Negative implications of anticoagulation can result in labile
INRs and reduced compliance to a treatment plan; thus, a tool such as DASS can aid in
improving patient outcomes (Samsa et al., 2004). A cost-analysis of POCT and clinic
managed INRs for patients with similar CHADS2 scores, age, and sex demonstrated a
cost of $32,484 for weekly POCT and $33,460 for the anticoagulation clinic. However,
the cost per quality adjusted life gain was $5,566, suggesting cost effectiveness and
patient preference for POCT (Phibbs et al., 2016).
Conclusions
Data suggest longer times in therapeutic INR range (TTR) reduce adverse patient
outcomes. A study concluded physician-managed INRs achieved TTR 30-50% of the
time, anticoagulation clinics achieved TTR 50-70%, and weekly POCT INRs achieved
TTR 73% of the time (DeSantis et al., 2014). Patients cannot only monitor their INR
levels (patient self-testing or PST) but can be trained to self-manage their warfarin dosing
(patient self-management or PSM); patients with PST, with or without PSM, have
demonstrated safety and efficacy in TTRs (Ansell, 2013). Weekly testing is
recommended to achieve more stable TTRs and reduce critical INR values. Patient selftesting can reduce provider workload and expand access to patients requiring INR testing
for warfarin (DeSantis et al., 2014). Advantages of POCT and patient self-management
of INRs compared to traditional clinic monitoring include the ability to easily and quickly
obtain a capillary sample of blood, increased TTR (4.86% compared to the control
group), a decrease in thromboembolism in 50% of patients, and a reduction in significant
bleeding by 49%. To improve the reliability of the device, as the coefficient of variation
between devices can differ from 1.4-1.8%, the accuracy of the device should be checked
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at the clinic at least twice annually when testing strips are changed. Inter-laboratory
variability can differ from 10-30%; thus, using the same lab is recommended for accuracy
of results (Pozzi et al., 2016). Point-of-care testing cannot be completed in patients with
a hematocrit greater than 50% or with anti-phospholipid syndrome (Barcellona et al.,
2016).
Management of Atrial Fibrillation
Treatment of atrial fibrillation includes reduction of risk factors, medications to
control the rate or rhythm of the heart, anticoagulants to prevent blood clots, and thus the
risk of stroke, and surgery (CDC, 2015).
Reduction of Risk Factors
Patients should be educated on reversible risk factors for AF including obesity,
alcohol overuse, hypertension, coronary artery disease, diabetes, infection, and
hyperthyroidism (Ganz & Spragg, 2016). Medical management of a secondary problem
contributing to the atrial fibrillation should be encouraged to help determine the etiology
of the disease as the inability to treat reversible comorbidities could result in recurrent
AF. Risk factors could be modified through lifestyle changes including physical activity,
weight loss, incorporating extra virgin olive oil and omega-3 polyunsaturated fatty acids
(fish oil) into the diet, and reducing the consumption of alcohol (Kumar, 2016b).
Physical activity is beneficial to the cardiovascular system; yet, it could increase the
lifetime incidence of AF with > 1,500 hours of endurance activity increasing atrial
hypertrophy and dilatation, further affecting volume load and autonomic tone in the heart.
Therefore, moderate physical activity is recommended as well as ablation therapy to
prevent AF episodes in athletes (Kirchhof et al., 2016).
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Heart failure. Atrial fibrillation and heart failure display similar
pathophysiology through cardiac remodeling, neurohormonal mechanisms, and impaired
left ventricular functioning, resulting in worse patient outcomes with these dual
diagnoses; treatment with anticoagulation could reduce the risk of strokes in this
population. Research has demonstrated treatment with an angiotensin-convertingenzyme inhibitor (ACE inhibitor) or angiotensin II receptor blocker (ARB) could reduce
the incidence of AF in patients with concurrent heart failure and hypertension (Kirchhof
et al., 2016) and is recommended for heart failure preserved ejection fraction (HFpEF)
patients with permanent AF (Class I, Level of Evidence B). Digoxin can control resting
heart rate in AF patients with heart failure reduced ejection fraction (HFrEF; Class I,
Level of Evidence C) or digoxin along with a beta blocker to control heart rate during
exercise (Class IIa, Level of Evidence B). Intravenous amiodarone is used as the last
resort in patients with AF and heart failure who are unable to achieve a normal heart rate
through other pharmacological methods (Class IIa, Level of Evidence C), as well as AV
node ablation or rhythm control treatments (Class IIa, Level of Evidence B/C; Kirchhof
et al., 2016).
Other comorbid diagnoses. Echocardiograms diagnose AF with valve disease in
30% of patients. Valvular AF classifies patients with mitral stenosis or mechanical heart
valves. With a diagnosis of severe mitral stenosis, referral for mitral valve surgery is
recommended to decrease stroke risk. Decreasing obesity by 10-15 kg can decrease AF
symptoms and recurrences. In diabetic patients, treatment with metformin can decrease
the risk of AF and stroke as poorly controlled diabetes increases the risk of
thromboembolism and bleeding while on NOACs. As obstructive sleep apnea
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contributes to AF, screening for this disease and treatment with continuous positive
airway pressure ventilation is recommended. In patients with chronic obstructive
pulmonary disease, beta blockers and theophyllines used to treat bronchospasm can
exacerbate AF and complicate rate control. Ventricular rate control with hyperthyroidism
or chronic obstructive pulmonary disease can be managed with beta blockers or
nondihydropyridine calcium channel blockers (Class I, Level of Evidence C; Kirchhof et
al., 2016). After acute coronary syndrome in patients with AF, warfarin with aspirin is
recommended to prevent future cardiovascular events compared to dual treatment with
aspirin and clopidogrel (Grade 2C; You et al., 2012).
Approximately 15 to 20% of patients with AF have chronic kidney disease (CKD)
(creatinine clearance < 60 mL/min); thus, dosages of NOACs are calculated through the
Cockcroft-Gault formula to determine their utility for renal patients (Kirchhof et al.,
2016). Evidence recommends all patients on oral anticoagulants have their kidney
function assessed prior to initiating direct thrombin or factor Xa inhibitors and receive a
minimum of annual screenings of renal function (Class I, Level of Evidence B; January et
al., 2014) to assess for CKD in addition to screening of all patients with AF through
serum creatinine or creatinine clearance for appropriate anticoagulation dosing (Class I,
Level of Evidence A; Kirchhof et al., 2016). After acute coronary syndrome in patients
with AF, warfarin with aspirin is recommended to prevent future cardiovascular events
compared to dual treatment with aspirin and clopidogrel (Grade 2C; You et al., 2012).
When postoperative AF occurs, first line treatment is a beta blocker (Grade I,
Level of Evidence A) with second choice of a nondihydropyridine calcium channel
blocker (Grade I, Level of Evidence B). Postoperative AF can be prevented through
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administration of amiodarone prior to the cardiac surgery (Class IIa, Level of Evidence
A). With postoperative AF, sinus rhythm can also be achieved through antiarrhythmics,
ibutilide, or direct-current cardioversion, urging the use of anticoagulants for
thromboembolism prophylaxis (Class IIa, Level of Evidence B; January et al., 2014).
Treatment Options
The treatment of AF consists of stroke prevention (anticoagulation) and symptom
management (rate and rhythm control; Kirchhof et al., 2016; Kumar & Manning, 2016).
A summary from the AHA/ASA (2016) simplifying the atrial fibrillation treatment plan
is illustrated within the Anticoagulation for Atrial Fibrillation Toolkit in Appendix A.
Anticoagulation. The selection of anticoagulant agent should be derived from
shared decision-making between the patient and provider assessed through a thorough
evaluation of thromboembolism, stroke risks, patient preference (Class I, Level of
Evidence C), and risk of bleeding (Class I, Level of Evidence B; January et al., 2014).
Atrial fibrillation management is improved when the treatment plan and patient education
are individualized (Class I, Level of Evidence C; Kirchhof et al., 2016). Factors to
consider when selecting an anticoagulant include risk factors, predominantly intracranial
bleeding, INR lability, drug interactions, adverse effects, cost, and patient choice
(Meschia et al., 2014). Furthermore, patients should be educated on the importance of
adhering to the treatment plan and not missing a dose of medication; as DOACs have a
shorter half-life than warfarin, missing only one dose can greatly increase the risk of
stroke. Net clinical benefit suggests DOACs offer benefits of improved convenience,
fewer lab monitoring and food and drug interactions, and comparable safety and efficacy
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profiles in preventing stroke in AF patients; yet, the choice of anticoagulant should
continue to be prescribed on a patient specific basis (Shahid et al., 2016).
The only approved anticoagulant for moderate to severe mitral valve disease
(valvular AF) or mechanical heart value replacement is warfarin (Class I, Level of
Evidence B--January et al., 2014; Class I, Level of Evidence B--Kirchhof et al., 2016),
with a target INR of 2.0-3.0 (Grade 1B; You et al., 2012). Aspirin with clopidogrel is a
suitable alternative for valve patients unable to take warfarin (Grade 1B; You et al.,
2012). Due to the heightened risk of stroke, a history of mitral stenosis with either a prior
embolus or a left atrial thrombus, even in the presence of sinus rhythm, warrants
anticoagulation (Class I, Level of Evidence B). With a bioprosthetic aortic or mitral valve
replacement, the two approaches to prevent stroke include aspirin or warfarin with a
target INR of 2.0-3.0 for the first three months after the valve is replaced (Class IIa,
Level of Evidence C; Meschia et al., 2014).
Rate versus rhythm control. Symptom management is dependent on patient
preference and can include pharmacological treatment, cardioversion, or catheter
ablation. Controlling ventricular rate is suggested initially to decrease symptoms.
Subsequent rhythm versus rate control is dependent on symptoms, left ventricular systolic
dysfunction, and patient preference with both methods displaying similar morbidity rates,
mortality rates, and quality of life assessments. Rates of thromboembolism are
comparable between rhythm and rate control therapies (You et al., 2012).
Rate control utilizes medications decreasing atrioventricular (AV) node
conduction including beta-blockers, digoxin, and non-dihydropyridine calcium channel
blockers (diltiazem or verapamil) or a combination of the aforementioned options
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(Kirchhof et al., 2016; Kumar, 2016b). The medication combination to control heart rate
is dependent on the left ventricular ejection fraction (LVEF): with an LVEF ≤40%, betablockers and/or digoxin is suggested while with an LVEF ≥40%, beta-blockers, digoxin,
and a calcium channel blocker are recommended (Class I, Level of Evidence B). The
goal of rate control therapies is a resting heart rate less than 110 beats per minute while
avoiding bradycardia (Class IIa, Level of Evidence B; Kirchhof et al., 2016). Rate
control tends to simplify the treatment regimen, costs less, and eliminates the risks
associated with antiarrhythmics and catheter ablation. Thus, rate control is preferred in
asymptomatic or mildly symptomatic patients 65 years of age and older (Kumar &
Manning, 2016) in addition to pregnant women with AF (Class IIa, Level of Evidence C;
Kirchhof et al., 2016).
Rhythm control utilizes antiarrhythmic drugs, percutaneous catheter ablation,
and/or surgery (Kumar & Manning, 2016) and is recommended in patients who are
unable to remain asymptomatic with rate control medications (Class I, Level of Evidence
B; Kirchhof et al., 2016). Flecainide, propafenone, or beta blockers are preferred
antiarrhythmics in patients without structural heart disease, bradycardia, or tachycardia;
dronedarone or statolol is preferred for coronary heart disease; and the combination of
amiodarone and dofetilide is preferred with heart failure (Kumar, 2016a). The European
Society of Cardiology (Kirchhof et al., 2016) also recommends flecainide or propafenone
for rhythm control of patients without structural heart disease (Class I, Level of Evidence
A), and prescribing amiodarone to prevent recurrent AF with heart failure (Class I, Level
of Evidence B) or for cardioversion with ischemic or structural heart disease (Class I,
Level of Evidence A). Nondihydropyridone calcium channel blockers are
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contraindicated with heart failure (Class IIb, Level of Evidence C; January et al., 2014).
Rhythm control is used more frequently in younger patients (less than 65-years-old) to
regain normal sinus rhythm, recurrent symptoms despite rate control, and persistent AF
with irreversible remodeling of the heart (Kumar & Manning, 2016). Other options to
achieve normal sinus rhythm include atrioventricular (AV) node ablation and ventricular
pacing (Kumar & Manning, 2016) in AF resistant to medication management; yet, the
majority of these patients eventually require pacemaker implantation to control
ventricular rate (Kirchhof et al., 2016). Even if patients with AF are treated via a rhythm
control method, their stroke risk and necessity for anticoagulation should be evaluated
equivalently to other AF patients (Grade 2C; You et al., 2012).
Left atrial appendage closure. In patients with contraindications to long-term
anticoagulation, since 2005 percutaneous left atrial appendage (LAA) procedures such as
WATCHMAN© (Boston Scientific, 2016) are an alternative within the United States and
Europe (Hijazi & Saw, 2016). With NVAF, greater than 90% of blood clots from the left
atrium originate in the left atrial appendage; thus, implantation of the WATCHMAN
device traps clots in the LAA. Under general anesthesia within the catheterization lab
and with the guidance of fluoroscopy and transesophageal echocardiography (TEE) to
ensure accurate LAA measurement and fit, WATCHMAN is inserted through the femoral
vein, advanced transseptally into the left atrium, and finally implanted into the LAA. The
WATCHMAN requires an hour to implant and approximately a one-day hospital
admission. Post implant, patients are required to take aspirin and warfarin for a minimum
of 45 days to ensure the LAA is encapsulated by heart tissue (confirmed by a TEE),
followed by clopidogrel and a higher dose of aspirin for six months, and finally aspirin
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for life. The WATCHMAN is covered by Medicare and most major insurance companies
and is a permanent device only requiring a one-time insertion.
Compared to warfarin, LAA closure has demonstrated a 52% reduction in
cardiovascular death, a 72% decrease in severe bleeding six months after the procedure,
and a 78% decrease in hemorrhagic stroke (Boston Scientific, 2016). However, LAA has
an increased risk of pericardial effusion, excessive bleeding, and procedure-related
complications compared to warfarin (You et al., 2012). Evidence has demonstrated LAA
closure is non-inferior to warfarin in preventing stroke in AF patients with reduced
bleeding risk. The AHA/ASA (2016) endorse left atrial appendage closure with AF;
patients demonstrating a high risk of stroke are poor candidates for anticoagulation if the
patient can temporarily take anticoagulation 45 days after the surgery (Class IIb, Level of
Evidence B; Meschia et al., 2014). The ESC (Kirchhof et al., 2016) also proposes
anticoagulation after LAA to prevent strokes (Class I, Level of Evidence B).
Furthermore, WATCHMAN is cost effective within seven years after implantation, costs
less, is more effective than five years of treatment with DOACs, and is more effective
than 10 years of treatment with warfarin (Desai et al., 2017).
Cardioversion. Patients may be candidates for cardioversion to restore sinus
rhythm before initiation of antiarrhythmics (Naccarelli, Ganz, & Manning, 2016). Two
forms of cardioversion are available--pharmacological and direct current (electrical);
pharmacological methods can restore sinus rhythm in 50% of patients with AF without
sedation or nothing by mouth while electrical methods can more successfully achieve
sinus rhythm within a shorter duration of time and are recommended with hemodynamic
instability. With electrical cardioversion, the patient is sedated with intravenous propofol
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and/or midazolam followed by synchronized shocks delivered through a biphasic
defibrillator to anterior and posterior electrodes. Risks with electrical cardioversion
include bradycardia and skin burns (Kirchhof et al., 2016). Direct current cardioversion
is suggested in patients with a rapid ventricular rate who are unable to be converted via
pharmacological means (Class 1, Level of Evidence B). Pharmacological cardioversion
can consist of the following agents: flecainide, dofetilide, propafenone, ibutilide (Class I,
Level of Evidence A) or amiodarone (Class IIa, Level of Evidence A; January et al.,
2014) with heart failure and ischemic heart disease. Patients with paroxysmal AF can
self-cardiovert at home (“pill in the pocket”) with one dose of flecainide or propafenone
when symptoms arise (Kirchhof et al., 2016) concurrent with a beta blocker or
nondihydropyridine calcium channel blocker (Class IIa, Level of Evidence B; January et
al., 2014).
In stable patients with atrial fibrillation duration greater than 48 hours, oral
anticoagulation should be started three weeks prior to cardioversion to reduce the risk of
stroke (Class I, Level of Evidence B--January et al., 2014; Class I, Level of Evidence B-Kirchhof et al., 2016; Naccarelli et al., 2016) and continued four weeks after the
cardioversion (Level of Evidence B--January et al., 2014; Class I, Level of Evidence B-Kirchhof et al., 2016; Class 1B--You et al., 2012; Class I). The CHEST (cited in You et
al., 2012) suggests either warfarin with a target INR of 2.0-3.0, dabigatran, or lowmolecular weight heparin as suitable options prior to cardioversion with AF duration
longer than 48 hours (Grade 1B). An alternative to anticoagulation prior to cardioversion
is a TEE to assess for the presence of cardiac thrombi; if a thrombus is not discovered in
the left atrial appendage, cardioversion is completed immediately (Class I, Level of
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Evidence B; Kirchhof et al., 2016). To prevent stroke, the American Academy of Chest
Physicians guidelines recommend brief anticoagulation before TEE guided cardioversion
(Grade 1B; You et al., 2012). The AHA/ACC/HRS (2014) recommends using warfarin
as the anticoagulant for four weeks after the cardioversion (Class I, Level of Evidence B),
or dabigatran, rivaroxaban, or apixaban (Class IIb, Level of Evidence C; January et al.,
2014).
With AF duration less than 48 hours, anticoagulating the patient with lowmolecular weight heparin or unfractionated heparin should occur prior to the
cardioversion (Grade IIb, Level of Evidence C--January et al., 2014; Grade 2C; You et
al., 2012); yet, starting anticoagulation should not delay an urgent cardioversion (Grade
2C; You et al., 2012). In emergent cases, heparin is utilized as the anticoagulant
(Naccarelli et al., 2016). Of note, the first 72 hours and up to 10 days after cardioversion
displays the highest risk of stroke and thromboembolism as it can take weeks for the
atrial dysfunction to subside. Within one year after cardioversion, one-half of the
patients will have a recurrence of AF (You et al., 2012). The necessity of anticoagulation
after cardioversion is based upon the patient’s individualized risk profile for
thromboembolism (Class I, Level of Evidence C; January et al., 2014).
Ablation. Radiofrequency ablation or cryotherapy balloon catheterization of the
pulmonary veins, a primary cause of paroxysmal AF, can be utilized to achieve normal
sinus rhythm and symptom control in patients who have failed antiarrhythmic therapies.
Anticoagulation should be prescribed eight weeks prior to the ablation to reduce the risk
of stroke. Catheter ablation results in a one-year period absent of symptomatic atrial
fibrillation in 80% of patients without structural heart disease; however, complications of
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this procedure include cardiac tamponade, stroke, and vascular trauma. With recurrent
AF after an ablation, a second ablation or antiarrhythmic medication may be warranted
(Passmar, 2016). In heart failure patients with AF, catheter ablation can reduce recurrent
AF and even improve LVEF (Kirchhof et al., 2016).
Cox-Maze. The Cox-Maze surgical procedure creates alternative electrical
pathways from the sinoatrial node to the atrioventricular node, preventing AF conduction
in patients with symptomatic persistent or long-standing persistent AF (Lee, 2017). The
Cox-Maze IV is completed to improve diastolic filling and atrial synchrony plus alleviate
AF. In this procedure, bipolar frequency and/or cryothermal energy are used to fabricate
scar tissue on the right atrium (superior vena cava to inferior vena cava), left atrium
(posterior wall), the four pulmonary veins forming a “box” attached to the mitral valve
annulus, and removal of the left atrial appendage. Often, the invasive sternal approach is
completed during a coronary artery bypass graft (CABG) or valve surgery or a less
invasive thoracotomy approach is available. Risks include increased incidence of
subsequent pacemaker implantation, pericardial tamponade, requirement of a sternotomy
approach, and TIA (Kirchhof et al., 2016). Anticoagulation is recommended for three
months after the Cox-Maze procedure in patients who have had the left atrial appendage
ligated or removed to decrease the risk of stroke (Lee, 2017).
Atrial fibrillation management team approach. The ESC (Kirchhof et al.,
2016) recommends the following approach to managing AF successfully:
1.

Patient involvement (patient education, patient empowerment, reduction of
risk factors, lifestyle modifications, and shared decision making)
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2.

Multidisciplinary team (primary care providers, cardiologists, AF
specialists, surgeons, and allied health providers working together
collaboratively)

3.

Navigation system for providers and patients (tools and checklists to
improve communication, clinical decision support, availability of
information on AF, and the ability to monitor the compliance and
effectiveness of the treatment plan)

4.

Complex management decisions (anticoagulation, rate control, lifestyle
modifications, antiarrhythmics, and catheter and surgical options).

The goals of this integrated approach to AF management include reduction of
hospitalizations, enhanced patient adherence to the treatment plan by incorporating
patient preference into the decision-making process, improved patient outcomes, and
decreased mortality. Atrial fibrillation can be well managed within the primary care
setting; however, a referral to an AF specialist is recommended in the presence of the
following factors: hemodynamic instability (severe symptoms), history of TIA or stroke
necessitating anticoagulation, symptomatic bradycardia, poor rate control (fast heart rate),
deteriorating left ventricular function, severe angina, assessment for rhythm control, or
special conditions (thyrotoxicosis, sepsis, or postoperative AF; Kirchhof et al., 2016).
Performance and quality measures. In 2016, the ACC and AHA (Heidenrich et
al., 2016) released performance and quality measures related to AF management in both
the inpatient and outpatient settings to improve the management, safety, and care
coordination of these patients. Performance measures for the outpatient setting include
documentation of a completed CHA2DS2-VASc score, prescribing anticoagulation when
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appropriate, and completing monthly INRs for patients on warfarin. Quality measures
include prescribing a beta blocker with a left ventricular ejection fraction < 40% and not
prescribing a direct thrombin inhibitor or factor Xa inhibitor with mechanical heart
values, end-stage kidney disease, or dialysis. Other quality measures include not
prescribing oral anticoagulants and antiplatelets (unless the patient has coronary artery
disease or vascular disease) to reduce bleeding risk, not prescribing a calcium channel
blocker with reduced ejection failure heart failure, and the necessity of shared decisionmaking between the patient and provider when prescribing anticoagulation (Heidenrich et
al., 2016).
Pregnancy. In pregnant women with atrial fibrillation, digoxin or beta-blockers
are safe for rate control during pregnancy and breast feeding. For rhythm control, sotalol
and flecainide are safe during pregnancy. Electrical cardioversion is a harmless
alternative during all stages of pregnancy, especially with hemodynamic instability.
Vitamin K antagonists should be avoided during the first trimester and two to four weeks
prior to delivery of the fetus due to bleeding risks and teratogenic effects. A safe
alternative for anticoagulation is low-molecular weight heparin as it does not cross the
placenta. In pregnant women with mechanical valves who decide not to continue with
warfarin, within 6 to 12 weeks of gestation, they should be transitioned to dose-adjusted,
subcutaneous, low-molecular weight heparin or unfractionated heparin. During the third
trimester, INRs should be checked every 10 to 14 days. Data have been inconclusive in
determining whether NOACs are excreted into breastmilk (Daiichi Sankyo, Inc., 2015;
Drugs.com, 2015a, 2015c, 2016). Warfarin is not present in breastmilk but should be
avoided during lactation due to the increased risk of bleeding for the fetus (Drugs.com,
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2015c). The pregnancy categories of NOACs are as follows: Category B--apixaban
(Drugs.com, 2016); Category C--rivaroxaban (Drugs.com, 2015b), dabigatran
(Drugs.com, 2015a), edoxaban (Daiichi Sankyo, 2015), and warfarin with mechanical
valves (Drugs.com, 2015c); and Category X--warfarin without mechanical valves
(Drugs.com, 2015c). However, due to lack of safety evidence, NOACs should be
avoided during pregnancy and in women attempting to become pregnant (Class III Harm,
Level C; Kirchhof et al., 2016).
Other comorbid diagnosis. With a diagnosis of hypertrophic cardiomyopathy,
lifetime anticoagulation with AF is recommended to decrease the risk of stroke regardless
of the CHA2DS2-VASC score (Class I, Level of Evidence B--January et al., 2014; Class
I, Level of Evidence B--Kirchhof et al., 2016). In the presence of an atrial septal defect,
surgical closure prior to 40-years-old or a Cox-Maze procedure are suggested to decrease
the risk of atrial fibrillation or atrial flutter. Treatments for atrial flutter with
anticoagulation (Class I, Level of Evidence C--January et al., 2014; Class I, Level of
Evidence B--Kirchhof et al., 2016; You et al., 2012), electrical cardioversion, and
antiarrhythmics are congruent with AF therapies as the stroke risk is comparable;
however, rate control is often more difficult to achieve with atrial flutter (Kirchhof et al.,
2016). With a CHA2DS2VASc score ≥ 2 in addition to hemodialysis or end-stage chronic
kidney disease (creatinine clearance < 15 mL/min), warfarin is the preferred
anticoagulant (Class IIa, Level of Evidence B). With the diagnosis of moderate to severe
chronic kidney disease and CHA2DS2VASc score ≥ 2, dose adjusted direct thrombin
inhibitors or factor Xa inhibitors are viable options instead of warfarin for anticoagulation
(Class IIb, Level of Evidence; January et al., 2014).
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With comorbid AF and acute coronary syndrome and a CHA2DS2VASc score ≥ 2,
anticoagulation is suggested (Class I, Level of Evidence C; January et al., 2014), more
specifically dose-adjusted warfarin with a target INR of 2.0-3.0 instead of warfarin
combined with aspirin (Grade 2C; You et al., 2012). Furthermore, CHEST (cited in You
et al., 2012) suggests triple therapy (oral anticoagulant, warfarin, and clopidogrel) for
three to six months after a drug-eluting stent is placed (Grade 2C), followed by dual
therapy for up to one year (Grade 2C) to prevent occlusion of the coronary artery and
further ischemic events. One year after placement of the stent, the same anticoagulant
recommendations for dose-adjusted warfarin in patients with stable coronary artery
disease (no incidence of acute coronary syndrome within the past year) and AF apply
(Grade 2C). In a patient with acute coronary syndrome and a CHADS2 score of 1 or
greater who does not receive a coronary stent, dose-adjusted warfarin plus aspirin of
clopidogrel is recommended for one year (Grade 2C; You et al., 2012).
Reversal Agents for Anticoagulants
Introduction
If the CHA2DS2-VASc recommends a patient initiate or continue anticoagulation,
the HAS-BLED score is useful for determining bleeding risk (Hwang, 2016b) as shown
within the Anticoagulation for Atrial Fibrillation Toolkit in Appendix A. A HAS-BLED
score of 1 suggests a risk of 1.13 bleeds per 100 patient-years, a score of 4 implies 8.70
bleeds, and scores > 5 display insufficient evidence to predict bleeding risk. Major
bleeding may result in hospitalization, the need for blood transfusions, surgery, or the
complication of intracranial hemorrhage (Manning et al., 2016). With minor bleeding
such as epistaxis or ecchymosis, applying manual compression to control the source of
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bleeding or stopping the anticoagulant with high bleeding risk are appropriate treatments.
is an appropriate treatment. With a major bleed, cessation of the offending anticoagulant
is warranted as well as administration of intravenous fluids, packed red blood cells, and
platelet transfusions as needed (Hu et al., 2016). Methods to reduce bleeding risk include
hypertension control using an agent other than dabigatran at patients with high risk of
gastrointestinal bleeding, and reducing alcohol consumption (Kirchhof et al., 2016).
Warfarin
If the patient develops life-threatening bleeding while on warfarin, the reversal
agent for warfarin is vitamin K1 (Hull & Garcia, 2016a). According to the European
Society of Cardiology, fresh frozen plasma and prothrombin complex demonstrate
quicker reversal of bleeding than vitamin K1 administration (Kirchhof et al., 2016).
Managing patients with high INRs on warfarin is very specific. With a high INR,
warfarin should be stopped as an INR will return to normal within four to five days. The
second choice is to administer the antidote vitamin K1 as needed. The third choice,
which would most quickly return the INR to normal, is administration of fresh plasma or
prothrombin concentrate. Below is a summary of the recommended reversal treatments
based on INR levels:
•

With an INR high but < 5, the warfarin dose can be reduced or omitted until
the INR nears the normal range.

•

With an INR between 5 and 9 without bleeding, the next one to two warfarin
doses are held with the dose lowered when the INR approaches normal or
vitamin K1 (1.5 to 2.5 mg) can be administered orally if the risk of bleeding
is high. If rapid reversal of warfarin is necessitated, such as for surgery,
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vitamin K1 (2.0 to 5.0 mg) can be given orally with a decrease in the INR
within the next 24 hours. If the INR is not therapeutic within 24 hours,
another dose of vitamin K1 (1.0 or 2.0 mg) can be administered.
•

With an INR >9 but without bleeding, vitamin K1 (3.0 to 5.0 mg) can be
given orally with a drop in the INR within 24 to 48 hours.

•

With an INR > 20 or severe bleeding, vitamin K1 (10 mg) should be given
intravenously followed by fresh plasma or prothrombin complex
concentrate; extra vitamin K1 may be given every 12 hours as needed (Hirsh
et al., 2003).

High doses of vitamin K1 should be avoided if possible, as resistance to warfarin can
occur for a duration of one week after reversal with vitamin K1. Thus, if warfarin is
administered after vitamin K1, heparin bridging may be necessary to achieve therapeutic
INRs (Hirsh et al., 2003).
Direct Oral Anticoagulants
Reversal of a DOAC can occur through drug removal, bypassing to other
coagulation pathways, or sequestration using precise reversal agents. Activated charcoal
(dabigatran and apixaban; Garcia & Crowther, 2017; Hull & Garcia, 2016b) and
hemodialysis (dabigatran) are methods to remove NOACs from the body (Samuelson &
Cuker, 2016), especially in the case of drug overdoses (Garcia & Crowther, 2017; Hu et
al., 2016). Nonspecific prothrombin complex concentrate, activated prothrombin
complex concentrate (PCC), and recombinant factor VIIa are means to bypass
coagulation pathways. The intravenous drug-specific agents bind to the NOAC molecule
to reverse the anticoagulant effects: Idarucizumab (humanized monoclonal antibody
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fragment) sequesters dabigatran, and Andexanet alpha (factor Xa decoy) and Ciparantag
(synthetic cationic molecule) are two factor Xa inhibitors currently undergoing clinical
investigation. If approved by the FDA as a universal reversal agent, Ciparantag could
also reverse the anticoagulant effects of dabigatran and heparin (Hu et al., 2016; Ruff,
Giugliano & Antman, 2016; Samuelson & Cuker, 2016).
Until a specific factor Xa inhibitor reversal agent is developed, severe or lifethreatening bleeding with these agents (edoxaban, rivaroxaban, and apixaban) can be
reversed with 4-factor PCC 50 IU/kg, which contains clotting factors, heparin, and
coagulation inhibitors protein C and protein S (Garcia & Crowther, 2017; Hull & Garcia,
2016a; Ruff, Giugliano, & Antman, 2016). Neither vitamin K1 nor fresh-frozen plasma
can reverse DOACs (Ruff et al., 2016). If major bleeding occurs during or post
procedure, antifibrinolytics such as tranexamic and Ɛ-aminocaproic acid are cost effective
and safe options (Garcia & Crowther, 2017; Hull & Garcia 2016b; Hu et al., 2016). Of
significance, drug specific antidotes should only be utilized in either the presence of life
threatening bleeding or for emergency surgery (Hu et al., 2016).
Switching Between Warfarin and
Direct Oral Anticoagulants
Direct Oral Anticoagulants
to Warfarin
Factors to consider when switching from a DOAC to warfarin and vice versa
include cost, interactions, and availability. When transitioning between classes of
anticoagulants (warfarin, factor Xa inhibitors, and direct thrombin inhibitors), an overlap
period must occur to prevent an increased risk of stroke while new drug levels are
becoming therapeutic. A minimum of a two-day overlap is recommended when
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switching from a DOAC to warfarin. As a DOAC can alter the accuracy of INR levels
for warfarin dosing, edoxaban and apixaban should be continued until the INR is ≥ 2.0.
A recommended regimen when transitioning from any of the four approved DOACS
(dabigatran, apixaban, edoxaban, and rivaroxaban) to warfarin suggests a reduced dose of
the DOAC, INR testing for a goal of ≥ 2.0, and adjusted dose of warfarin for up 14 days
(or until the INR is therapeutic) to decrease the risk of bleeding and stroke. Parental
agents are used concurrently with the DOAC as needed to achieve a therapeutic INR
quicker (Manning et al., 2016). A longer overlap is recommended between warfarin and
dabigatran if the CrCl is prolonged (Drugs.com, 2015a).
Warfarin to Direct Oral
Anticoagulants
When switching to apixaban (Drugs.com, 2016) or dabigatran (Drugs.com,
2015a), warfarin can be discontinued followed by initiating the DOAC once the INR is <
2.0. For rivaroxaban, warfarin can be discontinued and then followed by starting the
DOAC once the INR is < 3.0 (Drugs.com, 2015b). Of note, when switching between
DOACs, the current DOAC should be stopped with the new DOAC administered at the
standard dose time; no period of overlap between drugs is necessary (Guimaraes et al.,
2015; Manning et al., 2016). For edoxaban, warfarin can be discontinued, followed by
starting the DOAC once the INR is 2.5 (Daiichi-Sankyo, 2015; Guimaraes et al., 2015).
Cessation of Anticoagulants Prior to
Invasive Procedures and Surgery
Warfarin
Warfarin is usually stopped four to five days before surgery for the INR to
decrease to < 1.2. With a low risk of blood clots, the warfarin dose can also be reduced
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for this four to five-day period prior to surgery to achieve an INR of 1.3-1.5. For up to
two to three days postoperative, the patient is at risk for a thromboembolism. As a result,
prophylactic doses of heparin or low molecular weight heparin can be administered every
12 hours for four to five days until the INR becomes therapeutic again (Hirsh et al.,
2003).
Direct Oral Anticoagulants
Cessation of DOACs prior to an invasive procedure to decrease bleeding risk is
dependent on the anticoagulant. Recommendations for cessation of the individual DOAC
agents are as follows:
•

Rivaroxaban: Rivaroxaban is discontinued 24 hours pre-procedure and can
be resumed 6 to 10 hours after hemostasis is achieved post-procedure
(Drugs.com, 2015b).

•

Dabigatran: With a CrCl >50 mL/min, dabigatran should be held one to two
days prior to the procedure. With a CrCl < 50 mL/min, dabigatran should be
held three to five days prior to the procedure (Drugs.com, 2015a).

•

Apixaban: Apixaban should be discontinued 48 hours pre-procedure in
patients with a moderate to high risk of bleeding or 24 hours pre-procedure
with a low risk of bleeding. The anticoagulant should be resumed 12 to 24
hours post-procedure after hemostasis is achieved (Drugs.com, 2016).

•

Edoxaban: Recommendations suggest edoxaban be discontinued 24 hours
pre-procedure with a high risk of bleeding and then resumed as soon as
hemostasis is achieved. Indwelling intrathecal catheters and epidural
catheters should not be removed less than 12 hours after the last dose of
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edoxaban to prevent bleeding; the next dose should be given two hours after
the catheter is removed (Daiichi Sankyo, 2015).
In general, factor Xa inhibitors should be withheld a minimum of 24-48 hours
before a procedure with an intermediate bleeding risk and 48-72 hours before a high
bleeding risk procedure while direct thrombin inhibitors should be withheld a minimum
of 72 hours before the procedure. With renal impairment, the DOAC should be withheld
even longer. Permitting hemostasis is achieved, DOACs can be resumed within 24 hours
after the procedure and up to 48 hours with a high risk of bleeding (Doherty et al., 2017;
Hu et al., 2016).
Recommendations
The ACC (2012) released an expert consensus providing guidance on cessation of
anticoagulants in NVAF prior to procedures (periprocedurally) as every year
approximately 250,000 patients require this momentary disruption in therapy. The ACC
recommends assessing for stroke risk via the CHA2DS2-VASc (rather than the CHADS2)
score and utilizing a bleeding risk score through HAS-BLED to identify risk factors for
bleeding. Key components for providers to assess prior to interruption of anticoagulation
therapy include the need to interrupt (low, intermediate, or high risk of bleeding
periprocedure), when to interrupt, the need to bridge with a parenteral anticoagulant postprocedure, how to bridge, and when to restart oral anticoagulation. Recommendations
for cessation of anticoagulants periprocedurally are as follows:
•

Low bleeding risk procedures: Common procedures such as implantation of
a pacemaker/defibrillator or a catheter ablation demonstrate lower rates of
bleeding with uninterrupted oral anticoagulant during the procedure
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compared to bridging post-procedure. Specifically, a VKA should not be
interrupted prior to a procedure with a low bleeding risk and no patient
specific risk factors increasing bleeding risk (Doherty et al., 2017) such as
minor dental procedures, cataract surgery, and minor dermatological
procedures (University of Colorado Health North, 2015).
•

Intermediate and high bleeding risk procedures: A VKA should be
interrupted with an intermediate bleeding risk procedure, high bleeding risk,
or unknown bleeding risk. Prior to cessation of anticoagulation, an INR
should be checked five to seven days before the procedure. Cessation of the
INR before the procedure depends on the INR, which should be assessed 24
hours periprocedurally: the VKA should be interrupted three to four days
before a procedure with an INR of 1.5-1.9, five days prior to the procedure
with an INR of 2.0-3.0, and greater than five days with an INR greater than
3.0. Higher dosages of warfarin may require shorter periods of interruption
(Doherty et al., 2017).

Bridging with Heparin
As warfarin takes five to seven days to regain therapeutic effects once restarted,
bridging with parenteral low molecular weight heparin (LMWH) or unfractionated
heparin (UFH) is often required to prevent thromboembolism postprocedural, especially
with an INR < 2.0 in NVAF. Parenteral bridging initiation is recommended within 24
hours post-procedure with an intermediate to high risk of stroke or thromboembolism in
patients with NVAF and is contraindicated with high bleeding risk (delaying any
anticoagulation 48-72 hours post-procedure). Bridging does not come without its own
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perils such as increased cardiovascular sequalae and bleeding risk; recent evidence
suggests thromboembolic events are not decreased greatly with bridging (NVAF patients
have a 0.4% risk of thromboembolism regardless if they received or did not receive
bridging when starting warfarin; Doherty et al., 2017).
Parenteral agents. Length of hospital stay is shortened with parenteral LMWH
but UFH should be used in patients with a CrCl < 30 mL/min; both drugs demonstrate
comparable bleeding and thromboembolism risks. The level of anticoagulant effect can
be measured through an activated partial thromboplastin time (aPTT) for UFH and an
LMWH-specific antifactory Xa assay. Post-procedure, a VKA can be restarted within 24
hours at the prior therapeutic dose if hemostasis is achieved; the parenteral drug is
stopped once the INR is > 2.0. Furthermore, LMWH should be stopped 24 hours preprocedure and UFH stopped four to six hours pre-procedure (Doherty, et al., 2017).
Direct oral anticoagulants. Despite the lack of specific reversal agents for
DOACs, their short half-life requires less therapeutic interruption periprocedurally,
bridging is not required, and the drug can be started as soon as hemostasis is achieved.
For DOACs specifically, the bleeding risk, individual drug, and the creatinine clearance
predicted through the Cockcroft-Gault equation determine when to halt and resume
therapy for procedures. All the DOACs have a black box warning contraindicating the
use of these medications during neuraxial analgesia to prevent the occurrence of spinal or
epidural hematomas. Thus, direct thrombin inhibitors should be withheld four to five
days and factor Xa inhibitors held three to five days before neuraxial analgesia; these
drugs can be safely restarted 24 hours after the procedure. Current research recommends
against using DOACs for anticoagulation post mechanical valve surgery but can be used
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27 hours after hemostasis is obtained post coronary artery bypass grafting (Doherty et al.,
2017).
Conclusions. In a patient with a low thromboembolism risk (<5% annually), a
CHA2DS2-VASc score ≤4 with no history of a prior stroke, systemic embolism or
transient ischemic attack, a VKA can be restarted post-procedure without bridging.
With an intermediate risk of thromboembolism (5-10% annually) and a CHA2DS2
VASc score of 5-6, recommendations are based upon bleeding risk: with a higher
bleeding risk, bridging is contraindicated but with a low bleeding risk, parenteral
bridging is recommended only with a history of a prior stroke, systemic embolism, or
TIA. With a high risk of thromboembolism (> 10% annually), a CHA2DS2-VASc score
of 7-9, and a history of prior stroke, systemic embolism, or transient, bridging with a
parenteral agent is recommended (Doherty et al., 2017).
Drug and Food Interactions with Anticoagulants
Warfarin
With warfarin, cytochrome P450 inducers and inhibitors or CYP2C9, CYP1A2,
CYP2C19, and CYP3A4 isoenzymes influence the pharmacology of this medication and
thus its INR values. Predominantly, drug interactions with warfarin result in severe
bleeding and usually do not occur until three to five days after administration. Factors
influencing the effects of warfarin include age, broad spectrum antibiotics, intake of
vitamin K, sex, body surface area, substances with a high protein concentration, and
genetic polymorphisms CYP2C9 and VKORC1. Foods to avoid with warfarin include
grapefruit, green tea, chamomile, soybeans, mango, ginseng, St. John’s wort, ginkgo
biloba, cranberry, and green leafy vegetables with a high concentration of vitamin K.
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Concurrent use of NSAIDs, aspirin, and clopidogrel increase the risk of bleeding while
on warfarin; use of estrogen increases the risk of clotting (DiMinno et al., 2017).
Specific medications which can affect the INR are illustrated within the Anticoagulation
for Atrial Fibrillation Toolkit located in Appendix A.
Direct Oral Anticoagulants
Factor Xa inhibitors are influenced by administration of inducers or inhibitors of
CYP3A4 and P-gp. Specific to dabigatran, P-gp inhibitors and inducers should also be
avoided. Drug interactions with DOACs appear less severe than with warfarin; however,
limited evidence is available on food interactions with the DOACs (DiMinno et al.,
2017). Furthermore, protease inhibitors to treat human immunodeficiency infection
(HIV) and enzyme-inducing antiepileptics such as phenytoin and carbamazepine are
contraindicated with DOACs (Manning et al., 2016).
Anticoagulation in the Elderly Population
Research Studies
According to the AHA, “Atrial fibrillation (AF) is increasingly recognized as the
single most important cause of disabling ischemic stroke in the elderly” (Perera et al.,
2016, p. 2197). A survey of Medicare patients with atrial fibrillation demonstrated the
average age is 80-years-old and over 55% are female; new data suggest women with AF
over age 75 have a heightened risk of stroke compared to their male cohorts (Foody,
2017). When anticoagulating the elderly, a clinician should consider factors such as
polypharmacy, impaired cognition, fall risk, comorbidities contributing to bleeding risk,
CKD, nutritional status, and weight (Barbosa & Falcao, 2016). Other factors to
investigate include compliance to the treatment plan, health literacy, ability to obtain
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medications and INR monitoring, adverse drug effects, cognition, family support, and the
relationship between the patient and provider. Hospitalization for AF may be related to
drug-drug interactions with oral anticoagulants, contributed to the most frequent
comorbidities of heart failure, renal failure, chronic obstructive pulmonary disease, and
diabetes mellitus (Foody, 2017).
Advanced age ≥ 65 years old is a risk factor for thromboembolism, yet is also a
risk factor for increased bleeding risk. Non-vitamin K oral anticoagulants (NOACs)
selectively inhibit one coagulation pathway--either thrombin/factor IIa or factor Xa.
Resulting from the mechanisms of action, the NOAC effects are more predictable, have a
quicker onset of action, a reduced half-life, and a larger therapeutic window. Therefore,
NOACs do not require routine lab monitoring compared to warfarin and are more highly
recommended in the elderly. Non-vitamin K oral anticoagulants are not endorsed in
elderly patients with chronic kidney disease (CrCl < 30 mL/min with dabigatran and CrCl
< 15 mL/min with factor Xa inhibitors) nor with a body weight ≤ 60 kg (edoxaban and
apixaban). Other considerations in the elderly patient on warfarin include a deficient
vitamin K diet and alcohol consumption, which increase bleeding risk, as well as genetic
polymorphisms affecting metabolism of this drug. The overall bleeding risk for NOACs
is comparable to warfarin; however, the risk of GI bleeding is higher for NOACs.
Intracranial hemorrhage is the cause of 90% of warfarin-related deaths, yet NOACs have
demonstrated a reduced risk of this complication. Astonishingly, for an AF patient on
long-term anticoagulation, this patient could fall 300 times annually before the risk of
bleeding offsets the risk of anticoagulation use (Barbosa & Falcao, 2016). Another study
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suggests patients would have to fall over 5.7 times per week before the risk-benefit ratio
would favor no anticoagulation (Janssen Pharmaceuticals, 2014a).
Despite the three-fold risk of strokes in patients older than 75-years-old, only 30%
to 50% of applicable patients receive anticoagulation. In studies examining stroke
prevention in elderly NVAF patients, the NOACs rivaroxaban, apixaban, and dabigatran
demonstrated improved efficacy and safety compared to warfarin. Additionally, these
same three NOACs have been approved to decrease cardiovascular risk prior to
cardioversion in NVAF. Related to safety and efficacy data, particularly the decreased
risk of intracranial hemorrhage, this study concluded NOACs are superior to warfarin
when anticoagulating the elderly including NVAF. In summary, despite the increased
risk of stroke in this population, the elderly population is undertreated with
anticoagulation (Barbosa & Falcao, 2016).
Negative Outcomes with
Anticoagulation
Elderly patients demonstrate an amplified risk of hospitalization related to drug
reactions convoluted by factors such as polypharmacy, comorbid diseases, fragility, and
physiological changes associated with increasing age as evidenced by a seven-fold
increased risk compared to a younger population. A study in the New England Journal of
Medicine (Budnitz, Lovegrove, Shehab, & Richards, 2011) concluded two-thirds of
hospitalizations for patients 65 years of age and older were related to accidental
overdoses of four high-risk medications: warfarin (33.3%), oral antiplatelet medications
(13.3%), insulins (13.9%), and oral hypoglycemic medications (10.7%). Specific to
warfarin, 46.2% of emergency department visits for warfarin related adverse effects
resulted in hospitalization for patients. In addition, 50% of these hospitalizations were in
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patients older than 80 years of age. National hospitalization rates for adverse drug effects
related to warfarin included intracranial hemorrhage (5.6%), gastrointestinal hemorrhage
(40.8%), epistaxis (6.1%), hemoptysis (2.0%), genitourinary hemorrhage (4.7%),
abnormal laboratory value (increased INR or drug toxicity, 23.7%), or other hemorrhage
(5.3%; Budnitz et al., 2011). Furthermore, over 90% of elderly AF patients are at an
increased risk of stroke and less than 50% of patients with AF in a long-term care facility
receive adequate anticoagulation (Janssen Pharmaceuticals, 2014a).
Beers Criteria
The updated 2015 American Geriatrics Society (AGS) Beers Criteria, which
highlights medications deemed high risk for the elderly population, emphasized specific
recommendations for cautious use of aspirin, warfarin, and dabigatran in this population.
Quality of evidence (high, moderate, and low) and strength of recommendations (strong,
weak, and insufficient) were evaluated using the American College of Physician’s
guideline grading system. Aspirin to prevent cardiovascular events should be used
cautiously in patients 80 years of age or older (low quality of evidence, strong strength of
recommendation) due to insufficient data showing a risk-benefit ratio. Beers Criteria
recommends cautious use of dabigatran in patients 75 years of age or older with a CrCl <
30 mL/min as dabigatran has demonstrated a greater risk of gastrointestinal bleeding in
comparison to warfarin for anticoagulation purposes in this population (AGS, 2015).
Limited evidence is available on the safety of this drug with low CrCl levels (moderate
quality of evidence, strong strength of recommendation). Due the increased risk of
bleeding, the combination of warfarin and amiodarone should be avoided (moderate
quality of evidence, strong strength of recommendation) in addition to the combination of

73
warfarin and NSAIDS (high quality of evidence, strong strength of recommendation).
Furthermore, to minimize the risk of bleeding, Beers Criteria lists the following
recommendations: dabigatran and edoxaban should be avoided with a CrCl <25 mL/hr
and <30 mL/hr, respectively; the edoxaban dose should be reduced with a CrCl of 30-50
mL/hr and avoided with a CrCl < 30 or > 95 mL/hr; and rivaroxaban dose should be
reduced with a CrCl 30-50 mL/hr and avoided with a CrCl <30 mL/hr (moderate level of
evidence, strong strength of recommendation; AGS, 2015).
Recommendations
Evidence has demonstrated the bleeding risk while on oral anticoagulants does
not outweigh the benefits of stroke prevention including high risk populations such as the
elderly, cognitive dysfunction, or patients at high risk of falls. The bleeding risk is
equivalent with warfarin, NOACs, or aspirin; however, only NOACs and warfarin have
demonstrated a reduction in stroke risk. Bleeding risk is the primary reason for
discontinuing oral anticoagulation prematurely or failure to initially prescribe. Oral
anticoagulation should only be withheld in patients with severe falls related to epilepsy or
dementia where the patient is no longer able to comply with the treatment regimen
(Kirchhof et al., 2016). Furthermore, elderly patients within the nursing home on
anticoagulation display increased adverse outcomes: greater than 50% of patients have
subtherapeutic or supratherapeutic INRs, 65% of patients stop warfarin therapy
prematurely, concurrent use of warfarin with commonly used NSAIDs and antibiotics
increases bleeding risk, and warfarin dosing is one of the most common medication errors
within this setting (Janssen Pharmaceuticals, 2016a).
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As aforementioned, the risk factor of increasing age alone augments the risk of
ischemic stroke in the elderly population. As people age, bleeding risk--predominantly
intracranial, traumatic from falls, and gastrointestinal--complicates the use of
anticoagulation. Fear of bleeding risk in the elderly population inhibits its proper
utilization as evident by a study that concluded only 64% of Medicare patients with high
stroke risks were using warfarin (Desai et al., 2017). The safety of anticoagulation
studies is evaluated for the risk of severe bleeding; the risk of intracranial hemorrhage is
stable from age 60 to 80 years, yet rises greatly after 80 years old regardless of
anticoagulation status, suggesting increasing age alone may be sufficient to intensify
bleeding risk. A net clinical benefit (NCB) infers all elderly patients with AF 65 years of
age or older and with at least a CHA2DS2-VASc score ≥ 1 would benefit from
anticoagulation. Furthermore, as the CHA2DS2-VASc or HAS-BLED scores increase,
suggesting augmented risk of stroke and bleeding, respectively, the risk of stroke still
outweighs the risk of severe bleeding, thus confirming why high-risk populations require
anticoagulation. Comparisons of the NOACs (apixaban, edoxaban, rivaroxaban, and
dabigatran) to warfarin have demonstrated a reduced rate of intracranial hemorrhage and
a decreased risk of ischemic stroke in the elderly population. However, regardless of the
anticoagulant, intracranial bleeds occur in less than 1% of the population annually (Desai
et al., 2017).
With increasing age, the ability to metabolize drugs slows; thus, the weekly dose
of warfarin should decrease 0.4 mg/yr to prevent supratherapeutic levels and thus lower
augmented bleeding risk. The cost of NOACs may be more expensive to the individual
patient; yet on a system level, costs decrease significantly. Antiplatelets demonstrate
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reduced efficacy in preventing strokes and should not be used in the elderly; however,
left atrial appendage closure is a viable option for patients unable to take long-term oral
anticoagulation. Elderly patients with AF should strive for a heart rate control less than
80 bpm, moving to a rhythm strategy (with anticoagulation) or catheter ablation with
failure to control symptoms (Desai et al., 2017). A novel study examined 23,356 patients
with atrial fibrillation age 80- to 100-years-old who had suffered a recent ischemic stroke
from 2006 to 2013 (Appelros, Farahmand, Terént, & Asberg, 2017). Approximately 27%
(6,361) patients were started on anticoagulation after the stroke, demonstrating less
recurrent strokes in this population and only an increased incidence of bleeding in
patients older than 90 years old. The study concluded even this increased bleeding risk in
the older population did not outweigh the benefits of anticoagulation to prevent recurrent
ischemic strokes (Appelros et al., 2017).
Literature Review
The literature review was exhaustive and within the past five years including
systematic reviews obtained from a PubMed and an UpToDate database search. Other
noteworthy data if older than five years were also included in this paper as oral
anticoagulants have been utilized in practice since the 1950s. The literature review
focused on a comparison between the five oral anticoagulants predominantly used to
prevent thromboembolism in patients with atrial fibrillation (warfarin, apixaban,
dabigatran, rivaroxaban, and edoxaban) as displayed in Appendix B. Additionally, a
summary of noteworthy drug trials highlighting the safety and efficacy of oral
anticoagulants, reversal agents, and other novel treatments for atrial fibrillation are
displayed in Appendix C. The efficacy outcome of stroke incidence and safety outcome
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of bleeding events were the primary purposes of these anticoagulant drug trials to
promote their clinical relevance and utilization in practice. Finally, the most recent
guidelines from the American Stroke Association, American Heart Association,
American College of Chest Physicians, American College of Cardiology, and European
Society of Cardiology (ESC) were the foundation and final consensus of
recommendations for atrial fibrillation management addressed within this toolkit. The
summaries of these guidelines are attached in the appendices as follows: (a) 2016 ESC
Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with
EACTS (see Appendix D); (b) 2014 AHA/ACC/HRS Guideline for the Management of
Patients with Atrial Fibrillation: Executive Summary (see Appendix E); (c)
Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention
of Thrombosis (see Appendix F); and (d) 2014 AHA/ASA Guidelines for Prevention of
Primary Stroke; see Appendix G).
Problem Statement or Purpose
Integrated Summary of Literature
Research and practice have indicated patients, especially the elderly, do not
receive adequate assessment or management of atrial fibrillation, resulting in higher
ischemic stroke rates. A small percentage of patients with silent AF are diagnosed with
arrhythmia only after suffering from a stroke; in the primary care setting, an annual pulse
check with subsequent EKG for an abnormal rhythm could greatly reduce the incidence
of strokes in this high-risk population. Patients at moderate to high risk for stroke are not
receiving oral anticoagulants, predominantly due to the overexaggerated risk of bleeding
with these medications or lack of provider knowledge on current treatment
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recommendations for AF. Furthermore, inconsistencies exist with assessing bleeding risk
and stroke risk for every patient through reliable tools such as HAS-BLED and
CHA2DS2-VASc scores, respectively, as well as translating these scores into practice.
Consensus is universal on initiating anticoagulation with a CHA2DS2-VASc score ≥ 2;
yet, guidelines and organizations vary on their recommendations for anticoagulation with
a CHA2DS2-VASc score of 1, ultimately relying on patient and provider opinions that
may result in an increased frequency of stroke in patients with a higher risk profile.
Even though trends are slowly shifting, most patients are prescribed warfarin with
atrial fibrillation when newer anticoagulants are available. Anticoagulation is
recommended indefinitely for patients with AF and a moderate to high risk of stroke;
however, prescription of these medications becomes convoluted when factors such as
cost, patient compliance, adverse effects, safety, access, reversal agents, and provider
preference must be involved in the decision-making process. Due to these
inconsistencies and the lack of a comprehensive, universal guideline for assessment and
management of atrial fibrillation, this topic was selected for a capstone project. A toolkit
consisting of a guideline with algorithms and guideline was formulated to direct primary
care providers on an evidence-based path to diagnose and assess for atrial fibrillation in
the elderly as well as prescribe and manage anticoagulation safely and individually for
the patient with the overall objective of reducing the occurrence of ischemic stroke in this
high-risk population. The researcher utilized expert consensus, national and international
guidelines, and current literature reviews to develop this anticoagulation toolkit in its
entirety.
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Question Statement
In adult patients with atrial fibrillation older than 65 and at a moderate to high risk
of stroke, how effective is an anticoagulation toolkit in guiding primary care providers on
(a) diagnosing atrial fibrillation and (b) initiating and maintaining oral anticoagulation
safely to reduce the incidence of ischemic stroke?
Challenges
The providers themselves are a major challenge as generational gaps and
individual preferences and experiences influence their decisions to prescribe
anticoagulants in general--let alone a newer agent. Less safety and efficacy data are
available on the DOACs compared to warfarin, further complicating the prescription of
these novel drugs as providers often prescribe medications with which they are most
familiar and comfortable. A recent impetus in the anticoagulation movement is to
prescribe the best anticoagulant for the individual patient. By expanding the quantity of
available oral anticoagulants from only one with warfarin to five with the DOACs,
patients have more opportunities to find the most appropriate anticoagulant and thus
reduce their risk of stroke. Additionally, providers must be consistently up to date on
anticoagulant research findings and management of atrial fibrillation to utilize evidencebased practice, especially as the release of new research studies, antidotes for the new
agents, and alternative treatments become available on the market. Furthermore, many
providers continue to use the CHADS2 scoring system to assess for stroke risk; however,
this tool excludes patients with heightened risk factors that would be anticoagulated
based on CHA2DS2-VASc criteria. The evidence-based HAS-BLED tool is rarely
utilized in practice as providers deduce bleeding risk based on past history rather than

79
assessing for and reducing risk factors for bleeding, which is the essence of this tool.
Another key problem to diagnosis and management of atrial fibrillation is the patient.
With atrial fibrillation, there are varying presentations, effects on quality of life, and
patient preference for anticoagulation versus WATCHMAN (Boston Scientific, 2016) or
preferring no treatment at all. As far as anticoagulants themselves, cost, health literacy,
lab monitoring, support systems, transportation, and resources all influence the ability of
patients to take anticoagulants as prescribed. Furthermore, both patients and providers in
primary care often lack knowledge on the universal impact and significance of atrial
fibrillation contributing to ischemic strokes. Thus, improved education for all parties
involved is essential to advance management of this chronic disease.
Problems
Multiple factors influence the decision of the type of anticoagulant prescribed by
practitioners such as cost, insurance coverage, and reversal agent availability. Other
factors include patient preference; patient comorbidities such as renal function, hepatic
function, and artificial valves; the purpose of the anticoagulation, efficacy, and the
adverse effects profile of the drugs. Patient compliance is significant as dietary changes,
monitoring via lab work, access to care including lab monitoring facilities, reversal
agents, and adhering to the prescription regimen as directed are all essential to the careful
balance of preventing thromboembolisms while also reducing bleeding risk. Initiation of
treatment is challenging to primary care providers as well as managing this chronic
disease with anticoagulation. Four evidence-based guidelines exist for anticoagulation
with atrial fibrillation and are considerably congruent in their recommendations.
However, keeping up to date with updates is challenging for providers working in a
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primary care setting who cannot focus continuing education on only one medical
specialty. Providers should be familiar with multiple agents available for anticoagulation
and AF including alternative treatments such as WATCHMAN (Boston Scientific, 2016).
Yet, providers are often limited on their training and experience with these options and
treat the patient based on what they know rather than what could be best for the patient.
Providers who prescribe anticoagulation must be familiar with food and drug interactions,
temporary interruption of therapy for circumstances such as surgery, how to switch
between DOACs and warfarin, initiation and maintenance lab monitoring (including
home versus clinic INRs), recommendations for genetic testing, and how to treat severe
bleeding.
Assessing for atrial fibrillation through secondary prevention should be
incorporated into the annual physical examination, especially with the elderly; yet,
providers are not informed of the necessity of assessing and diagnosing an irregular
rhythm to ultimately prevent strokes. Furthermore, primary prevention of disease is more
significant than treating the disease after the fact; thus, providers should be aware of risk
factors for AF and teach their patients how to reduce these risk factors to improve their
health. Unfortunately, providers have limited time during appointments to educate
patients on anticoagulation, yet alone atrial fibrillation, contributing to limited
comprehension, noncompliance, and misinterpretations of the disease state or
medications. Relentless advances in medicine such as genetic testing, time constraints
with high patient loads, and limited or unknown resources to educate patients on
anticoagulant use further complicate this decision-making process; thus, directing
providers and patients to reliable resources and shared decision-making tools is essential
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to improve efficiency. Atrial fibrillation can be diagnosed and managed safety within the
primary care setting but providers should be trained on situations warranting a referral to
a specialist.
Situations
A chart review was conducted within a private primary care clinic in northern
Colorado, focusing on the diagnosis and management of patients with atrial fibrillation
during 2017. Through the confidential collection and assessment of patient
demographics, risk factors, patient presentation, diagnosis, treatment plan, and negative
outcomes all related to AF, the researcher could compare current evidence to practice,
assessing for any gaps and offering solutions.
Current evidence-based literature was utilized to formulate said toolkit with
guideline and algorithms including expert opinion and national and international
guidelines. Upon completion of this toolkit, it was distributed to two primary care clinics
as well as two cardiology clinics within northern Colorado; the goal was to achieve 70%
consensus from 13 providers (physicians, nurse practitioners, and physician assistants).
Even though this toolkit was designed and intended for the primary care setting, expert
opinions were obtained from specialists in cardiology when formulating and revising the
guideline with algorithms. Before analyzing the toolkit in Round 1 of the Delphi method,
providers within the primary care setting received via email a consent form (see
Appendix H) describing the purpose and phases of the project. Consent was implied if
the providers submitted the online survey through Survey Monkey within the two-week
period (see Appendix I).
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Opportunities
This project provided an opportunity to illustrate a comparison of the
anticoagulants in a table format including pharmacology, FDA (CDC, 2016b) prescribing
information, economics, and safety and efficacy of the drugs based upon clinical trials. A
summary of noteworthy drug studies for the five oral anticoagulants was provided to
address the safety and efficacy of these anticoagulants plus these drugs trials discussed
alternative treatments for AF such as WATCHMAN (Boston Scientific, 2016) left atrial
appendage implants. Additionally, providers were distributed an evidence-based toolkit
comprised of a guideline and algorithms to aid in the decision-making process of the
atrial fibrillation diagnosis as well as safe and effective initiation and management of the
appropriate anticoagulant for the individualized patient. The purpose of this toolkit was
not to persuade a provider to select one anticoagulant over another but allow an
opportunity to expose and educate providers to the vast array of products available to
select the best agent for each patient. This toolkit provided evidence-based practice and
reliable resources within one document to improve the overall treatment for atrial
fibrillation. Settings to obtain expert opinion and implement this project focused on
family practice (primary care) clinics as this setting is often where AF is diagnosed and
treated primarily. However, providers have limited knowledge and experience compared
to cardiology and electrophysiology specialists.
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Theoretical Framework
Promoting Action on Research
Implementation in Health
Services Framework
The Promoting Action on Research Implementation in Health Services (PARIHS)
framework created in 1998 was relevant to this capstone as it integrates the three
components of evidence, context, and facilitation into practice. These three elements are
ranked on a scale from low to high with improved implementation of evidence into
practice when all factors are ranked high. Evidence can be derived from experience
(patient and clinician), research (qualitative and quantitative), and local data. The context
of the practice can vary but is influenced by history, psychosocial factors, economics, and
politics, especially culture, leadership, and evaluation. Facilitation improves and
simplifies the process of implementing research into practice with strong facilitators
encompassing the characteristics of purpose, role, skills, and attributes and strives for a
holistic process (Rycroft-Malone, 2004).
The PARIHS framework has been effectively used to improve implementation of
retrospective and prospective healthcare research including 40 research papers from
2011-2016 alone. For instance, PARIHS was used in a retrospective study on improving
implementation of methicillin resistant staphylococcus aureus (MRSA) guidelines into
the U.S. Department of Veteran’s Affairs (VA), concluding high evidence, mixed
content, and mixed facilitation (Rycroft-Malone, 2004). Similarly, a prospective study
on the implementation of the VA’s MyHealtheVet personal health record portal, which
allows patients to access their medical health records, concluded low evidence, low
context, and high facilitation (Hill et al., 2017). The results from these PARIHS

84
frameworks were used to brainstorm strategies to improve the implementation of these
healthcare programs into practice. Strengths of this framework included investigating the
complexity of implementing research into practice, focusing on the context of the
research, ease of use, and clinical applicability (Harvey & Kitson, 2016).
A revised PARIHS framework was developed in 2008 to address limitations
including a lack of prospective studies, inadequate focus on the influence of individuals
and the system itself in implementation, a lack of theoretical foundations, and failure to
address the intended audience and external context of the practice (Harvey & Kitson,
2016). The revised (integrated) iPARIHS framework added the element of recipient and
innovation to the original triad of evidence, context, and facilitating, emphasizing
facilitation as the key factor to successful research implementation. Innovation included
balancing evidence, knowledge, and local practice when considering change. Recipients
of the change occur at the individual, local, organizational, and system levels. Context is
redefined as the inner context (local setting) and outer context (organization and system
levels). The facilitator role is expanded into the interplay of novice, experienced, and
expert facilitators who utilize their various skills to improve the implementation process
(Harvey & Kitson, 2016).
The plan for this project was an anticoagulation toolkit guiding providers on
improved diagnosis of atrial fibrillation as well as patient-centered anticoagulation
initiation and maintenance. The three elements of the PARIHS framework (evidence,
context, and facilitation into practice) were evaluated for this capstone project and ranked
on a scale from low to high. For this project, it was necessary to review patient charts for
local data, obtain a literature review on current evidence and best practice, and acquire
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expert opinion (evidence). Subsequently, this evidence and experience were incorporated
into an anticoagulation toolkit for managing atrial fibrillation in the primary care setting
(context) by integrating the components of culture, leadership, and evaluation in this
process. Applications of this project addressed the role of a facilitator in successfully
implementing this written material into practice, ultimately seeking expert commentary
on the efficacy and feasibility of it use (facilitation into practice). Elements of the
iPARIHS model were incorporated into the evaluation of this toolkit and focused on
innovation, recipients, and the influence of different context levels and experience of the
facilitators.
Reach, Effectiveness/Efficacy, Adoption,
Implementation, and Maintenance
Model
The reach, effectiveness/efficacy, adoption, implementation, and maintenance
(RE-AIM) framework is composed of five steps to “enhance the quality, speed, and
public health impact of efforts to translate research into practice” (RE-AIM, 2017: Reach
(target population), effectiveness/efficacy (impact of the intervention), adoption
(healthcare providers and setting willing to initiate the change), implementation
(reliability, costs, time constraints, transformations, and delivery to adopt the change),
and maintenance (ability to continue the change over time for at least six months). The
RE-AIM model has been successfully used to assess the impact of the WISEWOMAN
program to improve cardiovascular disease screening and lifestyle changes in uninsured
women (Farris, Will, Khavjou, & Finkelstein, 2007) and to hone strategies for chronic
disease management (Glasgow, McKay, Piette, & Reynolds, 2001).

86
The RE-AIM model was utilized for this capstone project to assist with the
effective implementation and evaluation of this anticoagulation toolkit. Reach addressed
the target population of elderly patients with a new or chronic diagnosis of atrial
fibrillation within the primary care setting. Effectiveness was the impact of this
anticoagulation toolkit to prevent stroke in patients with atrial fibrillation. Adoption
assessed the willingness and feasibility of primary care providers to incorporate this
toolkit into practice. Implementation addressed the factors contributing to the successful
use of this toolkit in primary care such as provider and patient preference, costs, access,
time constraints, and training. Maintenance assesses the duration of implementing this
toolkit in practice but was not feasible for this capstone project.
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CHAPTER II

PROJECT DESCRIPTION

Project Description
Synthesized Summary of Project
For this quality improvement capstone project, a retrospective chart review was
completed on the diagnosis and treatment of atrial fibrillation patients in the primary care
setting. Through implementation of two rounds of the Delphi technique, expert opinions
from providers in primary care and cardiology were utilized to create an anticoagulant
toolkit emphasizing improved diagnosis of atrial fibrillation in the elderly within the
primary care setting and followed by appropriate initiation and management of
individualized anticoagulation to reduce the incidence of stroke. Recommendations to
improve this variance between research and practice included evaluating the necessity of
anticoagulation through stroke risk (CHA2DS2-VASc) and bleeding risk (HAS-BLED)
scales, screening all elderly patients in the primary care setting for atrial fibrillation
through an annual pulse check with follow-up electrocardiogram as necessary, and
highlighting key resources for providers (guidelines, quality and performance measures,
and a shared decision-making tool) to improve implementation of evidence-based
research into practice. This toolkit also contained a tabular comparison of warfarin and
direct oral anticoagulants (edoxaban, rivaroxaban, dabigatran, and apixaban), and patientspecific factors to consider when selecting an anticoagulant.
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Project Objectives
The objectives of this capstone project were to (a) examine current and local
diagnosis and management of atrial fibrillation within the primary care setting, (b) create
a toolkit (guideline with algorithms) directing practitioners on diagnosis of atrial
fibrillation as well as initiation and maintenance of oral anticoagulation, (c) promote
safety and efficacy in the management of anticoagulants, (d) endorse patient-centered
anticoagulation based upon current evidence-based literature and expert opinion, and (e)
evaluate the effectiveness of a toolkit influencing the diagnosis of atrial fibrillation and
anticoagulation management within a primary care setting.
Congruence of Organization’s Strategic
Plan to Project
Confidential chart reviews of atrial fibrillation patients were completed at Family
Physicians of Greeley. Tentative primary care organizations in northern Colorado to
implement the toolkit included Family Physicians of Greeley-Central and University of
Colorado Health Family Medicine--North Loveland. Additionally, as cardiologists
specialize in atrial fibrillation, their expertise and experience were incorporated into the
construction and revisions of the anticoagulation algorithm and guideline. Proposed
cardiology sites included the Cardiovascular Institute of Northern Colorado and the
University of Colorado Health Heart Center--Fort Collins. Expert opinions from all sites
were obtained from physicians, nurse practitioners, and physician assistants. To more
effectively reach a diverse population with this toolkit, expert consensus was obtained
from providers who delivered care to patients in both rural and urban settings and were
employed at commercial and privately-owned clinics. Organizations aiding in the
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execution of this capstone project display similarities in their missions, values,
perspectives, and approaches to diagnosing and managing atrial fibrillation.
Project Design
Literature Review on Atrial Fibrillation
and Anticoagulation
For this quality improvement project, an extensive literature review included
relevant background information on AF that focused on the diagnosis and management,
especially with anticoagulants. Literature was current (within the past five years) and
relevant (inclusive of the key words of “atrial fibrillation”), obtained from PubMed and
UpToDate databases, as well as guidelines on anticoagulation with atrial fibrillation.
Additional necessary research compared oral anticoagulants (warfarin, apixaban,
dabigatran, rivaroxaban, and edoxaban) for patient-specific factors as well as assessed
safety and efficacy of each agent. As this project focused on a population of elderly
patients with AF, noteworthy literature was analyzed to discover how best to manage this
disease to reduce negative sequelae of stroke as well as its impact on patients and society
in general. Ultimately, this research was the foundation for the anticoagulation toolkit
designed for the primary care setting: guideline, algorithms, and provider resources to
manage AF. This research was also applied to identify practice gaps, effectively
translating research to practice to improve patient outcomes.
Patient Chart Reviews
A goal of 100 retrospective patient chart reviews through Next Generation was
confidentially reviewed at Family Physicians of Greeley-Central. Patients were included
if they had a diagnosis of atrial fibrillation and were seen in the clinic during 2017. Data
collected included demographics (age, sex, race/ethnicity, insurance status, and
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rural/urban residence), risk factors, patient presentation, diagnosis (focusing on pulse
checks and EKG results), comorbid diagnoses, imaging/laboratory data, treatment plan
(focusing on oral anticoagulants), negative outcomes, patient tolerance/quality of life,
follow-up, and interdisciplinary management for patients with atrial fibrillation.
Additionally, the patient charts were assessed for the use and interpretation of bleeding
risk and stroke risk scores (HAS-BLED and CHA2DS-VASc respectively). The purpose
of obtaining this data was to compare current evidence to practice.
Delphi Technique
The Delphi technique is utilized to obtain data from experts in a particular field
during a short time period to establish a group consensus from a series of surveys. The
Delphi technique is described as “iterative and sequential” (Hsu & Sanford, 2007, p. 5).
Since the 1950s, the Delphi technique has been used as a group communication tool to
obtain controlled expert consensus for “goal setting, policy investigation, or predicting
the occurrence of future events” (Hsu & Sanford, 2007, p. 1). This technique can be used
to offer choices, recognize assumptions, make predictions, set goals, increase knowledge,
and summarize judgments within a group for the purposes of program structuring, needs
evaluations, policy writing, and resource management. The researcher reviews each
survey from an expert and creates a group consensus that is returned to each expert along
with a summary of the expert’s own viewpoint. The purpose of repetitive surveys is to
obtain feedback from the experts; re-evaluations of perspectives can ultimately formulate
an improved consensus and communication among the group. The Delphi technique
maintains the confidentiality of subject identifiers, controls the feedback process (the
summary of the prior surveys is given to experts to decrease “noise” of the individuals,
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which inhibits problem solving and alters data), and multiple statistical analyses are
completed, all decreasing influences of coercion and biases common in group settings.
Usually a minimum of three rounds of survey distribution is sufficient for the Delphi
technique but up to five can be implemented to achieve group consensus.
In Round 1, a survey with open-ended questions or derived from a literature
review is given to the experts. In Round 2, a more structured survey is given to the
experts that requests the subjects create a summary of the results from the first round.
Also in Round 2, questions may require ranking or rationale to support their decisions. In
Round 3, the experts receive a summary of the results from Round 2 and the subjects are
asked to reassess their responses including rationale and to request further explanations.
In Round 4, an overall summary of the prior three rounds is given to all the subjects,
allowing one final chance to reassess their responses (Hsu & Sanford, 2007).
Subjects and time are essential factors to consider when determining if the Delphi
technique is the appropriate tool. Choosing subjects is important for the Delphi study as
it influences the quality of the data obtained. A minimum of 10-15 experts in a field is an
adequate sample size with an average of 15-20 subjects per study. The Delphi technique
assumes all the experts have similar experiences and knowledge of the subject matter are
stakeholders who will use these results either for clinical or research purposes, and these
subjects are willing to work as a team to reach a consensus. On average, 45 days are
required to complete the Delphi study in its entirety with a recommended two-week
period between administration and subject response for each individual survey. To
decrease time constraints, the use of e-mail or teleconferencing to distribute surveys was
utilized so feedback could be obtained more quickly and enhanced subject
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confidentiality. Methods of data analysis included central tendency (mean, median, and
mode) as well as level of dispersion (standard deviation and inter-quartile range) with
median and mode preferred. Consensus was attained when “80 percent of the subjects’
votes fall within two categories on a seven-point scale…at least 70 percent of Delphi
subjects need to rate three or higher on a 4-point Likert-type scale and the median has to
be a 3.25 or higher” (Hsu & Sanford, 2007, p. 4). Limitations of the Delphi technique
included potential molding of opinions to coincide with group opinion (through
persuasion of researchers or after receiving misleading feedback) and presumed all
experts in the field were equal in experience and knowledge in order to develop a general
rather than a topic-specific consensus. As multiple rounds are required for the Delphi
technique, possible low response rates from subjects could negatively influence feedback
and lengthy time commitments to collect and analyze data could limit the study’s
successful implementation (Hsu & Sanford, 2007).
The Delphi technique has been utilized to assess several atrial fibrillation studies
such as a systematic review with a one-round Delphi technique ranking 54 outcomes and
performance indicators internationally to better assess AF management (Berti, Van
Vlasselaer, Moons, & Heidbuchel, 2015). The Cardiovascular Health in Ambulatory
Care Research team (Tu et al., 2017) assessed performance indicators (risk factor
prevalence, screening, management, intermediate outcomes, and long-term outcomes) for
primary prevention of cardiovascular disease using a two round Delphi technique. This
study concluded the five key risk factors for cardiovascular disease were smoking,
obesity, hypertension, diabetes, dyslipidemia, and atrial fibrillation. These identified
performance indicators could be measured in the outpatient setting by researchers,
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stakeholders, and clinicians to prevent cardiovascular disease (Tu et al., 2017).
Furthermore, the AF-SCREEN International Collaboration (Freedman et al., 2017)
composed of 60 experts utilized the Delphi technique to establish a consensus on AF
screening. The collaboration focused on the importance of anticoagulation to prevent
stroke if AF was diagnosed via an EKG, the superiority of using handheld EKG devices
for screening, increasing monitoring of patients with recent embolic stroke to better
diagnose AF, and the importance of multidisciplinary management of AF regardless of
the clinic or health system (Freedman et al., 2017).
For this capstone, two rounds of the Delphi technique were utilized. Round 1
focused on a qualitative, open-end survey to assess the comfort level, experience, and
baseline knowledge of the expert providers diagnosing atrial fibrillation as well as
prescribing and managing anticoagulation for this high-risk population within the primary
care setting. Along with the first survey, the providers received a consent form
highlighting the purpose and format of this project. Additionally, providers were asked
to list their credentials, specialty, and years of expertise for demographic and statistical
purposes. The survey for Round 1 is provided in Appendix I; the consent form to
participate in the research that affirmed all identifying information would remain
confidential was also sent.
In Round 2 of the Delphi method, providers received a consensus of the group
from Round 1 and completed a second mixed quantitative and qualitative survey
addressing ease of use, applicability, relevance, and the impact of this toolkit on practice.
Providers were asked to evaluate the benefits and challenges of this toolkit and offer
feedback for revisions. To clarify, providers received the first draft of the anticoagulation
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toolkit composed of an algorithm and guideline during Round 2. The anticoagulation
toolkit was drafted after Round 1 and then revised further after Round 2 to incorporate
expert consensus into the toolkit, thus increasing relevancy and clinical applicability to
the primary care setting. The survey for Round 2 is provided in Appendix J.
The goal sample size was 10 to 15 family practice and cardiology practitioners
consisting of physicians, nurse practitioners, and physician assistants. Providers had two
weeks to complete each survey through Survey Monkey, which was accessible through
the link sent to each provider individually through e-mail. Upon completion of the two
rounds of the Delphi method, data and demographics were analyzed through standard
qualitative measures. Consensus was achieved if the panel agreed on the components in
Round 2 at least 70% of the time. If a consensus of 70% was not accomplished after two
rounds, subsequent rounds were indicated, time permitting.
Evidence-Based Projection Plan
The evidence-based projection plan consisted of the following six phases:
•

Phase 1: Thorough literature review on anticoagulation and atrial fibrillation.
Current literature focused on the diagnosis and management of atrial
fibrillation obtained from PubMed and UpToDate databases as well as
international and national guidelines. Novel drug trials and
pharmacokinetics/pharmacodynamics of the five most prescribed oral
anticoagulants (warfarin, dabigatran, apixaban, edoxaban, and rivaroxaban)
were summarized additionally.

•

Phase 2: Medical records review at Family Physicians of Greeley-Central,
assessing demographics, risk factors, patient presentation, diagnosis,
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comorbid diagnoses, imaging/laboratory data, treatment plan, negative
outcomes, and interdisciplinary management for patients with atrial
fibrillation. Records of patients on anticoagulation were reviewed for
assessment of stroke risk and bleeding risk through CHA2DS2-VASc and
HAS-BLED scores, respectively, as well as patient preference.
•

Phase 3: Development of an anticoagulation toolkit guideline and algorithms
based upon best evidence and expert opinion (literature review, clinical
practice guidelines, review of current practice, and consensus from primary
care providers and cardiologists). The design of this project was the Delphi
technique with a minimum of two rounds and a goal of 70% consensus. The
toolkit was devised after completion of Round 2 of the Delphi method.

•

Phase 4: Distribution and revision of the anticoagulation toolkit in the primary
care and cardiology settings. The goal was to reveal this toolkit to two or
three different primary care clinics and one to two cardiology clinics within
northern Colorado with a 100% participation rate of 10-15 providers.
Providers completed the first survey during Round 1 and the second survey
with toolkit evaluations during Round 2.

•

Phase 5: Using qualitative statistical analysis, the data and demographics from
patient charts and the Delphi surveys were evaluated to derive conclusions
comparing evidence to practice.

•

Phase 6: Future project involved a pilot study to assess any impact on patient
outcomes related to implementation of this toolkit into the primary care
setting.
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Timeline of Project Phases
The researcher utilized the following timeline for the project phases:
•

Phase 1 (literature review)--Completion by June 2017.

•

Statement of Mutual Agreement signed—July 6, 2017 (see Appendix K)

•

University of Northern Colorado (UNC) Institutional Review Board approval
--Obtained August 11, 2017 (see Appendix L).

•

Phase 2 (medical records review)--Completion by September 2017.

•

Phase 3 (development of anticoagulation toolkit)--Completion by September
2017.

•

Phase 4 (distribution and revision of toolkit)--Completion by October 2017.

•

Phase 5 (data analysis)--Completion by October 2017.

•

Phase 6 (pilot study)--Future research project
Subjects

Subjects for the patient chart review included any adult greater than 18 years of
age who required anticoagulation for the indication of atrial fibrillation for ischemic
stroke prophylaxis. Despite the focus of this project on elderly patients older than 65
years, a thorough assessment of the diagnosis of AF and anticoagulation management in
all adults was essential for the data analysis portion of this project to address current
practice. Subjects were obtained from the Next Generation electronic health records at
Family Physicians of Greeley-Central, focusing on patients who were seen in the clinic
during 2017 related to a diagnosis of atrial fibrillation. The sample size was based on
availability of patients meeting inclusion criteria; yet, the researcher aspired for a goal of
at least 75 patient chart reviews. The providers analyzing the toolkit were primary care
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and cardiology providers within northern Colorado including either physicians, nurse
practitioners, or physician assistants who prescribed anticoagulation. Specific patient
characteristics such as pregnancy status, heart valve replacement, increased risk of
gastrointestinal distress, decreased creatinine clearance, and poor patient compliance
were addressed in the toolkit to help providers manage future anticoagulant prescriptions
more safely and effectively.
Implementation Methods/Tools
An anticoagulation toolkit comprised of a guideline with algorithms was created
based upon recent literature and expert opinions. Two surveys were formulated to
evaluate the toolkit through the Delphi method. The first survey compared current
practice to literature. The second survey focused on the safety, efficacy,
comprehensiveness, and ease of administration of the toolkit. The second survey also
focused on how implementation of this toolkit influenced the initiation and management
of anticoagulation for AF in the primary care setting.
Resources
Personnel
Expert opinions were obtained from providers specializing in family practice and
cardiology in addition to the recommendations from national and international guidelines
on anticoagulation management.
Technology
Literature was acquired from the UNC library databases, PubMed, and
UpToDate. Microsoft Office was utilized to generate the toolkit. Patient charts were
reviewed through Next Generation. Electronic surveys were created and completed on
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Survey Monkey along with the consent form, survey link, and additional relevant
information delivered to providers via confidential e-mail.
Budget
At this point, no financial constraints were foreseen with planning, formulation,
revision, implementation, and evaluation of this project.
Risks and Benefits
A potential risk was a provider following the toolkit but not considering the
patient’s comorbidities, concurrent medications, and individualized indications and
contraindications, resulting in an incorrect prescription or management of
anticoagulation. Other risks included the provider not following the toolkit correctly, the
provider not incorporating the patient’s preferences into the decision of which
anticoagulation to prescribe (including self-monitoring of INRs with warfarin), or the
provider not staying up to date with current evidence and best practice recommendations
on anticoagulants. The primary benefit was evidence-based, patient-centered,
individualized prescription and management of anticoagulants. A strength of this
anticoagulation toolkit was its composition: a current and user-friendly guideline with
algorithms created and revised based upon expert consensus from both cardiology and
primary care experts within the field. Another benefit was a summary of the most current
guidelines from the leading medical associations (American Stroke Association,
American Heart Association, American College of Chest Physicians, American College
of Cardiology, Heart Rhythm Society, and European Society of Cardiology) driving best
practice. Additionally, key results, both positive and negative, from pharmaceutical drug
trials were summarized to help guide practice as well as a conclusive summary of the five
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most currently used oral anticoagulants in practice (warfarin, apixaban, edoxaban,
rivaroxaban, and dabigatran). Furthermore, this toolkit did not attempt to sway
practitioners toward one anticoagulant versus another but instead provided unbiased,
evidence-based data to promote the best anticoagulant initiation, management, and
monitoring for the individualized patient rather than provider preference.
Financial Plan
A financial plan was not applicable as no financial costs were presumed for this
project other than time and labor of the researcher and subjects. No cost was incurred
from the data collection and analysis completed by the researcher, and the surveys and
toolkit were created and distributed electronically.
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CHAPTER III

EVALUATION PLAN

The following objectives were evaluated in this capstone project:
1.

Examine current and local diagnosis and management of atrial fibrillation
within the primary care setting.
•

Plan: An analysis of 75 patient medical records during 2017 at a local,
privately owned primary care clinic (Family Physicians of GreeleyCentral) that would highlight current management and diagnosis of
atrial fibrillation while also identifying gaps in practice. Patient charts
were assessed for the diagnosis of atrial fibrillation, symptoms, risk
factors, diagnostics, laboratory and imaging data, comorbid diagnoses,
management (focusing on anticoagulation), negative outcomes, and
multidisciplinary providers managing the patient. Charts were also
reviewed for any assessment of stroke and bleeding risk through
CHA2DS2-VASC and HAS-BLED tools. Patient demographics
obtained included age, sex, race/ethnicity, rural or urban residence,
and insurance coverage.

•

Methods of analysis: Data were analyzed statistically through
measures of central tendency to determine the norms and exceptions
for diagnosis and management of atrial fibrillation in a primary care
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setting. These data were then compared to current evidence-based
guidelines to assess for gaps in practice and offer solutions for
improvement.
2.

Create a toolkit (guideline with algorithms) directing practitioners on
diagnosis of atrial fibrillation as well as initiation and management of oral
anticoagulation.
•

Evidence-based measures/instruments: The toolkit was created based
upon a literature review and expert opinions. Additionally, the most
recent guidelines from the American College of Cardiology, American
Stroke Association, American Heart Association, American College of
Chest Physicians, Heart Rhythm Society, and European Society of
Cardiology were implemented into this toolkit (see Appendices D, E,
and G). Expert opinions were obtained from northern Colorado
providers in primary care and cardiology. The toolkit provided a
simplified, evidence-based direction in diagnosing atrial fibrillation in
the primary care setting as well as prescribing and managing
anticoagulation in patients with atrial fibrillation to prevent stroke.

•

Methods of analysis: The Delphi method was utilized to formulate and
improve the anticoagulation toolkit through expert consensus. Two
surveys consisting of 8 to 10 questions each, one from Round 1 and
one from Round 2, were analyzed statistically (through measures of
central tendency) to determine providers’ comfort level and expertise
with providing anticoagulants and diagnosing atrial fibrillation as well
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as how incorporation of this toolkit could influence practice. The
survey for Round 1 was administered prior to providers viewing the
anticoagulation toolkit for the first time. The survey for Round 2 was
administered after reviewing the toolkit and obtaining consensus from
the group in Round 1 of the Delphi method. Round 1 and Round 2
Delphi survey questions can be found in Appendices I and J,
respectively.
•

Components of anticoagulation toolkit: Contents of this toolkit
included a guideline with algorithms in addition to resources for
providers on atrial fibrillation management.
o

Guideline: The guideline provided a step-wise recommendation
to:
1)

Reduce risk factors for atrial fibrillation (AF).

2)

Diagnose AF early through an annual pulse check in all
symptomatic or asymptomatic patients ≥65 years old. If an
irregular pulse is detected, confirm the rhythm through an
EKG.

3)

If a patient has AF, assess for bleeding and stroke risk
through the HAS-BLED and CHA2DS2-VASc scores
respectively to determine if that patient is a candidate for
oral anticoagulation.

4)

Prescribe the patient specific anticoagulant with a
CHA2DS2-VASc score ≥2 and a low risk of bleeding.
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Consider anticoagulating with a CHA2DS2-VASc score of
1, dependent on patient preference and clinical judgment.
o

Algorithms:
1)

Reduce risk factors for atrial fibrillation (AF)

2)

How to calculate and interpret the CHA2DS2VASc and
HAS-BLED scores was provided for easy reference.

3)

A comparison of warfarin and direct oral anticoagulants
was summarized in a table.

4)

An algorithm illustrating the indications and
contraindications for specific oral anticoagulants (warfarin,
dabigatran, apixaban, rivaroxaban, and edoxaban). More
specifically, this algorithm addressed rationale for selecting
an anticoagulant: mechanical or prosthetic valves, kidney
function, liver function, pregnancy, frequency of dosing,
reversal agents, lab monitoring, drug or food interactions,
age, gastrointestinal distress, cost, compliance, and weight
adjustments. The purpose of these algorithms was not only
to encourage improved diagnosis and management of AF
but to promote assessment for patient-specific factors
driving prescription of a specific anticoagulant.

o Atrial Fibrillation Resources for Providers: To simplify the
convoluted regimen of anticoagulation and managing AF in
general, this toolkit provided resources on appropriate reversal
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agents, assessment for symptom severity with AF, genetic
testing, lab monitoring (including home versus clinic INRs), and
discontinuation of anticoagulation prior to surgery or invasive
procedures including bridging therapy with warfarin. Food and
drug interactions, INR and warfarin dosing, transitioning
between warfarin and DOACs safely, and when to refer to a
specialist were also included. Essential anticoagulation websites
for anticoagulation (genetic testing, shared decision-making
tools, performance and quality measures), WATCHMAN, and
national/international guidelines for anticoagulation) were briefly
summarized within in the toolkit with their corresponding
references. Additional resources for providers were added or
eliminated based upon the results of the Delphi survey Round 1.
The toolkit offered one reliable resource for providers to review
when managing anticoagulants to improve safety and efficacy of
these drugs as well as provided resources to better educate
patients.
3.

Promote safety and efficacy in the management of anticoagulants.
•

Evidence-based measures/instruments. As aforementioned in objective
2, literature review and expert opinions were the foundation of this
guideline with algorithms. The purpose of this toolkit was to promote
safety and efficacy when prescribing anticoagulants. Thus, available
literature on all five anticoagulants (warfarin, dabigatran, apixaban,
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rivaroxaban, and edoxaban) was scrutinized thoroughly and presented in
a chart format. A shortened version of this chart was included in the
anticoagulation toolkit with websites provided to healthcare providers on
where to find more information on drug trials and individual oral
anticoagulant agents.
•

Methods of analysis: These data were analyzed statistically through
measures of central tendency to obtain expert feedback of what factors
influenced safe and efficacious prescription of anticoagulants, striving
for a 70% consensus.

4.

Endorse patient-centered anticoagulation based upon current evidence-based
literature and expert opinion.
•

Evidence-based measures/instruments. As aforementioned in
objective 2, literature review and expert opinions were the foundation
of this toolkit. Summaries from key anticoagulation guidelines and
landmark drug trials were also analyzed. Background information,
pharmacokinetics, and pharmacodynamics on the five individualized
drugs (warfarin, apixaban, rivaroxaban, edoxaban, and dabigatran)
were obtained from the FDA (CDC, 2016b) prescribing information
and summarized in a chart. Individual patient factors to consider when
prescribing anticoagulants were compared in a chart format. A
comparison of novel drug trials was included to assess the safety and
efficacy of the five commonly prescribed oral anticoagulants; these
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results were summarized in the capstone paper and the website link
was included in the anticoagulation toolkit.
•

Methods of Analysis. These data were analyzed statistically through
measures of central tendency to obtain expert feedback of what factors
influenced patient-centered management of anticoagulants, striving for
a 70% consensus.

5.

Evaluate the effectiveness of a toolkit influencing the diagnosis of atrial
fibrillation and anticoagulation management within a primary care setting.
•

Plan: The effectiveness of this toolkit was evaluated through a Round
2 Delphi survey completed by two primary care clinics and two
cardiology clinics within northern Colorado. Four providers examined
and critiqued this guideline for its usefulness and applicability in
practice. The surveys were completed through Survey Monkey with
the consent forms and other corresponding communication
individually delivered to providers via confidential e-mail.

•

Methods of analysis: To evaluate the effectiveness of the
anticoagulation toolkit, the PARIHS and RE-AIM frameworks were
utilized. Through the PARIHS framework, strategies were devised to
tailor the algorithm and guideline to the target population and
appropriate context while utilizing the best evidence innovatively.
Furthermore, this framework aided in applying the unique skills and
experience levels of the providers to improve facilitation of the
intervention. The RE-AIM framework examined how to reach the
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intended population, evaluate the impact of this toolkit in the primary
care setting, brainstorm techniques to enhance adoption by providers,
address barriers to implementation, and strengthen utilization of this
toolkit over time.
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CHAPTER IV

RESULTS AND OUTCOMES

Results from Literature Review
As this was a quality improvement project, the core of this capstone paper was an
extensive literature review on atrial fibrillation and anticoagulation, which was
successfully achieved. Through PubMed and UpToDate databases, the researcher located
current research studies (including systematic reviews and nationwide cohort studies)
within the past five years on atrial fibrillation diagnosis and management, displaying an
impressive collection of background information on the topic. As oral anticoagulation
(warfarin) has been prescribed since the 1950s, older but relevant research and evidence
were included in the literature review. Approximately 145 individual references were
reviewed including the most current recommendations from four international and
national guidelines on anticoagulation for atrial fibrillation. Over 25 components of atrial
fibrillation were researched in this literature review, e.g., novel evidence on anticoagulant
reversal agents, alternative treatments for AF, epidemiology, risk factors and
pathophysiology for AF, genetic testing with warfarin, lab monitoring, and the impact of
AF on patient quality of life and the economics of the United States. As the focus of this
project was reducing the incidence of stroke in elderly patients with AF, the researcher
found numerous studies discussing how best to manage AF in this high-risk population as
well as addressing the limited knowledge providers and society have on the contribution
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of AF to strokes in general. The objective was to obtain literature comparing the five
current oral anticoagulants (warfarin, apixaban, dabigatran, edoxaban, and rivaroxaban);
this was thoroughly completed based upon FDA (CDC, 2016b) prescribing information
and was ultimately summarized within a chart. This same evidence was utilized to create
the algorithm comparing warfarin to DOACs as well as the algorithm highlighting
patient-specific factors to consider when prescribing an oral anticoagulant. The objective
to research noteworthy drug trials for the oral anticoagulants was accomplished as the
researcher discovered and summarized 30 trials for these drugs including studies from
1989 to 2015 as well as discussed studies on WATCHMAN©, reversal agents, and dual
antiplatelet therapy, effectively accentuating the safety and efficacy data on these drugs.
The four-step guideline to diagnose and manage AF was based solely on current evidence
and recommendations from guidelines including the importance of utilizing CHA2DS2VASc and HAS-BLED scores to assess for stroke and bleeding risk with anticoagulants
and AF. The depth of this literature review allowed the researcher to create a resource
section for providers within the anticoagulation toolkit, addressed suggestions and
requests to improve management of AF, enhanced shared-decision making with the
patient, and promoted multidisciplinary care. Furthermore, this research was successfully
utilized to compare current evidence and practice (through the patient chart reviews),
identify gaps, and propose solutions through the anticoagulation toolkit. Due to the
complexity of atrial fibrillation, this literature review was more timely and lengthy than
originally anticipated but was highly inclusive of all necessary components to better
comprehend and address this cardiac disorder.
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Results from Patient Chart Reviews
Over 100 patient charts were retrospectively reviewed in the Next Generation
electronic health records at Family Physicians of Greeley-Central. Over 396 patients
who met the criteria of “atrial fibrillation” and “seen in the clinic during 2017” were
identified within Next Generation. Out of this population, 100 patients were randomized
alphabetically and each patient was identified with only a unique number and initials.
Patient charts were evaluated to obtain the following demographics: age, sex, ethnicity,
rural or urban residence, and insurance status. Other data collected included stroke or
bleeding scores, patient presentation (symptomatic or asymptomatic), clinical
manifestations, risk factors (AF, bleeding, and stroke), current anticoagulation agent,
negative outcomes, and gaps between evidence and practice. Statistical data analysis for
the patient chart reviews was calculated through measures of central tendency: mean,
median, and mode.
Age
The most common ages for patients with atrial fibrillation were ages 60 to 69
years (22%), ages 70 to 79 years (33%), and ages 80-89 years (24%), coinciding with the
increased incidence of patients with atrial fibrillation over 65 years of age (You et al.,
2012). A summary of the age demographics of patient chart reviews is provided in Table
2 and Figure 4.
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Table 2
Age Demographics of Patient Chart Reviews
Age (years)
30-39

Number of Patients
2

40-49

1

50-59

9

60-69

22

70-79

33

80-89

24

90+

9
Total: 100

Age
35
33

30

# of Patients

25
24

20

22

15
10
9

5
2

1

30-39

40-49

9

0
50-59

60-69
Age (Years)

Figure 4. Age demographics of patient chart reviews.

70-79

80-89

90+
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Sex
With regard to sex, out of 100 patients, 44 were female and 56 were male,
corresponding to the increased rate of AF in men compared to women (Kirchhof et al.,
2016). However, with increasing age, AF is more prevalent in women (Kirchhoff et al.,
2016). This statistic correlated to the chart reviews; of 33 patients older than 80 years of
age, 22 were female (15 patients age 80-89 years and seven patients age 90+), and 11
were male (nine patients age 80-89 years and two patients age 90+), suggesting how with
increased age comes an increased risk of disease.
Race/Ethnicity
Race/ethnicity was not mentioned in the literature as a risk factor for AF other
than an increased incidence with European heritage (Centers for Disease Control and
Prevention, 2015). This fact correlated with chart reviews where 94 of 100 patients were
Caucasian, 49 were Hispanic, one was Asian, and one was of mixed-race.
Health Insurance
Selection of an anticoagulation is often related to health insurance coverage and
the ability to pay for a prescription. Research indicated all major insurance companies
and Medicare cover warfarin, rivaroxaban, dabigatran, and apixaban, yet Medicare does
not cover edoxaban (GoodRx, 2017). The chart reviews displayed over 51 patients had
Medicare and 20 patients had MCR Humana; only five patients had either no insurance or
unknown insurance coverage. As 95% of patients had insurance coverage, the issue of
cost could be reduced through copays or drugs saving cards, offering more oral
anticoagulation options to fit individualized patients’ preferences, medical conditions,
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and budget. Insurance coverage of the patient chart reviews is provided in Table 3 and
Figure 5.

Table 3
Health Insurance Coverage Reflected in Patient Chart Reviews
Health Insurance

Number of Patients

Medicare

51

Cigna

3

Anthem Blue Cross Blue Shield

8

Banner

4

Colorado Choice (Medicaid)

1

Kaiser Permanente

2

MCR Humana

20

United Healthcare

6

Unknown/None/

5
Total: 100
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Health Insurance
60
51

# of Patients

50
40
30
20
20
10

8
3

4

1

2

6

2

3

0

Health Insurance Company

Figure 5. Health insurance coverage reflected in patient chart reviews.

Rural or Urban Residence
The researcher wanted to insure this project was inclusive of both rural and urban
residences as access to care was a large issue influencing patients’ ability to receive
appropriate medical care. The chart review demonstrated 70 patients resided rurally
while 30 patients lived in urban residences; thus, the researcher was successful in
targeting a diverse population.
Stroke and Bleeding Scores
Research demonstrated CHA2DS2-VASc scores (stroke risk) and HAS-BLED
scores (bleeding risk) are simple and efficient tools to assess whether anticoagulation is
appropriate for a patient with atrial fibrillation without warranting further testing or blood
work (Shahid et al., 2016). The CHAD2DS2-VASc is recommended over CHADS2 to
assess for stroke risk with nonvalvular AF as it highlights more risk factors and can better
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classify the degree of a patient’s stroke risk (Lane & Lip, 2012). Despite these
recommendations, only 29 patients had a documented CHADS2 score (13 patients or 9%)
or CHA2DS2-VASc score (19 patients or 20%) mentioned in their medical charts while
only 11providers utilized the more effective stroke risk tool of CHA2DS2-VASc.
Furthermore, no patients had records of their HAS-BLED scores in their medical charts.
These data greatly highlighted how providers in both primary care and cardiology were
not utilizing evidence-based tools to define a patient’s stroke risk and lessen their
bleeding risk, which ultimately could worsen patient outcomes (increased stroke risk) by
not prescribing anticoagulation appropriately. The utilization of screening tools by
providers within the patient chart reviews is summarized in Table 4 and Figure 6.

Table 4
Utilization of Screening Tools by Providers Within Patient Chart Reviews
Stroke and Bleeding Scores

Number of Patients

CHADS2

13 (9%)

CHA2DS2-VASc

19 (20%)

HAS-BLED

0 (0)%)

Unknown

68 (71%)
Total: 100
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STROKE AND BLEEDING SCORES
CHADS2
9%

CHA2DS2-VASc
20%

HAS-BLED
0%
Unknown
71%

Figure 6. Screening tools utilized by providers within patient chart reviews.

Patient Presentation: Symptomatic
of Asymptomatic
Approximately 30% of patients with AF present asymptomatically; yet, this
population demonstrates a higher CHA2DS2-VASc score and increased stroke risk.
Furthermore, 20% of patients are diagnosed with AF after suffering their first stroke
(Shahid et al., 2016). Patient chart reviews indicated 44 patients were asymptomatic and
56 were symptomatic, which was higher than the literature suggested. However, this
increase in asymptomatic patients could be related to the difficulty in determining
through chart reviews whether the patient was symptomatic when diagnosed since a large
percentage of patients was asymptomatic after being properly treated with rate and
rhythm control strategies.
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Clinical Manifestations
According to the CDC (2015), clinical manifestations of AF include heart
palpitations/irregular heart rate, dizziness, fatigue, shortness of breath, presyncope, and
chest pain. The researcher assessed for all the aforementioned clinical manifestations in
patient chart reviews. Of 56 patients who were symptomatic with AF, the following
symptoms were evident: 43 had fatigue, 21 had shortness of breath/dyspnea, 16 had chest
pain, 14 had dizziness/lightheadedness, 13 had fatigue, and 7 had syncope/pre-syncope.
Patients individually varied on the number of symptoms they experienced.
Risk Factors: Atrial Fibrillation,
Bleeding, and Stroke
During the chart reviews, risk factors for AF, bleeding, and stroke were all
evaluated. More specifically, risk factors for AF included obesity, heart failure, diabetes
mellitus, chronic kidney disease, hypothyroidism, alcohol abuse, obstructive sleep apnea,
and left ventricular hypertrophy (CDC, 2015; Ganz & Spragg, 2016). Risk factors for
stroke risk were obtained from the CHA2DS2-VASc criteria and included heart failure,
hypertension, age >65 years old, diabetes mellitus, prior stroke or TIA, vascular disease,
and female sex (Hwang, 2016a). Risk factors for bleeding risk were gathered from the
HAS-BLED criteria and included hypertension, abnormal renal disease, abnormal liver
disease, history of stroke, labile INR, age greater than 65 years old, concurrent drugs
increasing bleeding risk, and heavy alcohol use (Hwang, 2016b). Based upon these
results, the 10 most common risk factors for these 100 patients were age greater than 65
years old (78 patients), hypertension (71 patients), obesity (72 patients), female sex (44
patients), cigarette smoker (36 patients), diabetes mellitus (33 patients), chronic kidney
disease (33 patients), thromboembolism/hypercoagulable (31 patients), heart failure (29

118
patients) and valve disorder (29 patients). The significance of obtaining data was to
assess for risk factors increasing a patient’s risk for AF as treatment of these modifiable
risk factors could prevent the onset or progression of disease. In a patient with AF,
assessing for and reducing risk factors contributing to stroke risk and bleeding risk could
improve a patient’s treatment plan by ensuring the patient is receiving the correct
anticoagulant while minimizing negative sequeale of bleeding. Of note, 100% of patients
in these chart reviews were treated for modifiable risk factors for AF such as
hypothyroidism, hypertension, diabetes, sleep apnea, chronic kidney disease, and heart
failure, with appropriate lab monitoring to confirm the diseases were being controlled.
Also, providers were effective in educating patients on healthy lifestyle modifications
such as reducing alcohol consumption, weight loss, healthy diets, and smoking cessation,
which ultimately reduce the risk of AF as well as other chronic diseases. As early AF has
a genetic component (Shehab et al., 2010), patient charts were reviewed for a family
history of AF; only one patient mentioned a known family history of AF.
Current Anticoagulation Agent
According to 100 charts reviewed, 43 patients were on Warfarin©, 27 were on a
DOAC, 19 were on aspirin, 5 were on a combination therapy of aspirin and Plavix©, and
6 patients were on no anticoagulation to treat atrial fibrillation. The two most common
DOACs prescribed were Xarelto© (11%) and Eliquis© (13%). Literature recommended
aspirin for AF only with a CHA2DS2-VASc score of 1 (January et al., 2014; Meschia et
al., 2014); yet oral anticoagulants have proven superior to aspirin (Manning et al., 2016)
and due to the heightened bleeding risk, aspirin is not recommended as monotherapy
(Shahid et al., 2016). Thus, in this chart review, 24 patients with AF had not been treated
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according to current recommendations (monotherapty aspirin use or refusing any
anticoagulant treatment) and only 27 were prescribed DOACs when research clearly
demonstrated their safety and efficacy compared to warfarin. Dual antiplatelet therapy
with aspirin and Plavix© is recommended only if patients are unable to take oral
anticoagulants (Manning, Singer, & Lip, 2016; You, et al., 2012), thus justification can
be made for the five patients on Plavix and aspirin as an alternative anticoagulant
regimen. Rationales in the chart reviews for selecting an anticoagulant were limited but
included stroke risk, age, bleeding risk, dosing, patient preference, provider preference,
patient refusal, reversal agents, cost, food and/or drug interactions, insurance coverage,
renal function, compliance, and convenience. Better comprehension and awareness of
factors for prescribing a specific agent are essential to ensuring patients are receiving the
best individualized anticoagulant agent. The utilization of specific oral anticoagulation
agents with AF in these patient chart reviews is displayed in Table 5 and Figure 7.
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Table 5
Utilization of Specific Oral Anticoagulation Agents with Atrial Fibrillation
Current Anticoagulation Agent for AF

Number of Patients

Warfarin

43

Xarelto

11

Pradaxa

3

Eliquis

13

Savaysa

0

Aspirin

19

Aspirin + Plavix

5

None

6
Total: 100

CURRENT ANTICOAGULATION AGENT FOR AF
Aspirin + Plavix©
5%

None
6%

Aspirin
19%

Coumadin©
43%

Savaysa©
0%
Eliquis©
13%
Pradaxa©
3%

Xarelto©
11%

Figure 7. Specific oral anticoagulation agents utilized with atrial fibrillation.
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Negative Outcomes Related to Atrial
Fibrillation or Anticoagulation
The purpose of this capstone project was to decrease negative outcomes related to
poorly treated AF--predominantly reducing stroke risk. Strokes or TIAs occurred in nine
patients either before or after the diagnosis of AF, suggesting AF could have been a
contributing cause to this medical emergency. Approximately 750,000 hospitalizations in
the United States are related to AF (CDC, 2015) with 46.2% of emergency department
visits related to warfarin adverse effects (Budnitz et al., 2011). The researcher wanted to
evaluate how frequently patients were being hospitalized for AF (60 out of 100 patients),
with some patients requiring multiple hospitalizations and others requiring none,
primarily related to a new diagnosis of AF (symptomatic or atrial fibrillation rapid
ventricular rate) or supratherapeutic INRs. Only 27 patients went to the emergency
department related to AF, either for bleeding, supratherapeutic INRs, requiring a head
contrast tomography (CT) scan after a fall to assess for an intracranial bleed while on
anticoagulation or symptomatic AF.
Interesting, the annual bleeding risk while on anticoagulation is only 1.5%
(Hwang, 2016b); this was relevant as 18 patients in the chart reviews had
supratherapeutic (high) INRs, 13 had subtherapeutic (low) INRS, 7 suffered from
epistaxis, 8 had GI bleeds, 1 had hematuria, 1 had hemoptysis, and 2 patients required
reversal agents for bleeding.
The biggest concern with oral anticoagulants is intracranial hemorrhage;
regardless of the anticoagulant, intracranial bleeds occur in less than 1% of the population
annually (Desai et al., 2017). In these chart reviews, none of the 100 patients suffered
from an intracranial hemorrhage while on oral anticoagulation, enhancing the safety
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profile of these drugs to treat AF. Of note, the risk of intracranial hemorrhage was
reduced by half with NOACs in comparison to warfarin, yet the rate of gastrointestinal
bleeding increased, (Manning et al., 2016). This evidence corresponded to the patient
chart reviews as eight patients in this population developed gastrointestinal bleeds while
on anticoagulants. An assessment of HAS-BLED scores within the chart reviews would
have been helpful to determine if a reduction of risk factors for bleeding could have
diminished the incidence of bleeding in patients while on anticoagulation.
Approximately 17 patients displayed poor compliance to a treatment plan
including taking anticoagulants as recommended or follow-up with providers and INR
monitoring. Approximately 25 patients did not report any adverse outcomes related to
anticoagulation for AF, inferring these drugs could be safely prescribed when taken as
directed. However, these drugs do not come without risk and thus require close
monitoring by providers to assess for and treat any complications that might arise.
Providers must ensure they are thoroughly educating patients on the importance of taking
anticoagulants as directed to reduce negative sequelae on both ends of the spectrum-bleeding and stroke. Compliance is a factor that should be considered when prescribing
anticoagulation including the half-life of drugs, once or twice daily dosing, and INR
monitoring to improve patient outcomes. Negative outcomes related to AF and/or
anticoagulation for the patient chart reviews are summarized in Table 6.
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Table 6
Negative Outcomes Related to Atrial Fibrillation and/or Anticoagulation
Negative Outcomes Related to AF and/or
Anticoagulation
Stroke/TIA (before or after AF diagnosis)

Number of Patients
9

Hospitalization

60

Supratherapeutic INR

18

Subtherapeutic INR

13

Epistaxis

7

GI Bleed

8

Bleed Requiring Reversal

2

Fall

12

Emergency Department

27

Hematuria

1

Hemoptysis

1

Poor Follow-Up or Compliance
Intracranial Hemorrhage
None

17
0
25

N = 100

Gaps Between Evidence and Practice
The researcher discovered other gaps between evidence and practice for patients
with AF when reviewing local patient chart reviews. No annual EKGs were obtained for
patients greater than age 65 years old despite recommendations suggesting this aging
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population is at the highest risk for developing AF (Kirchhof et al., 2016; Meschia et al.,
2014; Shahid et al., 2016). Furthermore, providers did not consistently obtain an EKG
with an irregular pulse on examination to diagnose AF (Kirchhof et al., 2016). An EKG
was obtained more often in a patient who was symptomatic while in the clinic.
Interestingly, five patients were diagnosed with AF pre-operation or pre-procedurally
(mostly asymptomatic) and eight patients were diagnosed with AF post-operatively,
which is also a risk factor for AF onset (Kumar, 2016b). Despite inconsistencies of EKG
analysis, providers correctly ordered subsequent testing for AF such as thyroid
stimulating hormone, echocardiography, and ambulatory EKG monitoring (Kirchhof et
al., 2016). The researcher attempted to derive from chart reviews whether patients were
diagnosed with paroxysmal, persistent, or permanent atrial fibrillation. However, those
terms were not commonly used and were difficult to decipher within the charts as
multiple terms were often used to classify the type of AF for the same patient dependent
on the provider.
Commonalities between research and practice were also evident in the patient
chart reviews. With atrial fibrillation, providers consistently used a goal INR of 2.0 to
3.0 for warfarin as recommended by guidelines (You, et al., 2012). For providers
managing INRs within the clinic, anticoagulation tools were built into the electronic
health records (EHRs) to document the history and trends of the INRs and corresponding
warfarin levels as well as to determine the appropriate dose and frequency of warfarin.
This tool was helpful in maintaining more therapeutic INRs. Yet, chart reviews
demonstrated the INRs of 24 patients were managed by an anticoagulation clinic, INRs of
13 patients were managed by the primary care provider, and INRs of two patients were
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managed at home. As noted prior, a minimum of 18 patients had documented
supratherapeutic INRs and 13 had subtherapeutic INRs, suggesting the management of
warfarin was less than ideal to prevent negative outcomes. The risk of thromboembolism
increases with an INR < 2, and the risk of bleeding increases with an INR > 4, especially
> 5 (Hirsh et al., 2003); labile INR replacement of warfarin with a DOAC is
recommended (January et al., 2014). Research recommended INRs are best managed by
the patient or a clinic compared to provider management (Hull & Garcia, 2016b); thus,
increased utilization of anticoagulation clinics or home monitoring of INRs could reduce
labile INRs and associated negative outcomes of bleeding and stroke.
Providers used multiple recommended treatment options for AF in addition to
anticoagulation: rate control in 88 patients, rhythm control in 22 patients, MAZE
procedure in two patients, pacemaker implantation in 16 patients, WATCHMAN
insertion in three patients, ablation in 24 patients, and cardioversion in 32 patients. As
aforementioned, providers were congruent with treating risk factors and chronic
conditions associated with AF appropriately. However, medication reconciliation was
not consistent between providers and specialists, posing a safety issue for the patients
such as double dosing of anticoagulants. Also, the EHRs mislabeled patients with a
thromboembolism who required chronic anticoagulation as atrial fibrillation, marking an
incorrect diagnosis in patients’ charts.
According to the ESC (Kirchhof et al., 2016), patient involvement, a
multidisciplinary team, complex management decisions, and a navigation system are all
essential for successful management of AF. Multidisciplinary care was evident in the
chart reviews for patients with AF: 74 of the 100 patients were referred to cardiology, 11
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patients saw electrophysiology in addition, five patients were seen at the heart failure
clinic, and five patients received additional services through case management.
Providers, both primary care and specialists, were excellent educators when discussing
how medications such as antibiotics could affect INRs, explaining the differences
between oral anticoagulants including risks and benefits, patient preference into the
treatment plan, encouraging compliance to a treatment plan to reduce bleeding and stroke
risk, the importance of consistent INR monitoring, and symptoms signifying AF.
Results from Delphi Surveys
Phase 1: Delphi Study Round 1
Results
The Delphi Study Round 1 Survey was created via Survey Monkey with a
specific weblink e-mailed to each provider individually including the consent form as an
attachment (see Appendix H). Participation was implied if the provider completed the
survey via Survey Monkey. The Round 1 survey containing 10 qualitative and
quantitative questions was sent to 17 providers and the researcher received responses
from 13 providers. Five of these providers were forwarded the informed consent and
Survey Monkey link through e-mail via another provider. The Round 1 survey took
providers 2 to 20 minutes to complete with an average time of seven minutes. The
researcher was notified through e-mail when new survey results were received via Survey
Monkey and subsequently the data were easily accessible to statistically analyze. A
statistical data analysis for the Round 1 survey was calculated through measures of
central tendency: mean, median, and mode.
Regarding demographics, four providers were MDs, one was a DO, five were
NPs, and three were PAs. Four of the providers specialized in family practice, five in
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cardiology, two in electrophysiology, and one in cardiovascular surgery. The experience
level of providers ranged from less than one year to 20 years with an average of four to
seven years in practice. The comfort level of the providers in managing atrial fibrillation
varied; one provider ranked the comfort level as “0”--very uncomfortable, two providers
ranked the comfort level as “3,” three providers ranked the comfort level with a score of
“4,” and seven providers ranked the comfort level as “5”--very comfortable. Therefore,
the mix of survey responses was diverse and covered a wide range of specialties,
didactics, training, and experience levels. Out of 10 questions, >70% consensus was
achieved on the following questions:
•

Palpitation (11 providers) and syncope/presyncope (8 providers) were noted
as presenting symptoms of AF, warranting a further work-up.

•

100% of providers did not routinely screen for AF through a pulse check in
patients >65 years old.

•

An EKG was used by 12 providers to diagnose AF.

•

Oral anticoagulants were prescribed by 10 providers to treat AF.

•

Furthermore, the CHA2DS2-VASc score was a commonly used screen tool
for initiating anticoagulation according to nine providers (a score of >2
warranted anticoagulation with two providers, a score of 1 warranted
anticoagulation with two providers, and an unspecified score was elucidated
by six providers).

•

A CHA2DS2-VASc score was used to assess stroke risk by 11 providers, a
CHADS2 score was used by five providers to assess stroke risk, and the
HAS-BLED score was used by 7 providers to assess bleeding risk; multiple
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providers mentioned they utilized both the CHADS2 and CHA2DS2-VASc
tools.
The most common guideline utilized by providers to treat AF was the American
College of Cardiology (2012), yet a 70% consensus was not reached with this question.
Additionally, a 70% consensus was not achieved with questions asking what would be
most helpful in a guideline, least helpful in a guideline, and improve the management of
AF. Thus, the researcher attempted to include all these requests and suggestions into the
revised Anticoagulation for Atrial Fibrillation Toolkit in addition to the responses
achieving 70% expert consensus. The researcher originally attempted to create one
algorithm for this guideline but due to the complex nature of managing AF, four
algorithms were designed to simplify and clarify the treatment regimen. Providers were
given a summary of the 70% consensus from Round 1 when they were given the link to
take the Round 2 survey through Survey Monkey. Data analysis from Phase 1: Delphi
Study Round 1 is summarized in Tables 7 through 16 including clarification of which
responses obtained 70% expert consensus.
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Table 7
Summary of Responses for Survey Question 1: Please Fill in the Following
Demographics
Demographics

Number of Providers

Participants
MD
DO
NP
PA

4
1
5
3

Specialty
Family
Cardiology
Electrophysiology
Cardiovascular Surgery

4
5
2
1

Number of Years in Practice
0-3
4-7
8-11
12-16
17-20
Number of Providers = 13

2
5
1
3
2
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Table 8
Summary of Responses for Survey Question 2: What Patient Presentation (Symptoms and
Risk Factors) Warrants a Work-Up for Atrial Fibrillation?
Symptom or Risk Factor
Fatigue

Number of Providers (13 total)
3

Palpitations

11 (>70% consensus)

Chest Pain

4

Syncope/Presyncope

8 (>70% consensus)

Poor Sleep

1

Weakness

1

Shortness of Breath/Dyspnea on Exertion

5

Dizziness/Lightheadedness

4

Level of Consciousness

1

EKG Results

1

Stroke/TIA

3

History of AF

1

Congestive Heart Failure

1

Coronary Artery Disease

1

Unspecified

1
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Table 9
Summary of Responses for Survey Question 3: Do You Screen for Atrial Fibrillation in
All Your Elderly Patients Older Than 65 Years Old?
Screening for Atrial Fibrillation
Yes
No

Number of Providers
0
13 (>70% consensus)

Table 10
Summary of Responses for Survey Question 4: Explain Your Work-Up for Diagnosing
Atrial Fibrillation
Diagnostic Tool
12-Lead EKG

Number of Providers
12 (>70% consensus)

Thyroid Stimulating Hormone

3

Complete Blood Count

1

Echocardiogram

1

Event/Holter Monitor

8

Telemetry

3

Obstructive Sleep Apnea

2
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Table 11
Summary of Responses for Survey Question 5: How Do You Typically Treat Patients with
Atrial Fibrillation?
Treatment
Oral Anticoagulant (Warfarin or DOAC)

Number of Providers (13 total)
10 (>70% consensus)

Rate Control Medication

6

Echocardiogram

1

Treat Risk Factors

1

Cardioversion

2

Consider Rate vs. Rhythm Control

3

Rhythm Control

4

Refer to Cardiology

3

Treatment Dependent on Symptoms and Age

1

Treatment Dependent on Symptoms or Heart Failure

1
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Table 12
Summary of Responses for Survey Question 6: Which Factors Influence Your Decision to
Initiate Anticoagulation in a Patient With Atrial Fibrillation Including Selection of a
Particular Agent?
Factors Influencing Anticoagulation

Number of Providers (13 total)

CHA2DS2-VASc Score

9 (>70% consensus)

Score >1

2

Score ≥2

2

Unspecified

5

Cost of Medication/Insurance Coverage

4

Patient Compliance

1

Cognitive Ability

1

Valve Disease

2

Age

4

Patient Preference

4

Risk for Stroke

3

American College of Cardiology Guidelines

1

Bleeding Risk

2

Contraindications or Oral Anticoagulants

1

CHADS2 Score

1

Provider Preference

2

AF with a Duration >5 Minutes

1

Co-morbidities

1

Ease of Use

1

Does not Manage Anticoagulants

1
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Table 13
Summary of Responses for Survey Question 7: What Is Your Comfort Level with
Prescribing and Managing Anticoagulation for Atrial Fibrillation?
Comfort Level Score
0

Number of Providers (13 total)
1

1

0

2

0

3

2

4

3

5

7

Note: Scale of 0 very uncomfortable to 5 very comfortable

Table 14
Summary of Responses for Survey Question 8: Do You Use Any Screening Tools to
Assess for Stroke and Bleeding Risk with Anticoagulation and Atrial Fibrillation?
Screening Tool
CHADS2
CHA2DS2-VASc

Number of Providers (13 total)
5
11 (>70% consensus)

HAS-BLED

7

None

1
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Table 15
Summary of Responses for Survey Question 9: Atrial Fibrillation Guidelines and
Algorithms
What guidelines, algorithms, or resources
do you reference for anticoagulating and
treating atrial fibrillation?

Number of Providers (13 total)

Chest Guidelines
AF in American Family Physician
Magazine
UpToDate
American College of Cardiology (ACC)
CHA2DS2-VASc
American Heart Association (AHA)
None

1
1

What would you find most helpful in an
AF algorithm or guideline?
Simple/Straightforward
Unambiguous/Easy to follow
Evidence-Based
What is Considered Valvular Disease
List of Medication Options (including rate
and rhythm control)
Risk of Stroke Calculated
Not Applicable

Number of Providers (13 total)

What would you find least helpful in an
AF algorithm or guideline?
Too Complex or Lengthy
List of Medication Options
Ambiguity
Subjectivity (ex. definitions)
Focusing on the Negatives of NOACs
No Clear Recommendations
Not Applicable

Number of Providers (13 total)

1
5
2
1
2

4
2
2
1
2
1
2

2
2
1
1
1
1
4
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Table 16
Summary of Responses for Survey Question 10: Which of the Following Would Improve
Your Management of Anticoagulation for Patients with Atrial Fibrillation: Community
Resources, Specialists, Shared Decision-Making Tools, Websites, Phone Apps, More
Anticoagulation Clinics, Etc.?
Tools to Improve Management of AF

Number of Providers (13 total)

Specialists

2

Phone Apps

5

More Anticoagulation Clinics

3

Simplified Algorithms

3

Patient Education Resources

2

Shared Decision-Making Tools

2

CHA2DS2-VASc Calculation in Algorithm

1

Know When to Refer to Specialists

1

Ease to Find Current Guidelines

1

Cost of DOACs

1

Phase 2: Delphi Study Round 2
Results
The Delphi Round 2 survey link through Survey Monkey was e-mailed to the 13
providers who completed Round 1 of the survey along with a summary of the results
from Round 1, which received greater than 70% expert consensus. As the survey results
were anonymous, the researcher attempted to rationalize which providers responded to
the Round 1 survey based upon knowledge of the individual providers (specialty, title, or
years in practice). The attrition rate for this survey was low as only four providers
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completed Round 2. With no demographics listed, the researcher was unable to
determine which providers responded to Round 1 and thus could not send a reminder email to obtain more results nor readdress individual perspectives of the providers
discovered in Round 1.
A statistical data analysis for Round 2 was calculated through measures of central
tendency: mean and mode. Of these four providers, greater than 70% agreed the
anticoagulation toolkit was
•

Straightforward and user-friendly

•

Improved safety and efficacy of anticoagulation

•

Influenced future practice

•

Applicable to practice

•

Inclusive of evidence-based practice.

Consensus was achieved on a benefit of this toolkit as being user-friendly and
straightforward; yet, this response was already analyzed and accounted for in Question 1
of the survey. Consensus otherwise was not achieved on quantitative questions
addressing benefits, challenges, and other feedback for the anticoagulation toolkit.
However, providers noted the toolkit was too lengthy and contained too much
information, which was accounted for by the researcher and will be addressed in future
revisions of this toolkit. Overall feedback from the providers implied the providers
perceived this toolkit as beneficial. Table 17 provides Delphi Survey Round 2 results for
qualitative questions (open-ended) where 70% consensus was not achieved.
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Table 17
Delphi Survey Round 2 Results Where Consensus Was Not Achieved
Question

Open-Ended Answer

6. What are the benefits of this
toolkit?

Evidence-based

7. What are the challenges of this
toolkit?

Number of
Providers
1

Straightforward/Easy to
Follow
Compiles Many Resources
into One Place
Up-To-Date

3

Lengthy

1

Too Much Information
N/A

2
1

Thorough Toolkit
Look Forward to Using It
Passion for Topic
Minor Changes

1
1
2
1

1
1

8. Any other feedback, questions,
or concerns?

Objective One Outcomes
Objective 1 was to examine current and local diagnosis and management of atrial
fibrillation within the primary care setting; this objective was fulfilled in its entirety. A
total of 100 EHRs in Next Generation were confidentially reviewed retrospectively and
analyzed within a privately owned primary care clinic in Greeley. Patients were included
in the study if they met the criteria of a diagnosis of AF and were seen in the clinic for
this diagnosis during 2017. The researcher planned to retrospectively review only 75
charts, yet exceeded this goal by obtaining data from 100 electronic patient charts. All
required information was obtained from the 100 patient charts with AF including
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demographics, diagnosis, management, risk factors, negative outcomes, and utilization of
screening tools. Through statistical analysis of these data, the researcher was
successfully able to highlight current management and diagnosis of atrial fibrillation
while also identifying gaps in practice according to current evidence-based guidelines.
Objective Two Outcomes
The second objective was to create a toolkit (guideline with algorithms) directing
practitioners on diagnosis of atrial fibrillation as well as initiation and management of
oral anticoagulation; this objective was successfully executed. The evidence-based
Anticoagulation for Atrial Fibrillation Toolkit followed its original design based upon
literature review, current guidelines on anticoagulation, and expert opinion from two
rounds of Delphi surveys. Round 1 assessed providers’ comfort level and expertise with
prescribing anticoagulants and diagnosing and managing AF while Round 2 evaluated the
anticoagulation toolkit and how its incorporation could influence practice. Results from
Round 1 were utilized to revise the anticoagulation toolkit the researcher had drafted
based upon literature; data analysis concluded 70% consensus was achieved on at least
five questions. Even without 70% consensus, the researcher incorporated provider
expertise, suggestions, and requests into the anticoagulation toolkit. In Round 2, data
analysis of greater than 70% consensus suggested the anticoagulation toolkit was
evidence-based, safe, efficacious, user-friendly, and could positively impact practice.
The toolkit was revised after Round 1 and divided into two sections to enhance its
usability and relevance to practice. The first section, composed of the guideline with
algorithms, remained unchanged as these toolkit components were step-wise,
straightforward, concise, and evidence-based. The guideline with algorithms achieved
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the goal of not only encouraging improved diagnosis and management of AF but
promoting assessment for patient specific factors driving prescription of a specific
anticoagulant.
The second section of the toolkit contained multiple resources for providers and
was formulated based upon requests from providers as well as evidence suggesting how
best to manage atrial fibrillation. This toolkit achieved the purpose of providing one
reliable resource for providers to review when managing anticoagulants as well as
offering resources to better educate patients, enhance patient-provider relationships, and
promote multidisciplinary care.
Objective Three Outcomes
The third objective was to promote safety and efficacy in the management of
anticoagulants; this objective was completed simultaneously with the second objective as
the literature review and expert opinions were the foundation for this Anticoagulation for
Atrial Fibrillation Toolkit. A core element of this toolkit was promoting safety and
efficacy when prescribing anticoagulants; thus, available literature on all five
anticoagulants and their corresponding noteworthy drug trials, (warfarin, dabigatran,
apixaban, rivaroxaban, and edoxaban) were scrutinized thoroughly and presented in a
chart format in this capstone project. Two shortened versions of this chart--one
comparing anticoagulants in general and one comparing individual patient factors
influencing selection of a specific oral anticoagulant—as well as two algorithms were
included in the anticoagulation toolkit. Providers were given multiple resources in the
toolkit on where to find more reliable information on drug trials and individual oral
anticoagulant agents. As calculated through statistical analysis, greater than 70%
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consensus from the Delphi Round 2 survey implied providers agreed the Anticoagulation
for Atrial Fibrillation Toolkit could improve safety and efficacy of anticoagulant therapy.
Objective Four Outcomes
The fourth objective was to endorse patient-centered anticoagulation based upon
current evidence-based literature and expert opinion; this objective was achieved
alongside the first and second objectives as the literature review and expert opinions were
the foundation of this toolkit. Summaries from key anticoagulation guidelines and
landmark drug trials comprised the majority of literature reviewed on this topic. As
mentioned in the third objective within this capstone, background information,
pharmacokinetics, and pharmacodynamics on the five individualized drugs (warfarin,
apixaban, rivaroxaban, edoxaban, and dabigatran) were obtained from the FDA
prescribing information (CDC, 2015) along with a comparison of novel drug trials to
assess the safety and efficacy of the oral anticoagulants. The webpage link for novel drug
summaries was included in the anticoagulation toolkit to provide a reliable and easy to
navigate link for providers to review conclusions from drug trials on anticoagulants.
Within the Anticoagulation for Atrial Fibrillation Toolkit, two algorithms focused on
selecting the anticoagulant for the patient: (a) individual patient factors to consider when
prescribing anticoagulants and (b) a general summary comparing warfarin to DOACs.
As calculated through statistical analysis, greater than 70% consensus from the Delphi
Round 2 surveys implied providers considered this toolkit as inclusive of evidence-based
practice to promote individualized anticoagulation. Objectives 3 and 4 were synonymous
as prescribing patient-specific anticoagulation is dependent on the safety and efficacy of
the anticoagulant agent.
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Objective Five Outcomes
The fifth objective was to evaluate the effectiveness of a toolkit influencing the
diagnosis of atrial fibrillation and anticoagulation management within a primary care
setting. This objective was effectively accomplished as the Anticoagulation for Atrial
Fibrillation Toolkit was evaluated through the Round 2 Delphi survey by four providers
who through greater than 70% consensus agreed this guideline was straightforward, userfriendly, influential, and applicable to practice. The Delphi surveys were 100%
completed through Survey Monkey, allowing the provider to easily review the data and
analyze the results. Furthermore, the PARIHS and RE-AIM frameworks were
successfully utilized to evaluate the anticoagulation toolkit. In accordance with the
PARIHS framework, this evidence-based and innovative toolkit was tailored to the target
audience (providers treating patients with AF) and context (primary care setting).
Providers who completed the Delphi surveys varied in their comfort level with AF
management, experience, and specialty; thus, the results of these surveys were utilized to
create a toolkit inclusive of diverse knowledge and input, which ultimately would
improve its facilitation into practice. The RE-AIM framework successfully examined
how this toolkit could reach its intended population (primary care providers managing AF
patients), evaluate the impact of this toolkit in the primary care setting, brainstorm
techniques to enhance adoption by addressing barriers to implementation, and strengthen
utilization of this toolkit over time (through Delphi surveys). Implementation of this
toolkit into practice and evaluating its influence on reducing stroke in AF is a future
extension of this project.
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Key Facilitators, Key Barriers, and Unintended
Consequences to Project Objectives
Key Facilitators
This researcher was very passionate with the topic of this project, enhancing its
success and contributing to its comprehensiveness and effective execution. Dedication,
ambition, and curiosity fueled the extensive evidence-based literature review including a
comprehensive summary of oral anticoagulants and noteworthy drug trials. For the chart
reviews, the researcher was very familiar with the EHR (Next Generation) and thus could
easily navigate through patient records to obtain the desired information. Also, the clinic
manager selected only the patients seen in the clinic for 2017 with a diagnosis of AF, thus
simplifying relevant patients to review. The researcher had a goal of 75 patient charts to
review and exceeded this goal by reviewing 100 charts of diverse patients with AF.
Survey Monkey streamlined the process of the Delphi surveys immensely as the
researcher easily created surveys, designed a unique web-link, and e-mailed this web-link
to providers individually and confidentially. The researcher was even alerted via e-mail
when surveys were returned and could access and statistically analyze these results
effortlessly and quickly. Measures of central tendency--mean, median, and mode--were
utilized to analyze the data for the Delphi surveys and patient chart reviews. The
guideline and algorithm components of this toolkit were evidence-based, user friendly,
applicable and influential to practice, and could improve the safety and efficacy of
anticoagulation as demonstrated by >70% consensus in Round 2 of the Delphi survey.
Furthermore, the first round of the Delphi survey and consent form were forwarded and
completed by five interested providers, not only increasing the number of subjects for the
Delphi surveys but also expanding the specialties to include electrophysiology and
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cardiovascular surgery. The researcher utilized evidence from research as well as expert
requests and suggestions when modifying this Anticoagulation for Atrial Fibrillation
Toolkit by adding a large section on provider resources to improve the practice of
diagnosing and managing AF, especially with the targeted population of older adults.
This capstone project was technologically savvy by utilizing electronic databases for
literature review, EHRs to compare evidence to practice, Survey Monkey to complete
surveys, e-mail communication, and Microsoft Office to formulate the capstone paper
and anticoagulation toolkit.
Key Barriers
The researcher was unaware of the complexity of AF management when initiating
this project as anticoagulation is only a fragment of the entire treatment plan. The
researcher expanded the literature review on AF to be inclusive of all relevant avenues of
risk factors, diagnosis, treatment, and negative outcomes of the disease; however, this
also become problematic when trying to make the anticoagulation guideline succinct
while also relevant to the desired audience. The researcher concluded EHRs are not user
friendly and important data were often hidden, misconstrued, or difficult to find,
especially when records from outside sources were intermingled. Consequently, the chart
reviews become more complex and took longer than anticipated to obtain all the required
data.
Regarding the Delphi surveys, the researcher was unable to determine which
providers returned the surveys due to anonymity. A good return rate was noted for the
first round of the survey (13 out of 17 providers), yet there was a poor return rate for the
second round (4 of 13 providers). An original two-week return rate was proposed for the
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Delphi surveys; yet due to time constraints, providers were requested to return the
surveys within one week. The lack of time to complete the surveys could have
contributed to the poor return rate. In Round 1, providers were reminded via e-mail to
complete the survey if they did not return it within the requested time, increasing the
response rate by three providers. However, time constraints and anonymity of the
providers (as demographics were not collected in Round 2) limited the ability to wait for
further results from the Round 2 survey. In the Round 1 survey, a limited 70% consensus
was obtained so the researcher attempted to include suggestions and requests from
providers to improve AF management despite this lack of consensus. In Round 2, a 70%
consensus was achieved for all five of the qualitative questions; however, the poor
attrition rate was attributed to the length of the toolkit and extent of content as these
challenges were noted by providers in the survey. Due to the intricacy of the evidence
available to diagnose and manage AF, the researcher had difficulties trying to divide the
toolkit into a guideline with algorithm section followed by a provider resources section.
The table of contents helped with this delineation but despite requesting providers at a
minimum review the guideline and algorithms for this project, it is presumed this clarity
was not apparent and providers did not choose to review a 30-page toolkit. Reformatting
the toolkit to be more concise or possibly dividing it into two separate papers--one a
guideline with algorithms and the other with provider resources--are plausible future
expansions of this project to improve its relevancy and implementation into practice.
Unintended Consequences to
Project Objectives
Unfortunately, the clinic where the chart reviews were completed displayed a
poor attrition rate for the Delphi survey portion of this test. The clinic was welcoming,
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helpful, and supportive of this research project but the lack of follow-up and participation
with the project was discouraging. One provider wanted to know the results of the chart
reviews to help utilize these conclusions to improve practice; the researcher will followup with the results of this entire study with any providers who voice interest in learning
more about this AF toolkit, its implementation into practice, and how to improve the
overall diagnosis and management of AF in the primary care setting. Even though this
project was directed toward primary care providers, only four of the 13 providers who
volunteered to participate in this study specialized in primary care, leaving nine providers
who specialized in cardiology or some specialty. One primary care provider even noted a
poor comfort level with AF, refusing to treat these patients and referring them to
cardiology. Knowing one’s comfort level, scope of practice, and expertise are necessary
to practice medicine well; however, primary care is the first place most acute and chronic
diseases are presented, diagnosed, and treated so AF cannot be the exception. These
findings clearly represented how little emphasis providers, especially in the primary care
realm, gave to AF despite the high risk of stroke and its effect on quality of life. The lack
of response from primary care providers suggested improved education and awareness
are both needed to improve the diagnosis and management of AF. The Anticoagulation
for Atrial Fibrillation Toolkit is a straightforward, evidence-based, and comprehensive
resource to guide providers on the recommended path to properly treat AF to reduce its
negative sequelae; with implementation, it offers the possibility of improved management
of AF. No issues with breeches of confidentiality with either patient- or provider-specific
data occurred with this project. No harm to participants was evident and no unexpected
financial costs arose.
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CHAPTER V

RECOMMENDATIONS AND IMPLICATIONS
FOR PRACTICE

Conclusions
The purpose of this capstone project was to address the following problem
statement: In adult patients with atrial fibrillation older than 65 years old and a moderate
to high risk of stroke, how effective is an anticoagulation toolkit in guiding primary care
providers on (a) diagnosing atrial fibrillation and (b) initiating and maintaining oral
anticoagulation safely, to reduce the incidence of ischemic stroke? An extensive and
current literature review was completed on atrial fibrillation, focusing on the diagnosis
and management of atrial fibrillation. As the capstone highlighted the importance of
anticoagulating elderly patients with atrial fibrillation to prevent the incidence of stroke, a
comprehensive comparison of warfarin and the four DOACs as well as a summary of
noteworthy drug trials were included to address safety and efficacy of these drugs. The
literature review not only provided extensive background information on atrial fibrillation
and anticoagulation but also highlighted key references to first compare evidence to
practice (analyze patient chart reviews) and then utilized these identified gaps to translate
evidence into practice (create the anticoagulation toolkit).
Chart reviews were retrospectively reviewed on 100 patients in a primary care
setting, assessing the diagnosis and treatment of AF. In comparing evidence to practice,
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inconsistencies were evident--predominantly a lack of utilization of CHA2DS2-VASc and
HAS-BLED scores to assess for stroke and bleeding risk, poor continued monitoring of
AF in the primary care setting, a disconnect between the treatment plan and providers,
and the absence of consistently diagnosing an irregular pulse as AF through an EKG.
Through utilization of two rounds of the Delphi method, expert opinions, and
recommendations of national and international guidelines, an evidence-based
anticoagulation toolkit was created and modified to guide primary care providers on
improving diagnosis of atrial fibrillation and enhanced initiation and maintenance of oral
anticoagulation to reduce the incidence of stroke in elderly patients with atrial fibrillation.
This toolkit consisted of a four-step, simplified guideline supported by four algorithms:
(a) CHA2DS-VASc score, (b) HAS-BLED score, (c) comparison of anticoagulants, and
(d) patient-specific factors influencing selection of anticoagulant. Additionally, this
toolkit offered in one document a summary of additional information and resources for
providers to improve the overall management of atrial fibrillation. Round 1 of the Delphi
method suggested no providers assess for AF annually through a pulse check in patients
older than 65 years old despite the increased risk of AF in the elderly and the high
incidence of asymptomatic patients. In Round 2 of the Delphi survey, all providers felt
the AF toolkit was evidence-based, applicable, influential to practice, user-friendly, and
promoted safety and efficacy; however, the toolkit was too extensive and lengthy.
In summary, this capstone project answered the problem statement. The literature
review, patient chart reviews, and two rounds of the Delphi method addressed how to
effectively and safely diagnose atrial fibrillation in the elderly population as well as
initiate and manage anticoagulation. However, a future research project focusing on
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implementation of this toolkit in practice could better evaluate the maintenance phase of
anticoagulation and how this toolkit could reduce the incidence of stroke in this high-risk
population.
Recommendations for Guideline Implementation Within
the Framework of the Organizations’ Strategic Plan
Phase 6 of this project entails a future pilot study to assess the impact on patient
outcomes related to implementation of this anticoagulation toolkit into the primary care
setting. Thus far, this capstone project has only completed two rounds of the Delphi
method and requires further consensus on how to make the toolkit more concise and
relevant to providers within the primary care setting. Obtaining input from specialists is
essential to determine what resources, guidelines, and practices are utilized by experts in
the field. However, the toolkit must be tailored to the audience and ultimately reflect
what the primary care providers, in this instance, require and want to improve their
practice while still ensuring their practice is current and based upon expert and evidence
consensus. Expanding knowledge on atrial fibrillation diagnosis and management is a
priority action to ensure providers are up to date and providing the best practices for their
patients, thus supporting this extensive toolkit with a guideline and algorithms. Providers
do not have time to seek reliable and most current resources for every diagnosis they
encounter, especially in primary care; thus, by educating providers on how this toolkit
summarizes multiple reliable resources in one document, the diagnosis and treatment of
AF can be step-wise, simplified, and manageable to improve patient outcomes.
Additionally, encouraging providers to follow this evidence-based guideline and remain
up to date with guidelines is essential. For instance, the consensus from the first round of
the Delphi survey suggested 100% of 13 providers did not screen annually for AF in
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every elderly patient older than 65 through a pulse check, even though this is
recommended by the AHA/ASA and ESC as a means of primary prevention (Kirchhof et
al., 2016; Meschia et al., 2014).
Through the first round of the Delphi survey, providers were asked what
resources would be beneficial to improve their management of atrial fibrillation.
Although 70% consensus was not achieved for any of these requests, the researcher still
incorporated all these ideas into the toolkit, especially phone apps, referrals to specialists,
and shared decision-making tools. Further revisions of this toolkit through consensus of
more Delphi rounds is necessary to meet the following requirements for an effective
toolkit: the importance of including patients in the plan of care, making evidence easy to
access and utilize, and incorporating multidisciplinary care into the treatment plan. To
improve the implementation of this toolkit, organizations should provide care to a diverse
population of patients with AF; display similarities in their missions, values, perspectives,
and approaches to diagnosing and managing atrial fibrillation; and remain open-minded
to change.
Recommendations for Evaluation of
Anticoagulation Toolkit
Delphi Surveys
The Anticoagulation for Atrial Fibrillation Toolkit (guideline with algorithms)
was evaluated based upon its ability to uphold the elements of the PARIHS framework
and RE-AIM model. The second round of the Delphi survey evaluated the benefits and
challenges of this toolkit and achieved 70% consensus for its ability to be straightforward
and user-friendly, evidence-based, applicable to practice, influential to practice, and
promote safety and efficacy of anticoagulation therapy. However, the responses were
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limited in this second round compared to the first, contained mostly close-ended
questions, and only touched the surface of how to improve this toolkit. Further rounds of
the Delphi survey through Survey Monkey would be helpful to better assess and meet the
requirements and requests of providers who manage AF, ensuring this toolkit is more
applicable and relevant to practice. Reducing the length of this toolkit could be less
intimidating to providers to review, which could reduce the low attrition rate of the
surveys.
Promoting Action on Research
Implementation in Health
Services Framework
The three elements of the PARIHS framework (evidence, context, and facilitation
into practice) were ranked on a scale from low to high (Rycroft-Malone, 2004). Onehundred patient charts in Greeley were reviewed to assess for data, a comprehensive
literature review on current evidence and best practice was completed, and expert
opinions from 13 providers were acquired through two rounds of the Delphi surveys
(High Evidence). Evidence from the literature review and expert consensus from the
Delphi surveys were incorporated into an anticoagulation toolkit for diagnosing and
treating atrial fibrillation in the primary care setting (High Context). The expert
consensus was diverse including primary care, cardiology, cardiothoracic surgery, and
electrophysiology providers; the more experienced clinicians and those who specialized
in the cardiovascular system acted as leaders when voicing their opinions on the Delphi
surveys. The chart reviews were culturally diverse as well as they were composed of 100
patients in both rural and urban settings, ranging from ages 30 to 100, both male and
female, and comprised of many races/ethnicities. The facilitator for this project was the
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researcher who compiled a large array of research on the topic of AF into one resource
(the anticoagulation toolkit) for providers to utilize to improve practice. Observations
from the chart reviews were analyzed to compare evidence to practice. Utilization of the
Delphi surveys was a means to seek expert comments on the efficacy and feasibility of
the toolkit’s use (Low Facilitation into Practice). Facilitation was ranked low as only two
rounds of the Delphi surveys were completed and this toolkit has not yet reached
adequate consensus to be implemented into practice. Elements of the iPARIHS model
(Harvey & Kitson, 2016) were incorporated into the evaluation of this toolkit: this toolkit
was comprised of a simple guideline and four complementary algorithms followed by a
section summarizing additional information and resources for providers (innovation).
Also in accordance with the iPARIHS model, the focus for this toolkit was primary care
providers; the presumption was knowledge on AF was more limited for a generalist
rather than a specialist (recipients, context levels, and experience of the facilitators), thus
requiring a more comprehensive resource section to better manage AF.
Reach, Effectiveness/Efficacy,
Adoption, Implementation,
and Maintenance Model
The RE-AIM model was utilized for this capstone project to assist with the
effective implementation and evaluation of this anticoagulation toolkit (RE-AIM, 2017).
Reach addressed the target population of elderly patients with a new or chronic diagnosis
of atrial fibrillation within the primary care setting including patients with diverse
demographics, co-morbidities, and treatment plans. Effectiveness was the impact of this
anticoagulation toolkit to prevent stroke in patients with atrial fibrillation. As this toolkit
has not yet been implemented into practice, this element of the RE-AIM model was not
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met. Adoption assessed the willingness and feasibility of primary care providers to
incorporate this toolkit into practice. This toolkit has not been implemented into practice
but in Round 2 of the Delphi Survey, greater than 70% consensus agreed this toolkit was
applicable to practice and could influence future practice of AF. Implementation
addressed the factors contributing to the successful use of this toolkit in primary care,
which was evident in the algorithm comparing oral anticoagulants in general as well as
the algorithm assessing patient specific factors to consider when selecting an oral
anticoagulant. Maintenance assesses the duration of the implementation of this toolkit in
practice; however, as this toolkit is only in its preliminary stages, this component of REAIM was not currently applicable to this capstone project.
Ongoing Activities or Evaluations Outside the Scope
of the Doctor of Nursing Practice Project
This Doctor of Nursing Practice (DNP) project shed light on the limited
knowledge healthcare providers and the general public have on the contribution of atrial
fibrillation to strokes. For instance, the AHA/ASA (2016) created a public service poster
on atrial fibrillation: even though 15% to 20% of all strokes are related to AF, only 50%
of patients with AF think they are at risk for a stroke. Research and observation of
practice have demonstrated healthcare providers underestimate the increased risk of
stroke with AF (especially with paroxysmal AF), overestimate the bleeding risk with
anticoagulants, and do not consistently utilize screening tools such as CHA2DS2-VASc or
HAS-BLED to assess for stroke and bleeding risk with AF despite evidence-based
practice suggesting otherwise.
To stay current with technological advances, medication safety, and treatment
updates, subscribing to e-mail updates from reliable organizations for medication safety
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(FDA MedWatch, Prescribing Letter, UpToDate) and newsletters from medical
organizations (American Academy of Family Physicians, American College of
Cardiology) is recommended for providers to increase evidence-based practice. To
simplify the practice of medicine and have updated practice available at their fingertips,
providers can access toolkits and phone apps from reliable organizations such as the
American College of Cardiology, Medscape, and Epocrates. Promoting self-efficacy in
patients, expanding public education efforts, and utilizing shared decision-making tools
are proposals to enhance patient-provider relationships and influence patients to take
control of their health to improve outcomes. Working as a multidisciplinary team,
including the collaboration with case managers, specialists, and anticoagulation clinics,
could ensure practice for AF is evidence-based, patient-centered, cost-effective, and
incorporates all available resources. Atrial fibrillation is a complicated disease to
manage, thus improving education and awareness is essential in this ever-changing and
technologically advancing world of healthcare.
Personal Goals and Contributions to
Advanced Practice Nursing
Nurses enter health care to help people; advanced practice nurses seek this role to
make a difference not only in their patients’ lives but to expand the roles, opportunities,
autonomy, leadership, and abilities of their profession. Advanced practice nurses are not
merely a mid-level provider but are the foundation of a unique branch of medicine,
utilizing the nursing model, theoretical frameworks, and scientific advances to treat the
entire patient holistically. A doctoral-prepared nurse practitioner can effectively conduct
research, evaluate data impeccably, and successfully translate research into project; thus,
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when passion, ambition, and fighting for a cause are intermeshed in the picture, the result
is a meticulous capstone project.
The purpose of this capstone project was quality improvement. Prevention of
disease is the basis for reducing health care costs, decreasing disease sequelae, and
ultimately averting the onset of disease. Atrial fibrillation is a significant example of
how if executed effectively, primary prevention (reduction of risk factors) and secondary
prevention (screening for AF through an annual pulse check in the elderly) could
minimize the incidence of stroke. Incorporating observations of practice through patient
chart reviews, extensively reviewing literature, and gathering expert consensus from
Delphi surveys, this Anticoagulation for Atrial Fibrillation Toolkit offers primary care
providers a simple and comprehensive resource to improve the diagnosis and
management of AF. Ultimately, the goal of this anticoagulation toolkit is sufficient
expert consensus through Delphi surveys and enough revisions to become ready for
implementation and subsequent evaluation in the primary care setting. If implementation
of this toolkit in practice reduces the onset of even one stroke in a patient with atrial
fibrillation, it has served its purpose to improve patient outcomes and has greatly
contributed to the advanced practice of nursing.
Five Criteria for Executing a Successful Doctor of
Nursing Practice Final Project
In 2004, The American Association of Colleges of Nursing (AACN; 2006)
declared the Doctor of Nursing Practice (DNP) as the final degree for advanced practice
nurses (nurse practitioners, nurse midwives, nurse anesthetists, and clinical nurse
specialists). According to the AACN, “DNP programs’ goal are to produce nurses that
are uniquely prepared to bridge the gap between the discovery of new knowledge and the
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scholarship of translation, application, and integration of this new knowledge in practice
(Waldrop, Caruso, Fuchs, & Hypes, 2014, p. 300). The AACN created the following
eight essentials of doctoral education in advanced nursing practice:
•

Scientific underpinnings in science

•

Organizational and systems leadership for quality improvement and systems
thinking

•

Clinical scholarship and analytical methods for evidence-based practice

•

Information systems/technology and patient care technology for the
improvement and transformation of health care

•

Health care policy for advocacy in health care

•

Interprofessional collaboration for improving patient and population
health outcomes

•

Clinical prevention and population health for improving the nation’s health

•

Advanced nursing practice (p. 1).

The acronym of EC as PIE suggests five criteria that ensure DNP programs
uphold these eight outcomes of the AACN: Enhances, Culmination, Partnerships,
Implements, Evaluation. Upon meeting these five criteria, the project is deemed
appropriate at the practice doctoral level (Waldrop et al., 2014). The EC as PIE criteria
are depicted graphically in Figure 8.
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Figure 8. EC as PIE: Five criteria for executing a successful Doctor of Nursing Practice
final project. Adapted from Waldrop et al. (2014).

The first EC as PIE criterion for the DNP project “enhance(s) health outcomes,
practice outcomes, or health care policy” (Waldrop et al., 2014, p. 301). This quality
improvement capstone project addressed health outcomes of reduced strokes and practice
outcomes of consistent, evidence-based diagnosis and management of AF. Health care
policy was not addressed in this capstone but providers were encouraged to utilize
national and international guidelines on anticoagulation with AF to enhance practice.
The second EC as PIE criterion reflects a “culmination of practice inquiry…the
DNP student must identify and become an expert on a specific problem....to enact
change” (Waldrop et al., 2014, p. 302). Through comprehensive literature reviews on
atrial fibrillation including summarizing noteworthy drug trials and comparing oral
anticoagulants, the researcher became an expert on background information, atrial
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fibrillation, and anticoagulation for this capstone project. Through the step-wise
guideline with corresponding algorithms, the researcher urged the change of improved
diagnosis and management of atrial fibrillation in the elderly, focusing on anticoagulation
to reduce the incidence of strokes.
The third EC as PIE criterion “require(s) engagement in partnerships” (Waldrop
et al., 2014, p. 302). The patient chart reviews for this capstone project were
retrospectively reviewed confidentially from the EHRs of a local and privately owned
primary care clinic. Additionally, primary care and cardiology providers were invited to
participate in the two Delphi surveys with the researcher collaborating to receive expert
consensus for the toolkit while also building partnerships with these clinicians. Providers
were encouraged to contact the researcher if they wanted additional information on the
final results of this capstone project or to discuss the anticoagulation toolkit further,
thereby enhancing interdisciplinary/interprofessional care.
The fourth EC as PIE criterion entails the DNP student “implement/apply/
translate evidence into practice” (Waldrop et al., 2014, p. 302). The researcher attained a
solid comprehension of the research itself, its implications, and how best to translate this
evidence into practice through an anticoagulation guideline with algorithms. This toolkit
was initially derived from conclusions from the literature review and chart reviews but
was modified based upon expert consensus and requests. In an extension of this project
with further rounds of the Delphi method, the goal would be to implement this guideline
into primary care practice. In compliance with this fourth criterion, the DNP student was
able to take into account the needs of individual patients, providers, and society in
general related to AF diagnosis and management.
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The fifth EC as PIE criterion expects the DNP student “require evaluation of
health care, practice or policy outcomes. The DNP may include outcome measures such
as direct patient health care measures, costs, quality improvement, and accessibility of
care” (Waldrop et al., 2014, p. 302). As this capstone project has not been implemented
into practice, evaluation of this quality improvement Anticoagulation for Atrial
Fibrillation Toolkit for was based upon the consensus of experts from the second round
of the Delphi survey. However, greater than 70% consensus suggested this toolkit could
improve the safety and efficacy of anticoagulation, influence future practice, be
applicable to practice, and be inclusive of evidence-based practice. In summary, this
capstone project successfully met all five EC as PIE criteria, approving it as a project at
the doctoral practice level.
Summary
Atrial fibrillation is the most common cardiac arrhythmia in the United States
(CDC, 2015), increasing the stroke risk by five times and contributing to 25% of strokes
in the elderly population (Desai et al., 2017). Research has demonstrated the bleeding
risk of oral anticoagulants does not outweigh the benefits of stroke prevention in the
elderly population (Kirchhoff et al., 2016); yet only 30 to 50% of applicable elderly
patients receive anticoagulation (Barbosa & Falcao, 2016) and intracranial bleeds are less
than 1% of the population on anticoagulants (Desai et al., 2017). Overexaggerated
bleeding risk in the elderly, the lack of head-to-head studies comparing anticoagulants,
cost, patient compliance, safety, lab monitoring, and reversal agents all convolute the
process of prescribing anticoagulation for atrial fibrillation, especially in a primary care
setting where providers are not specialists with this disease. Furthermore, variations exist
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with assessing bleeding risk and stroke risk for every patient through reliable tools such
as HAS-BLED and CHA2DS2-VASc scores, respectively, and translating these scores
into practice.
Due to inconsistencies and misconceptions observed in the diagnosis and
management of atrial fibrillation, an extensive literature review, retrospective chart
reviews on 100 patients, and expert consensus from two rounds of the Delphi survey
method were utilized to create the Anticoagulation for Atrial Fibrillation Toolkit. A
thorough review of research and statistical analysis of data clearly identified gaps
between research and practice, suggesting areas to improve practice, enhanced provider
education, increased multidisciplinary care and shared decision making between the
patient and provider, and development of a comprehensive, all-in-one resource for
providers to better diagnose and manage AF. Despite the toolkit being lengthy, expert
consensus from Round 2 of the Delphi survey implied the guideline and algorithms were
user friendly, evidence-based, and could safely and effectively enhance the care of
patients with atrial fibrillation. This toolkit offered evidenced-based recommendations to
diagnose and treat AF; in addition, it was a means to implement primary and secondary
prevention efforts to reduce the incidence of stroke.
For this capstone project, the PARIHS framework and RE-AIM model were
effectively utilized to assess the ability to translate this research into practice. This
capstone project met all five criteria of the EC as PIE model (Waldrop et al., 2014),
inferring this was a successful Doctor of Nursing Practice capstone project. A future
extension of this project would evaluate patient outcomes with AF, predominantly a
reduction in stroke incidence, after implementation of this toolkit in the primary care
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setting. In conclusion, through improved acknowledgement of the devastating sequelae
of AF in addition to consistent diagnosis and thorough treatment for all elderly patients,
one of the most predominant and preventable causes of stroke could be minimized. This
Anticoagulation Toolkit for Atrial Fibrillation is an innovative concept which if executed
effectively could improve education and awareness of AF diagnosis and management,
enhancing quality of life and ultimately saving lives.
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Patient Specific Factors Influencing Selection of an Oral Anticoagulant
(OAC) for Atrial Fibrillation (1)
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Patient Specific Factors Influencing Selection of an Oral Anticoagulant (OAC) for
Atrial Fibrillation (2)

*All OAC are covered by commercial insurance and the DOACs

*Coumadin©: avoid CYP2C9, CYP1A2, and CYP3A4 inducers/inhibitors;

▪
▪
▪
▪

*Pradaxa©: no CYP450 interactions; cannot crush pills; high fat meals delay
*Xarelto© and Eliquis©: avoid CYP3A4/5 inducers/inhibitors10, 12

*Savaysa©: avoid CYP3A4 inhibitors/inducers, Rifampin, Digoxin,
*With all OAC, avoid other drugs increasing bleeding risk (antiplatelets,

▪

•
▪
▪
▪
▪
▪
▪
▪
▪
▪

*All

DOACs: avoid drugs with P-glycoprotein transport5,9,10,12, protease
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APPENDIX B
COMPARISON OF ANTICOAGULANTS
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Pradaxa®
(Dabigatra
n etexilate
mesylate)

Name
Brand
(Generic)

Coumadin®
(Warfarin
sodium)

Xarelto®
(Rivaroxaban)

Pharmaceutical
Company

Bristol-Myers
Squibb
Company
(1954)

Janssen
Pharmaceutica
ls (2011)

Boehringer
Ingelheim
Pharmaceutica
ls (2010)

Inhibits the
production of
vitamin Kdependent
coagulation
factors (Factors
II, VII, IX, and X;
anticoagulant
proteins C and S)
(Bristol-Myers
Squibb, 2015;
Drugs.com,
2015c).

Selective factor Xa
inhibitor - inhibits
platelet
aggregation by
reducing thrombin
production
(Drugs.com,
2015b)

*Prophylaxis and
treatment of:
venous
thrombosis,
pulmonary
embolism,
thromboembolic
complications
with atrial
fibrillation, and
thromboembolic
complications
with cardiac
valve
replacements.
*Reduction in
stroke, subsequent
myocardial
infarction, or
death after a
myocardial
infarction
(Bristol-Myers
Squibb, 2015;
Drugs.com,
2015c).

*Reduction of
stroke and
systemic
embolism in nonvalvular atrial
fibrillation
(NVAF)
*Prophylaxis
and treatment of
deep vein
thrombosis and
pulmonary
embolism,
including knee or
hip replacement
surgery
*Reduction in
recurrence of
DVT or PE
*Nonvalvular
atrial fibrillation:
absence of mitral
valve repair,
rheumatic mitral
stenosis, and a
prosthetic heart
valve (Drugs.com,
2015b).

*Peak plasma
levels: 72-96
hours
*Duration of 1
dose: 2-5 days
*Rapid
anticoagulation
requires bridging
with Heparin for
4- 5 days
(Bristol-Myers
Squibb,
2015; Drugs.com,
2015c)

Peak plasma
levels following
oral
administration:
2-4 hours
(Drugs.com,
2015b)

Selective,
competitive,
reversible direct
thrombin
inhibitor- prevents
conversion of
fibrinogen to
fibrin and inhibits
thrombinmediated platelet
aggregation
(Drugs.com,
2015a; Boehringer
Ingelheim, 2015a)
*Reduction of
stroke and
systemic
embolism in
NVAF
*Treatment and
secondary
prevention of
DVT or PE
*Prevention of
stroke and
systemic
embolism during
cardioversion of
atrial fibrillation
or atrial flutter
*Prevention of
DVT and PE
during total hipreplacement or
total kneereplacement
surgeries
*Secondary
prevention of
cerebral embolism
in patients with
TIA, ischemic
stroke, or atrial
fibrillation
(Drugs.com,
2015a;
Boehringer
Ingelheim, 2015a)
Peak plasma
levels following
oral
administration:
1-2 hours
(Drugs.com,
2015a; Boehringer
Ingelheim, 2015a)

(U.S.
Approval
Date)

Mechanism
of Action

Indications

Pharmacokinetics

Eliquis®
(Apixaban)

Savaysa®
(Edoxaban)

BristolMyers
Squibb
Company
(2012).

Daiichi Sankyo,
Inc.
(2015)

Reversible
direct Factor
Xa inhibitorprevents
conversion of
prothrombin
to thrombin
and thrombus
production;
does not
require a
cofactor
(Drugs.com,
2016)
*Reduction
of stroke and
systemic
embolism
with nonvalvular
atrial
fibrillation
*Thrombopro
p hylaxis in
hip or knee
replacement
surgery
*Treatment
and secondary
prevention of
DVT and/or
PE
(Drugs.com,
2016)

Selective, factor
Xa inhibitorprevents
thrombininduced platelet
aggregation to
decrease the
production of
thrombin
(Daiichi
Sankyo, 2015).

Peak plasma
levels
following oral
administration
: 3-4 hours
(Drugs.com,
2016)

*Reduction of
systemic
embolism in
non- valvular
atrial
fibrillation
*Thromboprop
hy laxis of DVT
and PE after 510 days of IV
anticoagulation
(Daiichi
Sankyo, 2015).

*Peak plasma
levels: 1-2
hours
(Daiichi Sankyo,
2015).
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Name
Brand
(Generic)

Oral Dosing

Absorption

Distribution

Coumadin®
(Warfarin
sodium)
Dose is adjusted
based upon the
patient's INR:
*Non-Valvular
Atrial
Fibrillation:
target INR 2.5
(range 2.0-3.0)
*Mechanical and
Bioprosthetic
Heart Valves:
bileaflet
mechanical aortic
valve- INR 2.5
(range 2.0-3.0),
bileaflet mitral
valve- INR 3
(range 2.3-3.5),
bioprosthetic
mitral valve- INR
2.5
(range 2.0-3.0)
*INR >4
increases the risk
of bleeding
*Initial dose: 25 mg daily
(dependent on
age, race, body
weight, sex,
comorbidities,
and concurrent
medications)
*Determination
of CYP2C9 and
VKORC1
genotypes
influences
the dosing
*Maintenance
dose: 2-10 mg
daily (dependent
on INR) (BristolMyers Squibb,
2015; Drugs.com,
2015c).
*Bioavailability:
100% absorption
orally
*Tablets can be
crushed
*Avoid foods
high in vitamin
K (BristolMyers Squibb,
2015;
Drugs.com,
2015c)

90% bound to
plasma proteins
(Bristol-Myers
Squibb,
2015; Drugs.com,
2015c)

Pradaxa®
Xarelto® (Dabigatran
(Rivaroxaban) etexilate
mesylate)
*Non-valvular
atrialfibrillation: CrCl
>50 mL/min (20
mg daily with
evening meal)
CrCl 15-50
mL/min (15 mg
daily with
evening meal)
CrCl <15
mL/min (not
recommended)
[CrCl =
creatinine
clearance]
(Drugs.com,
2015b).

Bioavailability:
*80-100% for 10
mg dose
(unaffected by
food) *66% for
20 mg dose
without food,
*76% for 20 mg
dose with food
*15 and 20 mg
tablets should be
taken with food
to increase
absorption.
*Tablets can be
crushed
(Drugs.com,
2015b)
92-95% bound to
plasma proteins
(Drugs.com,
2015b)

*Embolism with
atrial fibrillation:
CrCl >30 mL/min
(150 mg BID);
CrCl 15-30
mg/Min
(75 mg BID)
CrCl < 15
mL/min or
hemodialysis (not
recommended)
(Drugs.com,
2015a;
Boehringer
Ingelheim,
2015a)

*Bioavailability:
37%
*Tablets must be
taken wholecannot crush.
*High fat meals
delay peak
plasma
concentration by
2 hours but do
not affect
bioavailability
(Drugs.com,
2015a;
Boehringer
Ingelheim,
2015a)
35% bound to
plasma proteins
(Drugs.com,
2015a;
Boehringer
Ingelheim,
2015a)

Eliquis®
(Apixaban)

Savaysa®
(Edoxaban)

*Embolism
with
atrial
fibrillation: 5
mg BID
(reduce dose
to 2.5 mg BID
with >2
characteristics
:
>80 years old,
body weight
<60 kg, Cr
>1.5
mg/dL)
*Administrati
on with
inhibitors or
CYP3A4 and
Pglycoprotein:
reduce dose
by 50% with
>2.5 mg
Apixaban
daily
(Drugs.com,
2016)

*Non-valvular
atrial fibrillation:
60 mg daily with
CrCl between 5095 mL/min 30
mg daily with
CrCl 15-50
mL/min.
Not indicated with
a CrCl <15 or >95
mL/min.
*No dosage
adjustments with
mild or moderate
hepatic impairment
*Reduce dose to 30
mg with body
weight <60 kg or
P-gp inhibitor use

*Bioavailabilit
y
: 50%
*Tablets can
be crushed
*Can be taken
with or
without food
(Drugs.com,
2016)

*Bioavailability:
62%
*Unknown
whether tablets
can be crushed
*Can be taken
with or without
food
(Daiichi Sankyo,
2015).

87% bound to
plasma
proteins
(Drugs.com,
2016)

55% bound to
plasma proteins;
steady state
reached in 3 days
(Daiichi Sankyo,
2015).

Cockcroft-Gault
CrCl = (140-age) x
(weight in kg) x
(0.85 if female) /
(72 x creatinine in
mg/dL)
(Daiichi Sankyo,
2015).
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Name
Brand
(Generic)

Metabolism

Half-Life

Excretion

Monitoring

Pregnancy
Category

Coumadin®
(Warfarin
sodium)

Xarelto®
(Rivaroxaban)

CYP450 enzymes,
primarily CYP2C9
(Bristol-Myers
Squibb, 2015;
Drugs.com,
2015c)

CYP450 enzymes,
primarily
CYP3A4/5
(Drugs.com, 2015b)

*Effective half-life:
mean 40 hours
*Terminal half-life:
1 week
(Bristol-Myers
Squibb, 2015;
Drugs.com,
2015c)

Terminal half-life:
5-9 hours
(Drugs.com, 2015b)

Inactive metabolites
in urine (92%)
(Bristol-Myers
Squibb, 2015;
Drugs.com, 2015c).

Inactive metabolites
in urine (30%) and
feces (21%)
(Drugs.com, 2015b)

INR: daily until
stabilization then
every 1-4 weeks
(Bristol-Myers
Squibb, 2015;
Drugs.com,
2015c)

*Category C:
pregnant women
with mechanical
values
*Category X: all
other women
(Warfarin
embryopathy)
*Crosses the
placenta
*Not present in
breastmilk; avoid
during lactation due
to increased risk of
bleeding in the
infant
(Bristol-Myers
Squibb,
2015; Drugs.com,
2015c)

Pradaxa®
(Dabigatran
etexilate
mesylate)

Eliquis®
(Apixaban)

Savaysa®
(Edoxaban)

*Not metabolized
by CYP
enzymes.
*Dabigatran
extexilate is a
prodrug that is
rapidly absorbed
and hydrolyzed by
the liver and plasma
into the active form
of dabigatran.
(Drugs.com, 2015a;
Boehringer
Ingelheim, 2015a)

*CYP450
enzymes,
primarily
CYP3A4/5
*Substrate of Pglycoprotein
but does not
inhibit Pglycoprotein.
(Drugs.com,
2016)

*Unchanged in
plasma
*Nominal
metabolism
through
CYP3A4,
hydrolysis, and
conjugation
*Primary
metabolite is M-4
through
hydrolysis
(Daiichi Sankyo,
2015).

*Terminal half-life:
12-17 hours
*Increased half-life
with renal
impairment (15-28
hours)
(Drugs.com, 2015a;
Boehringer
Ingelheim, 2015a)
*Inactive
metabolites in urine
(80%), 86% of total
dose is excreted into
feces
(Drugs.com, 2015a;
Boehringer
Ingelheim, 2015a)

*Terminal halflife: 6 hours
*Half-life of 12
hours with
repeated
administration
(Drugs.com,
2016)

*Excreted as an
unchanged drug
*Half-life: 10-14
hours
(Daiichi Sankyo,
2015).

*Inactive
metabolites in
urine (25%),
hepatic
metabolism,
intestinal, and
biliary
excretion
(Drugs.com,
2016)

*50% renal
clearance, 50%
intestinal and
biliary clearance
(Daiichi Sankyo,
2015).

*Routine lab
monitoring not
required
*Prolongs PT,
aPTT, and Factor
Xa
(Drugs.com, 2015b)

*Routine lab
monitoring not
required
*Prolongs aPTT,
PT, INR, and ECT.
ECT is the preferred
test for Pradaxa©
monitoring
(Drugs.com, 2015a;
Boehringer
Ingelheim, 2015a)

*Routine lab
monitoring not
required or
recommended
*Inhibits Factor
Xa and
prolongs aPTT,
PT, INR, and
anti-factor Xa
assays
(Drugs.com,
2016)

*Routine lab
monitoring not
required or
recommended
*Prolongs aPTT,
PT and INR
*Does not
prolong QT
interval
(Daiichi
Sankyo, 2015).

*Category C
*Crosses the
placenta
*Unknown whether
Xarelto© is
excreted in
breastmilk
(Drugs.com, 2015b)

*Category C
*Unknown whether
Pradaxa© is
excreted into
breastmilk
(Drugs.com, 2015a;
Boehringer
Ingelheim, 2015b)

*Category B
*Unknown
whether
Eliquis© is
excreted into
breastmilk
(Drugs.com,
2016)

*Category C
*Discontinue prior
to breastfeeding,
unknown whether
Savaysa® is
excreted into
breastmilk
(Daiichi Sankyo,
2015).
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Name
Brand
(Generic)

Demographic
Considerations

Adverse
Effects

Pradaxa®
(Dabigatran
etexilate
mesylate)

Coumadin®
(Warfarin
sodium)

Xarelto®
(Rivaroxaban)

*Reduce dose in
geriatric patients
>60 years old due
to increased INR
*Reduce dose in
Asians
*Initial and
maintenance
dosing is based
upon patient's: age,
body weight, sex,
race, concurrent
medications,
comorbidities, and
genetic factors
*Dosing in
pediatrics
is unknown
*With known
CYP2C9
and
VKORC1
genotypes, initial
and maintenance
dosage is
dependent on the
combination of
these genetic
variants
(Bristol-Myers
Squibb, 2015
Drugs.com, 2015c)

*Dosing in
pediatrics is
unknown
*Increased risk of
thrombosis and
bleeding rates in
the elderly - reduce
dosage
*Renal
insufficiency:
avoid use in
patients with a
CrCl <30 mL/min
*Avoid use in
patients with
moderate or
severe hepatic
impairment
(Child-Pugh B and
C)
*No influence of
gender
*Differences in
effects for Asian
race are reduced
when corrected
for body weight
*No prolongment
of QT/QTc interval
(Drugs.com,
2015b)

*Dosing in
pediatrics is
unknown
*No current
dosage
recommendations
for hepatic
impairment
*Bleeding risk
increases with
age- reduce
dosage
*Reduce dose with
renal insufficiency
(Drugs.com,
2015a; Boehringer
Ingelheim, 2015a)

*Hemorrhage/blee
ding risk *Tissue
necrosis
*Systemic
atheroemboli or
cholesterol
microemboli
(purple toes
syndrome) *Limb
ischemia,
necrosis,
gangrene with
heparin-induced
thrombocytopenia
*Hypersensitivit
y (7.5 mg tablets
containing
FD&C Yellow
No. 5)
*Vasculitis
*Hepatobiliary
disorders *Nausea,
vomiting, diarrhea,
bloating
*Rash, dermatitis,
pruritus
(Bristol-Myers
Squibb, 2015;
Drugs.com,
2015c)

*Bleeding risk
*Increased risk of
stroke after
discontinuation of
Xarelto© in
patients with nonvalvular atrial
fibrillation
*Spinal/epidural
hematoma
*Abdominal pain,
dyspepsia
*Fatigue
*Sinusitis, urinary
tract infection
*Back pain,
osteoarthriti
s
*Oropharyngeal
pain *Pruritus
*Hypersensitivity
(Drugs.com,
2015b)

*Bleeding risk
*GI: Gastritis,
GERD, GI ulcer,
dyspepsia, upper
abdominal pain,
nausea, diarrhea,
gastrointestinal
hemorrhage
(Drugs.com,
2015a; Boehringer
Ingelheim, 2015a)

Eliquis®
(Apixaban)
*Dosing in
pediatrics is
unknown
*Not
recommend
ed with
severe
hepatic
impairment
*Reduce
dosage to 2.5
mg BID in
patients with
Cr>1.5
mg/dL if >80
years old
body and
weight <60
kg.
*Hemodialys
is: 5 mg
BID.
*>80 years
old or body
weight
<60 kg: 2.5
mg BID
*No
adjustment
s based on
race
*Pharmacoki
net ics and
pharmacodyn
a mics not
affected by
renal
impairment
(Drugs.com,
2016)
*Bleeding risk
(Drugs.co
m,
2016)

Savaysa®
(Edoxaban)
*Dosing in
pediatrics
is unknown
*Similar
safety and
efficacy in
patients >65
years old
and <65
years old
*No dose
adjustment
s based on
sex or race
(Asian
versus
NonAsian)
(Daiichi
Sankyo,
2015).

*Bleeding
risk
*Indicated
for nonvalvular
atrial
fibrillation:
anemia,
bleeding
(5%)
*Indicated
for DVT and
PE: anemia,
abnormal
liver
function
labs, rash,
bleeding
(1%)
*Rash
*Abnormal
liver
function
tests
*Interstitial
lung
disease
(Daiichi
Sankyo,
2015).
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Name
Brand
(Generic)

Contraindications/
Precautions

Food/Drug
Interactions

Pradaxa®
(Dabigatran
etexilate
mesylate)

Coumadin®
(Warfarin
sodium)

Xarelto®
(Rivaroxaban)

*Narrow
therapeutic index
*Contraindication
s: Pregnancy;
Blood dyscrasias;
Bleeding tendencies
(GI, GU,
respiratory, cardiac,
CNS); Threatened
abortion, eclampsia,
preeclampsia;
Recent surgery or
the CNS, eye, or
large trauma; Noncompliant patients;
Procedures with
potential
uncontrolled
bleeding; Severe
hypersensitivity
reaction to
Warfarin;
Malignant
hypertension; Major
regional or lumbar
block anesthesia
*Precautions:
Moderate to severe
hepatic impairment
or hypertension;
Diabetes mellitus;
Polycythemia Vera
(Bristol-Myers
Squibb, 2015;
Drugs.com, 2015c)

*Contraindication
s: Active bleeding;
Severe
hypersensitivity
reaction to
Xarelto©
*Precautions:
Increased risk of
thrombotic events
with premature
discontinuation of
anticoagulants; Risk
of bleeding;
Spinal/epidural
anesthesia or
puncture; Renal
impairment (CrCl
<30 mL/min);
Moderate/severe
hepatic impairment;
Pregnancy-related
hemorrhage;
Hemodynamic
instability;
Prosthetic heart
valves (has not been
studied)
(Drugs.com, 2015b)

*Contraindication
s: Active bleeding;
Severe
hypersensitivity
reaction to
Pradaxa©;
Mechanical
prosthetic heart
valves
*Precautions:
Increased risk of
thrombotic events
with premature
discontinuation of
anticoagulants;
Spinal/epidural
hematoma; Risk of
bleeding
(Drugs.com, 2015a;
Boehringer
Ingelheim, 2015a)

*Contraindicat
ions: Active
bleeding;
Severe
hypersensitivity
reaction
*Precautions:
Increased risk
of thrombotic
events with
premature
discontinuation
of
anticoagulants;
Spinal/epidural
hematoma;
Risk of
bleeding;
Prosthetic heart
valves
(Drugs.com,
2016)

*Contraindicati
on: active
bleeding
*Precaution:
increased risk of
ischemic stroke
with CrCl <95
mL/min.
*Not
recommended
with moderate to
severe mitral
stenosis or
mechanical heart
valves.
*Increased risk of
ischemic event
with premature
discontinuation
of Savaysa®
*Concurrent use
of neuraxial
anesthesia or
spinal puncture
and Savaysa®
can result in
spinal or epidural
hematoma.
(Daiichi Sankyo,
2015).

*Foods high in
vitamin K,
grapefruit juice,
herbal supplements
*Drugs metabolized
by CYP450: 2C9,
1A2, 3A4 (inhibitors
of CYP increase the
INR of Warfarin;
inducers of CYP
decrease the INR of
Warfarin)
*Drugs increasing
the risk of bleeding
with Warfarin:
anticoagulants,
antiplatelets,
NSAIDS, SSRI
(Bristol-Myers
Squibb,
2015; Drugs.com,
2015c)

*15 and 20 mg
tablets should be
taken with food, 10
mg tablet can be
taken with or
without food
*Avoid use with
combined P-gp and
strong CYP3A4
inducers or
inhibitors *Avoid
anticoagulants,
NSAIDS, Plavix©,
Aspirin, and SSRI
due to increased
risk of bleeding
(Drugs.com, 2015b)

*Avoid drugs
affecting Pglycoprotein
transport
*Unlikely
interactions with
drugs metabolized
by CYP isoenzymes
*Avoid drugs
increasing the risk
of bleeding
(Drugs.com, 2015a;
Boehringer
Ingelheim, 2015a)

*Unlikely drug
interactions
with Pglycoprotein or
CYP3A4
*Avoid use of
dual inhibitors
of Pglycoprotein
and CYP3A4/5
inhibitors or
inducers
*Avoid drugs
increasing the
risk of bleeding
(Drugs.com,
2016)

*Avoid Rifampin
(P-gp inhibitorreduces the blood
levels of
edoxaban)
*Avoid drugs
increasing the
risk of bleeding:
anticoagulants,
aspirin,
fibrinolytics,
antiplatelets, and
NSAIDS
*Edoxaban
increases the
Cmax of digoxin
and decreases the
Cmax of
verapamil
(Daiichi Sankyo,
2015).

Eliquis®
(Apixaban)

Savaysa®
(Edoxaban)
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Name
Brand
(Generic)

Reversal
Agent

Temporary
Interruption of
Therapy

Coumadin®
(Warfarin
sodium)

Xarelto®
(Rivaroxaban)

Oral or parenteral
Vitamin K1
*Vitamin K1
(Phytonadione)2.5-10 mg SubQ,
max of 25 mg. Can
repeat dose in 6-8
hours if
prothrombin time
has not shortened
adequately
(Drugs.com, 2013).

*No specific
reversal agent
(Drugs.com.
2015b)

*Obtain the INR
immediately before
any surgical
procedures
*Consider the
duration of one dose
lasting 2-5 days.
*For minimally
invasive
procedures,
maintain the INR at
the lower end of the
therapeutic range
(Bristol-Myers
Squibb, 2015;
Drugs.com, 2015c)

*Discontinue
Xarelto© 24 hours
prior to the
procedure to
minimize bleeding
risk. *Resume
Xarelto© 6-10
hours after surgery
once hemostasis is
achieved
(Drugs.com, 2015b)

Pradaxa®
(Dabigatran
etexilate
mesylate)

Eliquis®
(Apixaban)

Savaysa®
(Edoxaban)

Praxbind
(Idarucizumab) – 5
gm IV push.
Limited data on a
second additional
dose.
*Monoclonal
antibody fragment
*Indicated for
uncontrolled or lifethreatening
bleeding, or for
urgent/emergent
surgical procedures.
*Pradaxa is
dialyzable- 50% can
be cleared from
plasma over four
hours.
*Approved in U.S.
in 2015 (Boehringer
Ingelheim, 2015a;
Boehringer
Ingelheim, 2015b)

*No specific
reversal agent
(Drugs.com,
2016)

*No specific
reversal agent.
*Anticoagulation
effects continue
24 hours after the
last dose was
administered.
*Hemodialysis
does not improve
clearance of
Savaysa
*Protamine
sulfate, vitamin K
and tranexamic
acid do not
reverse Savaysa’s
effects (Daiichi
Sankyo, 2015)

*For CrCl >50
mL/min: withhold
Pradaxa© 1-2 days
prior to procedure.
*For CrCl<50
mL/min: withhold
Pradaxa© 3-5 days
prior to the
procedure
(Drugs.com, 2015a;
Boehringer
Ingelheim, 2015a)

*Discontinue
48 hours prior
to procedures
with a moderate
or high risk of
bleeding.
*Discontinue
24 hours prior
to procedures
with a low risk
of bleeding.
*Resume
Eliquis® 12-24
hours after
surgery once
hemostasis is
achieved
(Drugs.com,
2016)

*Discontinue 24
hours prior to
procedures with
high bleeding
risk
*Resume
Savaysa® as
soon as
hemostasis is
achieved postprocedure
*Do not remove
indwelling
intrathecal or
epidural catheters
< 12 hours after
the last dose of
Savasya®. Do
not administer
Savaysa® until 2
hours after the
catheter is
removed
(Daiichi Sankyo,
2015).
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Name
Brand
(Generic)

Cost

Coumadin®
(Warfarin
sodium)

Xarelto®
(Rivaroxaban)

$11 monthly
(GoodRx, 2017)

$371 monthly
(GoodRx, 2017)
*Commercial
coverage: 95% 74%
of patients payed
<$50
*Medicare Part D:
96% coverage, 58%
paid <$50
*Medicaid: covered
*Xarelto©
CarePath: savings
for commercial
insurance: $0 copay
every month for
patients with
commercial
insurance (15 or 20
mg tablets), max of
$3,400 annual
benefit with no
monthly cap;
assistance with
Medicaid,
Medicare, Tricare,
or commercial
insurance- free 30day trial of 15 or 20
mg tablets (Janssen
Pharmaceuticals,
2016a)

Pradaxa®
(Dabigatran
etexilate
mesylate)
$377 monthly
*99% coverage in
Colorado by
Medicare Part D
(Good Rx, 2017)
*Praxbind©:
available in all 50
states (Boehringer
Ingelheim, 2015b)
*Pradaxa© savings
card: $0 monthly
co-pay or a free 30day supply
(Boehringer
Ingelheim, 2016).

Eliquis®
(Apixaban)

Savaysa®
(Edoxaban)

$395 monthly
(GoodRx, 2017)
*Medicare D:
93% national
coverage
*Commercial
insurance: 87%
coverage with no
prior
authorization
restriction
*73% of
commercially
insured patients
pay <$25 on a
30-day
prescription
*Eliquis®
savings card: free
30-day trial
(including
Medicaid,
Medicare, and
cash-pay), $10
co-pay for
commercial
insurance for a
30-day supply,
up to 24 months
for a maximum
annual benefit of
$3,800 (BristolMyers Squibb,
2016)

$326 monthly
(Good Rx, 2017)
*Savaysa® drug
savings cards: $4
for a 30-day
prescription (max
benefit or $12 for
a 90-day
prescription for 1
year (Daiichi
Sankyo, 2017)
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APPENDIX C
KEY DRUG TRIALS FOR ANTICOAGULANTS, REVERSAL
AGENTS, AND ALTERNATIVE TREATMENTS
FOR ATRIAL FIBRILLATION
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Trial
APIXABAN
(Eliquis®)
ARISTOTLE
(Apixaban for
Reduction in
Stroke and Other
Thromboembolic
Events in Atrial
Fibrillation)
(Granger et al.,
2011)

Design/Method Sample
Randomized, doubleblind, multicenter,
noninferiority study
comparing apixaban to
warfarin in subjects with
atrial fibrillation to
prevent stroke.
Apixaban was administered
5 mg BID. Warfarin was
administered to reach a
target INR or 2.0-3.0. These
anticoagulants were
administered for a median
duration of 1.8 years. This
study was completed from
2006-2010 at 1,034 sites in
39 countries.
The efficacy outcome was
ischemic stroke,
hemorrhagic stroke, or
systemic embolus
occurrence. Safety
outcomes were bleeding
risk and death from any
cause.

AVERROES
(Apixaban Versus
Acetylsalicylic
Acid to Prevent
Stroke in Atrial
Fibrillation
Patients)
(Connolly et. al.,
2011).

A total of 18,201 subjects with
atrial fibrillation or atrial flutter and
at least one other stroke risk factor
were randomized to the warfarin or
apixaban group. The median age of
subjects was 70 years old with
35.3% women and an average
CHADS2 score of 2.1.
Inclusion criteria: at least two
episodes of atrial fibrillation or
atrial flutter on EKG, at least 2
weeks apart within one year prior to
initiation of this study. At least one
risk factor for stroke: age >75 years
old, prior stroke, transient ischemic
attack (TIA), or systemic embolism,
symptomatic heart failure within the
past 3 months or a left ventricular
ejection fraction (LVEF) <40%,
diabetes, or hypertension.
Exclusion criteria included
moderate or severe mitral stenosis,
prosthetic heart valve, atrial
fibrillation due to a reversible cause,
stroke within the past 7 days, the
need of aspirin and Plavix© or
aspirin dose >165 md daily, or
severe renal insufficiency (CrCl <25
mL/Min).

Double-blind, randomized,
multicenter study
investigating subjects with
atrial fibrillation, an
increased risk of stroke, and
an inability to take vitamin
K antagonist
anticoagulation. Subjects
received apixaban 5 mg BID
or aspirin 81- 342 mg daily,
assessing for superiority.

Out of 5,599 subjects, 40% used a
vitamin K antagonist as a prior
anticoagulant. Subjects were
randomly assigned to either the
apixaban or aspirin group.
Approximately 37% of the subjects
were from North America or
Europe with a mean age of 70 years
old and approximately 58- 59%
men per group. The mean CHADS2
score was 2.0-2.1.

Apixaban or aspirin were
administered for a followup of 1.1 years. This study
was completed at 522 sites
within 36 countries from
2007 to 2009.

Inclusion criteria: Subjects were at
least 50 years old with at least a 6month diagnosis history of atrial
fibrillation.
Subjects required at least one of
the following risk factors for
stroke: age 74 or older, history of
stroke or TIA, treated arterial

Findings and
Conclusions
The efficacy outcome of apixaban
occurred annually in 1.27% of
subjects in the apixaban group [HR
(CI: 95%): 0.79 (0.66, 0.95); P<0.001
for
noninferiority; P=0.01 for
superiority]. Ischemic or unknown
type of stroke occurred annually in
0.97% of subjects in the apixaban
stroke, compared to 1.05% of
subjects in the warfarin group [HR
(CI: 95%): 0.92 (0.74,
1.13); P=0.42].
Safety Outcomes:
*Major bleeding occurred annually
in 2.13% of subjects in the apixaban
group compared to 3.09% in the
warfarin group [HR (CI: 95%): 0.69
(0.60, 0.80); P<0.001].
*Death from any cause occurred in
3.52% of subjects in the apixaban
group compared to 3.94% in the
warfarin group [HR (CI: 95%):
0.89
(0.80, 0.99); P=0.047].
*Hemorrhagic stroke occurred
annually in 0.24% of subjects in the
apixaban group compared to 0.47%
of subjects in the warfarin group [HR
(CI: 95%) 0.51 (0.35, 0.75);
P<0.001].
Conclusion: Apixaban was superior
to warfarin in preventing systemic
emboli or strokes in patients with
atrial fibrillation, in addition to
demonstrating decreased bleeding
risk
and reduced mortality.
The study was terminated early due
to clear superiority of apixaban to
aspirin in preventing strokes.
The efficacy outcome was evident
annually in 51 (1.6%) of subjects in
the apixaban group, compared to 113
(3.7%) of subject in the aspiring
group [HR (CI: 95%): 0.45 (0.32,
0.62): P<0.001].
Safety outcomes:
*Death rates occurred annually in
3.5% of subjects in the apixaban
group, compared to 4.4% in the
aspirin group [HR (CI: 95%): 0.79,
(0.62,
1.02)].
*Major bleeding presented annually
in 44 (1.4%) of subjects in the
apixaban group, compared to 39
(1.2%) of
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The efficacy outcome was
stroke or systemic embolus
occurrence. The safety
outcome was the rate of
severe bleeding and death.

hypertension, treated diabetes
mellitus, heart failure (New York
Heart Association class 2 or
higher), left ventricular ejection
fraction of 35% or less,
documented peripheral artery
disease, or not currently on vitamin
K antagonist therapy.
Exclusion criteria: valvular heart
disease requiring surgery, serious
bleeding within the past 6 months
or a high risk of bleeding, a
condition other than atrial
fibrillation necessitating
anticoagulation, platelet count
<100,000/mm3, hemoglobin <10
g/dL, hemorrhagic tendencies,
blood dyscrasias, current alcohol or
drug abuse, current psychosocial
issues, life expectancy <1 year,
severe renal insufficiency (CrCl
<25 mL/min) liver transaminases
>2x the upper limit, a bilirubin
>1.5x the upper
limit, or allergy to aspirin.

Trial
DABIGATRAN
(Xarelto®)
PETRO
(Ezekowitz et al.,
2007)

Design/Method Sample
Randomized, double- blind,
open-label, multicenter
study comparing dabigatran
(with or without aspirin) to
warfarin in preventing
thromboembolism in
patients with nonvalvular
atrial fibrillation. The goal
of this study was to
determine in patients with
atrial fibrillation the safe
dose of dabigatran.
The study was designed for
a duration of 12 weeks and
was completed at 53 sites
within Denmark,
Netherlands, Sweden, and
the United States.
Labs were measured at
baseline, 1, 2, 4, 8, and 12
week intervals throughout
the study, evaluating
dabigatran plasma
concentrations, activated
partial thromboplastin time,
D-dimer, liver function,
and urinary 11dehydrothromboxane B2
(DTB2).
The efficacy outcome
measured the incidence of
stroke or

A total of 502 subjects were
randomly assigned to one of four
major groups 1) dabigatran 50 mg
(105 subjects) 2) dabigatran 150
mg (166 patients), 3) dabigatran
300 mg (161 subjects), or 4) dose
adjusted warfarin (70 subjects).
Dabigatran was administered with
or without aspirin. Subjects were
assigned to one of a total of 10
groups.
The dabigatran dose was either 50,
150 or 300 mg daily, the aspirin
dose was either 81 or 325 mg daily,
and the warfarin was dose adjusted
to reach a therapeutic INR of 2.03.0; these medications were
administered for 12 weeks. 411 or
81.9% of subjects were men with a
mean age of 70.9 years with
coronary artery disease and 68
years without coronary artery
disease.
Inclusion criteria: documented
diagnosis of atrial fibrillation
coronary artery disease (with the
initial half of participants) with a
minimum of at least one of the
following high-risk factors:
hypertension, diabetes,
symptomatic heart failure or a left
ventricular ejection fraction
<40%, prior stroke or transient
ischemic attack, or age >75 years
old.

subjects in the warfarin group
[HR (CI: 95%): 1.13 (0.74,
1.75)].
Intracranial bleeding occurred in 13
subjects in the apixaban group and
13 in the aspirin group.
*Reduced risk for hospitalization
annually related to a cardiovascular
cause was evident in both apixaban
(12%) and aspirin (15.9%);
P<0.001.
Conclusion: In atrial fibrillation
patients who are unable to take
vitamin K antagonists as an
anticoagulant to decrease the risk of
stroke or systemic embolism,
apixaban is a suitable alternative to
aspirin without enhancing the risk of
severe bleeding including
intracranial hemorrhage.

Findings and
Conclusions
Efficacy
outcomes:
Thromboembolism occurred only in
the 50-mg dabigatran group in 2 out of
107 subjects (2%).
Safety outcomes:
*Severe bleeding occurred only in
the dabigatran 300 mg plus aspirin
group in 4 out of 64 subjects. In
comparison, 0 out of 105 subjects
had severe bleeding the dabigatran
only group (p
<0.02).
*Total bleeding events in the
dabigatran group were as following:
300 mg (39 out of 169 subjects,
23%,
p = 0.0002), 150 mg (30 out of 169
subjects, 18%; p = 0.01), and 50 mg (7
out of 107 subjects, 7%).
Labs:
*D-dimer levels were suppressed
in the 300 mg and 150 mg
dabigatran doses as well as
warfarin.
*In 0.9% of patients on dabigatran,
aminotransferase levels were
greater than 3 times the normal
level, with 2 subjects developing
gallstones (aminotransferase levels
>5 times normal).
*Activated partial thromboplastin
times were higher than baseline in
the dabigatran group (1.2 with 50
mg, 1.5
with 150 mg, and 1.8 with 300 mg).
*DTB2 concentrations were
higher than baseline with the
dabigatran group (31% with 50
mg, 17% with
150 mg, and 23% with 300 mg).
Conclusion: Severe bleeding
occurred only with the combination
of

228
thromboembolism. The
safety outcome measured
the rate of bleeding events.

Trial
RE-LY Trial
(Randomized
Evaluation of
Long-term
Anticoagulation
Therapy)
(Connolly et.al.,
2009)

Exclusion criteria: mitral stenosis,
prosthetic heart valves, scheduled
cardioversion, myocardial infarction
within the past month, recent stroke
or transient ischemic attack,
contraindication to anticoagulation,
coronary artery stent placement
within the past 6 months, major
bleed within the past 6 months,
glomerular filtration rate ≤30
mL/min, pregnancy, abnormal liver
function, or use of any other
investigational drugs within the
past 30 days.

dabigatran 300 mg with aspirin and
thromboembolism only occurred with
dabigatran 50 mg. Severe liver
toxicity did not arise with dabigatran.

Design/Method

Sample

Findings and
Conclusions

Noninferiority, randomized
study comparing
dabigatran to doseadjusted warfarin in
prevention of stroke in
patients with nonvalvular
atrial fibrillation (NVAF).

A total of 18,113 subjects with atrial
fibrillation were randomly assigned
to a dabigatran group (110 or 150 mg
BID) or an adjusted- dose of
warfarin. Subjects were from 44
countries with a mean age of 71
years, 63.6% men, mean CHADS2
score of 2.1, and 50% of patients had
a history of long-term term with
vitamin K antagonists.

Discontinuation rates of
anticoagulation: 1 year
later: dabigatran 110 mg
(14.4%),
dabigatran 150 mg (15.5%), and
warfarin (10.2%)
2 years later: dabigatran 110 mg
(20.7%), dabigatran 150 mg (21.2%),
and warfarin (16.6%)
In the warfarin group, the INR was
therapeutic 64% of the time.

Inclusion criteria: documented
atrial fibrillation through an EKG
within the past 6 months and at
least one of the following
characteristics: prior stroke or TIA,
LVEF <40%, heart failure (New
York Heart Association class II or
higher) within the past 6 months,
age >75 years old, or age 65-74
years old with diabetes,
hypertension, or coronary artery
disease.

Efficacy outcome: 1.69% annually in
the warfarin group compared to
1.53% annually in the 110-mg
dabigatran [relative risk (CI: 95%):
0.91 (0.74, 1.11); P<0.001 for
noninferiority] and 1.11% annually in
the 150-mg dabigatran group
[relative risk (CI: 95%): 0.66 (0.53,
0.82); P<0.001 for
superiority]. *Hemorrhagic stroke
occurred in 0.38% of subjects
annually on warfarin, 0.12% of
subjects on dabigatran 110 mg, and
0.10% of subjects on dabigatran 150
mg.

This study was completed
at 951 sites within 44
countries from 2005-2007.
Median follow-up was 2
years in 99.9% of patients.
The efficacy outcome
measured stroke or
systemic embolism
occurrence. Safety
outcomes measured the
incidence of severe
bleeding and death.

Exclusion criteria: severe valvular
disease, stroke within 14 days
before the study, severe stroke
within the past 6 months, high
bleeding risk, creatinine clearance
<30 mL/min, liver disease, and
pregnancy.

Safety outcomes:
*Major bleeding occurred annually
in 3.36% of patients on warfarin,
2.71% of patients on 110 mg
dabigatran, and 3.11% on 150 mg
dabigatran.
*Mortality rate annually was 4.13%
in patients on warfarin, 375% in
patients on 110 mg dabigatran, and
3.64% in patients on 150 mg
dabigatran.
Conclusions:
*Dabigatran 110 mg demonstrated
similar rates of stroke and embolism
in patients with atrial fibrillation
compared to warfarin, yet displayed
less major bleeding. Dabigatran 150
mg demonstrated lower rates of toke
and embolism compared to
warfarin,
but displayed more major bleeding.
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*Increased risk of gastrointestinal
bleeds and gastrointestinal effects
(gastritis and dyspepsia) in patients
taking 150 mg Dabigatran compared
to Warfarin.
*The risk of major bleeding was similar
between Dabigatran and Warfarin,
except for a higher risk of bleeding
evident in patients >75 years old taking
Dabigatran
*The rate of all-cause mortality was
lower in patients on Dabigatran than
Warfarin.
*After publishing of this article, safety
and efficacy outcomes were expanded
to include 81 new events in 80 patients:
4 myocardial infarctions, 1
stroke, 1 systemic embolic events, 69
major hemorrhages, and 5 transient
ischemic attacks. Conclusions to the
original study remained the same
(Connolly, et.al., 2010).
*1500 cases were re-evaluated for
stroke, systemic embolism, major
bleeding or life-threatening bleeding as
1,387 deaths occurred during the RELY trial. Data was altered but even
with these alterations, no changes were
made to the conclusions in the
original study (Connolly, et.al., 2014).

Trial
RELY-ABLE
(Long-Term
Multicenter
Observational
Study of
Dabigatran
Treatment in
Patients with
Atrial Fibrillation)
(Connolly et.al.,
2013).

Design/Method

Sample

Randomized, descriptive,
longitudinal cohort study
evaluating the two-year
follow-up of atrial
fibrillation patients taking
dabigatran 110 mg or
dabigatran 150 mg and
their effects on the
prevention of stroke or
systemic embolism.

A total of 5,581 subjects were
randomly assigned to a dabigatran
group during the RE-LY trial were
included in this trial if they had
continued dabigatran for
anticoagulation. These patients
received the same dose of
dabigatran (110 mg or 150 mg) they
received during RE-LY for a mean
follow-up of 2.25 years.

Efficacy Outcomes:
*Stroke and systemic embolism
occurred in 1.46% of patients on
dabigatran 150 mg BID and in 1.60%
of patients on dabigatran 110 mg BID
[HR (CI: 95%) 0.91 (0.69, 1.20].
*Annual hemorrhagic stroke rates
were 0.13% for dabigatran 150 mg
compared to 0.14% for dabigatran 100
mg.

This study extended the
RE-LY trial for an extra
2.25 years.

Compared to RE-LY, more
subjects in RELY-ABLE were
male and had paroxysmal atrial
fibrillation compared to
permanent atrial fibrillation.
Similarly, to RE-LY, patients in
RELY-ABE had diabetes mellitus
and coronary artery disease.

Safety Outcomes:
*Bleeding rates were 3.74% on
dabigatran 150 mg compared to 2.99%
on dabigatran 110 mg [HR (CI: 95%):
1.26 (1.04-1.53)].
*Death rates were 3.02% on dabigatran
150 mg compared to 3.10% on
dabigatran 110 mg [HR (CI: 95%): 0.97
(0.80, 1.19)].

The efficacy outcome
measured stroke or
systemic embolism
occurrence. The safety
outcome measured
bleeding rates and death.

Inclusion criteria: participants in
the original RE-LY trial who were
not assigned warfarin. In RELYABLE, subjects were 48% of the
original subjects in the RE-LY trial.
Exclusion criteria included:
necessity for anticoagulation for
other reasons, a gastrointestinal
ulcer within the past 30 days,

Findings and
Conclusions

Conclusion: Longer-term use of
dabigatran 150 mg BID demonstrated
an increased risk or major bleeding
compared to dabigatran 100 mg BID.
Rates of stroke and death were similar
between the two doses of dabigatran.
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anemia (hemoglobin <100 g/L),
thrombocytopenia (platelet count
<100x109L), liver transaminases
>2 times normal, CrCl <30
mL/min, pregnancy, high risk of
bleeding, scheduled ablation for
AF, and unstable cardiovascular
disease.

Trial
RE-ALIGN
(Randomized,
phase II study to
Evaluate the
Safety and
Pharmacokinetics
of Oral
Dabigatran in
Patients are Heart
Valve
Replacement)
(Eikelboom et al.,
2013).

Design/Method
Prospective, randomized,
phase 2, open-label trial
investigating warfarin
versus dabigatran in
patients undergoing aortic
or mitral valve replacement
within the past 7 days or a
history of a valve
replacement within the past
three months.
This study was completed
at 39 sites within 10
countries from 2011-2012.
Initial dabigatran dose was
based upon kidney function,
with adjustments based
upon reaching a trough
plasma level of 50 ng/mL.
INR dose was based upon
attaining an INR of 2-3
(low thromboembolic risk)
or 2.5.-3.5 (immediate or
high thromboembolic risk).
Patients were administered
the anticoagulant for 12
weeks.
The efficacy outcome was
the trough plasma level of
dabigatran. The safety
outcome measured was
major bleeding.

EDOXABAN
(Savaysa®)
Edoxaban Study
018
(Weitz et al., 2011).

Randomized, doubleblind, multicenter,
multinational, parallel
group, phase 2 study
comparing four doses of
edoxaban to warfarin in
patients with nonvalvular atrial

Sample
Out of a total of 252 subjects, 168
were randomly assigned to the
dabigatran group while 84 were
assigned to the warfarin group in a
2:1 ratio. Approximately 64-67% of
the subjects were male and the
mean age was 56 years old.
Approximately 79% (199) subjects
were scheduled for the valve
replacement, with 172 (68%) aortic,
71 (28%) mitral, and 9 (4%) both
valves. Out of the subjects, 74
(24%) were low risk for
thromboembolic complications after
the procedure, and 178 (71%) were
intermediate or high risk.
Inclusion criteria: age 18-75 years
old and either scheduled for
implantation of a mechanical
bileaflet valve in the aortic or mitral
valve or received a mechanical
bileaflet mitral valve within 3
months prior to this study.

Findings and
Conclusions
The trial ended prematurely after
increased VTE and bleeding
events presented in the dabigatran
group.
In 52 (32%) of the 162 dabigatran
patients, dabigatran dose was
adjusted or discontinued.
Efficacy outcome: Stroke (ischemic
or unspecified) manifested in 9 (5%)
of dabigatran subjects compared to
zero patients in the warfarin group.
Safety outcome: Major bleeding
(pericardial bleeding) presented in 7
(4%) subjects of the dabigatran
group compared to 2 (2%) of the
warfarin subjects.
Conclusion: Due to the increased
risk of VTE and bleeding risk in
patients with mechanical heart
valves, dabigatran displays
increased risk compared to
warfarin.

Exclusion criteria: prior prosthetic
valve replacement, aortic surgery,
endocarditis, complex congenital
heart anomalies, history of
hemorrhagic stroke, high bleeding
risk, uncontrolled hypertension,
abnormal liver functions >3 times
the normal limit or active hepatitis,
creatinine clearance
<40mL/min, chronic
anticoagulation for reasons other
than AF, myocardial infarction
within the past month, recent
radiation treatment or cancer,
pregnancy, scheduled surgery
within one month, or
contraindications to warfarin or
dabigatran.

A total of 1,146 subjects were
randomized to edoxaban (30 mg
daily, 30 mg twice daily, 60 mg
daily, or 60 mg twice daily) or
dose-adjusted warfarin with a
target INR of 2.0-3.0. The average
age of subjects was 65 years old
with 65.4% warfarin naïve.

Safety outcome: Bleeding occurred
in 3.2% of subjects in the warfarin
group, compared to 10.6% in the
edoxaban 60 mg twice daily group
(p
= 0.002) and 7.8% in the edoxaban
60 mg twice daily group (p = 0.029).
Bleeding occurred less in the
edoxaban 60 mg daily group
(3.8%)
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fibrillation to prevent
stroke.

and edoxaban 30 mg daily group
(3.0%) compared to warfarin.

Safety outcomes
measures were bleeding
events, elevated liver
enzymes, and elevated
bilirubin levels.

Labs: Liver enzyme levels and
bilirubin levels were not significantly
elevated in any of the edoxaban
groups.
Conclusions: With comparable
bleeding risk profiles, edoxaban 30
mg or 60 mg daily is a safe alternative
to warfarin in preventing stroke in
patients with atrial fibrillation. Due to
the heightened bleeding risk,
edoxaban 30 mg twice daily or
edoxaban 60 mg twice daily are not
recommended.

Trial
ENGAGE AFTIMI 48
(Effective
Anticoagulation
with Factor Xa
Next Generation in
Atrial Fibrillation)
(Giugliano et al.,
2013).

Design/Method
Randomized, doubleblind, double-dummy
study comparing
edoxaban and warfarin
in patients with atrial
fibrillation and an
intermediate to high risk
of stroke or systemic
embolism.
Patients received
warfarin or edoxaban for
a median of 2.5 years.
This study was
completed at 1,339 sites
within 46 countries from
2008-2010.
The efficacy outcome
was incidence of stroke
or systemic embolism.
The safety outcome was
major bleeding and
cardiovascular deaths.

Sample
Out of 21,101 subjects with
atrial fibrillation were randomly
assigned to one of three groups:
1) 7,030 received edoxaban 60
mg
daily, 2) 7,034 received edoxaban
30 mg daily, and 3) 7,037
received warfarin daily with a
target INR of 2.0-3.0. The
average age of subjects was 72
years old with 38% females per
group.
Inclusion criteria: >age 21 years
old, documented AF through an
EKG within the past year, and
CHADS2 score >2.
Exclusion criteria: atrial
fibrillation with a reversible cause,
a creatinine clearance <30
mL/min, high risk of bleeding,
dual antiplatelet therapy, moderate
to severe mitral stenosis, chronic
anticoagulation for other reasons,
acute coronary syndrome,
coronary revascularization, or
stroke within 30 days.

Findings and
Conclusions
Efficacy Outcome: stroke or
thromboembolism occurred in 1.50%
of subjects in the warfarin group
(therapeutic INR 68.4% of the time),
compared to 1.18% with edoxaban 60
mg (HR 0.78; 97. % CI 0.63-0.99;
p<0.001 for noninferiority) and
edoxaban 30 mg (HR 1.07; 95% CI
0.87-1.31; p = 0.005 for
noninferiority). Edoxaban 60 mg was
preferred to warfarin for intention-totreat (HR 0.87; 97.5% CI 0.73-1.04; p
= 0.08). Conversely, warfarin was
preferred to edoxaban 30 mg in the
intention-to-treat (HR 1.13; 97%F CI
0.71-0.91; p<0.0001)
Safety Outcome:
*Subjects on edoxaban 60 mg
demonstrated less severe bleeding
annually (3.43%) compared to
warfarin (2.75%; HR 0.80; 95% CI
0.71, 0.91), p<0.001]. The same
results were seen with edoxaban 30
mg, with 1.61% annual bleeding
compared to warfarin (HR 0.47; 95%
CI, 0.41-0.55; p<0.001). The most
common site of major bleeding was in
the GI tract: 205 (1.78) with edoxaban
and 150 (1.27) with warfarin.
*Annual cardiovascular deaths
occurred in 3.17% of subjects on
warfarin compared to 2.74% with
edoxaban 60 mg (HR 0.86; 95% CI
0.77-0.97; p=0.01), and 2.71% with
low dose edoxaban (HR 0.85; 95% CI
0.76-0.96; p=0.008).
Conclusion: In patients with atrial
fibrillation, edoxaban 30 mg and 60
mg were noninferior to warfarin in
preventing stroke or systemic
embolism, in addition to decreased
bleeding risk and cardiovascular
death.
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Trial
RIVAROXABAN
(Xarelto®)
ROCKET AF
(Rivaroxaban
once daily, oral,
direct factor Xa
inhibitor
Compared with
Vitamin K
Antagonist for
Prevention of
Stroke and
Embolism Trial in
Atrial Fibrillation)

Design/Method
Multi-national doubleblind, double-dummy,
event driven study
comparing rivaroxaban
to dose-adjusted
warfarin in stroke
prevention of
nonvalvular atrial
fibrillation
Patients were randomized
to a study treatment of
warfarin or rivaroxaban for
a mean of 590 days.

(Patel et al., 2011)
This study was complete at
1,178 sites within 45
countries from 2006-2010.

Primary efficacy outcomes
measured the incidence of
stroke or systemic
embolism. Safety
outcomes measured major
and non-major bleeding
events.

X-VeRT
(Explore the
Efficacy and
Safety of OnceDaily
Rivaroxaban for
the Prevention of
Cardiovascular
Events with NonValvular Atrial
Fibrillation
Scheduled for
Cardioversion)

Prospective, randomized,
open-label, parallel group
study comparing safety
and efficacy of
rivaroxaban to warfarin in
patients with non- valvular
atrial fibrillation
scheduled for
cardioversion.
This ongoing study will
be completed in 17
countries.

Sample
A total of 14,264 patients were
randomized to rivaroxaban (7,131
subjects) or adjusted-dose
warfarin (7,133 subjects) with a
target INR of 2.0-3.0.
Rivaroxaban was administered 20
mg daily or 15 mg daily with a
creatinine clearance of 30-49
mL/min. The mean age of
subjects was 71 years, the mean
CHADS2 score of 3.5, 60% male,
83% Caucasian, 13% Asian, and
1.3% Black.
Inclusion criteria: AF had to be
diagnosed by EKG within 30
days. Patients were required to
have the following risk factors: a
prior stroke (ischemic or unknown
type), transient ischemic attack, or
non-CNS systemic embolism. In
addition, patients were required to
have 2 or more of the following
risk factors: age >75 years,
hypertension, heart failure or left
ventricular ejection fraction
<35%, or diabetes mellitus. The
CHADS2 score had to be >2.
Exclusion criteria: severe mitral
stenosis, prosthetic heart valve,
scheduled cardioversion, AF with
a reversible cause, atrial myxoma,
endocarditis, active bleeding, high
bleeding risk, thrombocytopenia
(<90,000 μ/L), uncontrolled
hypertension ≥180/100, prior
stroke or TIA, chronic
anticoagulation for other reasons,
current use of antiplatelets,
chronic NSAID use, use of
cytochrome P450 3A4 inhibitors
or inducers, anemia (hemoglobin
<10 g/dL), pregnancy or
breastfeeding, HIV positive, liver
disease, or creatinine clearance
<30 mL/min
A total of 1,500 patients will be
randomized into two groups in a
2:1 ratio of rivaroxaban to
warfarin. Subjects can be further
randomized into two groups: 1)
rivaroxaban or warfarin with
heparin given 1-5 days prior to
cardioversion with a
transesophageal echocardiography
to assess for atrial thrombi or 2)
rivaroxaban or warfarin given 2156 days before the cardioversion.
Rivaroxaban or warfarin will be
continued 6 weeks after the
cardioversion. Rivaroxaban 20 mg

Findings and
Conclusions
Efficacy outcomes:
*Stroke or systemic embolism
occurred in 188 of the subjects in the
rivaroxaban group annually (1.7%),
compared to 241 in the warfarin group
(2.2%; HR 0.79, 95% CI 0.66-0.96,
p<0.001 for
noninferiority).
*In the intent-to-treat analysis, stroke
or systemic embolism occurred
annually in 269 subjects in the
rivaroxaban group (2.1%) compared to
306 subjects in the warfarin group
(2.4%; HR 0.88, 95% CI 0.74-1.03;
p<0.001 for
noninferiority; p=0.12 for superiority).
Safety outcomes:
*Major and non-major bleeding
occurred in 1,475 patients in the
rivaroxaban group annually
(14.9%) and 1,449 in the warfarin
group annually (14.5%).
*Intracranial hemorrhage (0.5%) and
fatal hemorrhage (0.2%; p=0.003)
occurred less with rivaroxaban than
warfarin (0.7% intracranial
hemorrhage and 0.5% fatal
hemorrhage, p=0.02).
Conclusions: Rivaroxaban was noninferior to warfarin to preventing
first occurrence of stroke or systemic
embolism in nonvalvular atrial
fibrillation [HR (95% CI): 0.88 (0.74,
1.03)]. Bleeding events was nonsignificant between groups but
rivaroxaban demonstrated less fatal
and intracranial bleeding compared
to warfarin.

This ongoing trial will assess the
safety and efficacy of rivaroxaban
versus warfarin in preventing stroke
and reducing bleeding risk for nonvalvular atrial fibrillation patients
requiring cardioversion.
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(Ezekowitz et al., The efficacy outcome is
2014)
incidence of strokes, TIA,
myocardial infarction,
noncentral nervous system
systemic emboli, and
cardiovascular death. The
safety outcome is the
incidence of bleeding
events.

daily will be the administered
dose unless the patient has a
creatinine clearance <30-40
mL/min, warranting rivaroxaban
15 mg daily. The target INR for
warfarin will be 2.0-3.0.
Inclusion criteria: adults older
than 18 years old with nonvalvular atrial fibrillation lasting
longer than 48 hours and
hemodynamic stability. These
patients must be scheduled for
cardioversion, either electrical or
pharmacologic.
Exclusion criteria: severe mitral
stenosis, prosthetic heart valve,
severe stroke within the past 3
months, left atrial thrombus, TIA,
thromboembolus, or myocardial
infarction within the past 2 weeks,
high bleeding risk, active
bleeding, chronic anticoagulation
for another reason, dual
antiplatelet therapy or chronic
aspirin use >100 mg daily, use of
CYP3A4 and P-gp inhibitors,
pregnancy or breastfeeding,
contraindications to rivaroxaban
or warfarin, hepatic disease, or
alcoholism.

Trial
PIONEER AFPCI
(Gibson, et al.,
2015)

Design/Method Sample
Exploratory, open-label,
randomized, controlled,
multicenter study
comparing the safety of
rivaroxaban and
warfarin in patients with
non-valvular atrial
fibrillation who have
received percutaneous
coronary intervention
(PCI) with stent
implantation.
Safety outcomes
measured the incidence
of thrombolysis in
myocardial infarction,
major bleeding, or minor
bleeding. Patients were
followed-up for an
average of 12 months.
Dual antiplatelet therapy
is considered aspirin plus
clopidogrel (or an
alternative P2Y12
inhibitor: prasugrel or
ticagrelor). Triple
therapy is considered
dual therapy plus an oral
anticoagulant.

A total of 2,100 subjects have
been enrolled in this study and are
being randomized to three groups
(700 subjects per group): 1)
rivaroxaban 15 mg daily with
clopidogrel 75 mg daily for 12
months, 2) rivaroxaban 2.5 mg
twice daily with dual antiplatelet
therapy (clopidogrel 75 mg daily
and aspirin 75-100 mg daily) for a
predetermined duration of 1, 6, or
12 months, or 3) dose-adjusted
warfarin daily (target INR 2.03.0) with dual antiplatelet therapy
for a predetermined duration of 1,
6, or 12 months. If clopidogrel
was not used, an alternative
P2Y12 inhibitor could be used in
its place.
Inclusion criteria: at least 18
years old with AF diagnosed by
an EKG and have completed PCI.
Exclusion criteria: active
bleeding, thrombocytopenia
(platelets <90,000 µ/L), history of
intracranial bleed, severe
gastrointestinal bleed within the
past year, history of TIA or
stroke, cardiogenic shock, trauma

Findings and
Conclusions
This trial is currently ongoing to
evaluate bleeding risks between
warfarin and rivaroxaban in
patients with non-valvular atrial
fibrillation who have undergone
PCI.

234
within 30 days, creatinine
clearance <30 mL/min, anemia
(hemoglobin <10 g/dL), liver
disease, history of HIV, planned
CABG, contraindications to
aspirin, warfarin or clopidogrel.

Trial

Design/Method

WARFARIN
(Coumadin®)

Randomized, doubleblind study comparing
warfarin, aspirin, and
AFASAK-I:
placebo in patients with
(Copenhagen
Atrial Fibrillation, non-valvular atrial
fibrillation.
Aspirin, and
Anticoagulation)
This study was completed
from 1985-1988 with a
(Petersen,
patient follow-up of 2
Godtfredsen,
years.
Boysen,
Andersen, &
Andersen, 1989)

BAATAF
(Boston Area
Anticoagulation
Trial for Atrial
Fibrillation
Investigators,
1990)

Sample

Findings and
Conclusions

Subjects were randomized to a
treatment group: warfarin (335),
aspirin 75 mg daily (336) and
placebo (336).

Efficacy outcome: Thromboembolic
complications and mortality from a
vascular etiology were decreased in
the warfarin group (5 patients)
compared to the placebo (20 patients)
and aspirin (21 patients) groups.

Safety outcome: Bleeding was evident
in 21 subjects on warfarin, 2 on
aspirin, and 0 on the placebo.

Primary outcomes
measured included stroke,
transient ischemic attack
(TIA), embolic
complications. Death was a
secondary outcome
assessed.

Unblended, randomized,
controlled study
investigating the safety and
efficacy of warfarin in
preventing stroke in
patients with nonvalvular
atrial fibrillation.
Average follow-up time
was 2.2 years.
The efficacy outcome
measured was incidence of
ischemic stroke. The safety
outcomes measured were
major and minor bleeding
events and death.

Conclusion: In patients with nonvalvular atrial fibrillation, warfarin
is recommended to prevent
thromboembolism.

Patients were randomized to the
warfarin group (212 subjects with
a target prothrombin time ratio of
1.2-1.5) or the control group (208
subjects). The control group was
given the preference of taking
aspirin. The mean age of subjects
was 68 years old with 72% men.
Inclusion criteria: adults diagnosed
with non-rheumatic (valvular) AF
through at least two separate EKGs.
With intermittent AF, an EKG must
document the rhythm within 18
months of the study. Thyroid
function must be normal to
participate.
Exclusion criteria: planned
cardioversion, transient AF related
to another diagnosis, cardiac
thrombus, left ventricular aneurysm,
severe heart failure, prosthetic heart
valves, severe stroke within the past
6 months, TIA, intracranial
hemorrhage, contraindications to
anticoagulation (liver disease or
peptic ulcer disease), recent
thrombophlebitis, or chronic aspirin
use.

Prothrombin time was therapeutic
in 83% of the subjects.
Approximately 10% of the subjects
in the warfarin group chose to stop
taking warfarin during the study.

Efficacy outcome: The annual
incidence of stroke was 2 (0.41%) in
the warfarin group compared to 13
(2.98%) in the control group,
suggesting warfarin decreases the risk
of stroke by 86% (95% CI, 0.04-0.49;
p = 0.0022).

Safety outcomes:
*A total of 37 subjects died during the
study, with 2.25% annually in the
warfarin group and 5.97% annually in
the control group (95% CI, 0.17-0.82;
p
= 0.005), with one patient
succumbing to a severe bleed in each
group.
*Bleeding requiring a transfusion or
hospitalization was comparable in both
groups. Minor bleeding was higher
with warfarin (38 subjects) compared
to the control group (21 subjects).
Warfarin at lower doses is safe and
effective in preventing stroke with
non- valvular atrial fibrillation.
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Trial
SPAF I:
(Stroke
Prevention in
Atrial Fibrillation)
(Stroke
prevention, 1991)

Design/Method

Sample

Findings and
Conclusions

Multicenter, randomized,
double-blind study
comparing aspirin (325
mg daily) to warfarin
group with a placebo
group to prevent stroke
and systemic embolization
in patients with atrial
fibrillation.

Group 1 was composed of patients
randomly assigned to the warfarin
group (210 subjects), aspirin group
(206 subjects), or placebo group
(211 subjects). Patients unable to
take anticoagulation were
randomized Group 2: either the
aspirin (346 subjects) or placebo
group (357 subjects). Out of the
1,330 subjects, the average age of
subjects was 67 years old, 71%
men, 85% Caucasian, 6%
Black, and 10%
Asian/Hispanic/other race.

Efficacy outcomes:

1,300 patients were
followed for an average of
1.3 years at 16 facilities
with the United States
from 1987-1992.
The efficacy outcome
measured incidence of
stroke or systemic
embolization. The safety
outcome measured
bleeding events.

Inclusion criteria: diagnosis
through an electrocardiogram of
non-valvular atrial fibrillation
within the past year.
Exclusion criteria: contraindication
to aspirin or warfarin, mitral
stenosis, congestive heart failure
(New York Heart Association class
4), myocardial infarction within the
past three months, coronary bypass
surgery within the past year,
unstable angina pectoris within the
past year, stroke or TIA within the
past two years, life expectancy less
than two years, chronic renal
failure, thrombocytopenia, severe
alcoholism, other indications for
chronic warfarin therapy, chronic
NSAID use.
Exclusion criteria for
anticoagulation: age greater than
75 years old, unable to adhere to
INR monitoring, history of falls,
positive occult blood in stool,
chronic alcoholism, uncontrolled
hypertension, syncope or seizures,
previous intracranial bleed, poorly
controlled INR levels, or prior
bleed while on anticoagulation.

*Patients assigned to the warfarin
group versus placebo displayed a
decrease of stroke or systemic
embolism by 67% annually (2.3% with
warfarin and 7.4% with placebo, p =
0.01; 95% confidence interval,
27.85%). *Patients assigned to the
aspirin group versus placebo
demonstrated a 42% reduction of
stroke or systemic embolism annually
(3.6% with aspirin and 6.3% with
placebo, p = 0.02; 95% confidence
interval, 9-63%).
*These primary events of stroke or
systemic embolism, as well as death
were decreased by 58% with
warfarin (p = 0.01) and 32% with
aspirin (p = 0.02) with aspirin.

Safety outcome: The annual
bleeding rates 1.5% with warfarin,
1.4% with aspirin, and 1.6% with
the placebo.

The risk of stroke and systemic
embolism in patients with atrial
fibrillation can be reduced with
aspirin or warfarin, yet data is not
conclusive for preferring one drug
versus the other.
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Trial
CAFA:
(Canadian Atrial
Fibrillation
Anticoagulation)
(Connolly et al.,
1991).

Design/Method

Sample

Findings and
Conclusions

Randomized, doubleblind, placebo-controlled
study investigating the use
of warfarin versus a
placebo in preventing
stroke in patients with
atrial fibrillation.

Patients were randomly assigned to
the warfarin group with a target
INR of 2.0-3.0 (187 subjects) or the
placebo group (191 subjects).

This trial was stopped prematurely
because of two similar studies
displaying superiority in warfarin
compared to a placebo in
decreasing stroke risk in patients
with atrial fibrillation.
Over 26% of subjects stopped warfarin
prematurely as well as 23% of the
placebos. An average of 43.7% of the
subjects maintained the therapeutic
INR of 2.0-3.0 in the warfarin group.

Primary efficacy
outcomes measured
included incidence of
nonlacunar stroke and
noncentral nervous
system embolism.
Primary safety outcomes
measured included fatal
bleed or intracranial bleed
within 28 days of
completing the study.

Efficacy outcome: A primary effect
was noted in 3.5% of the warfarin
subjects compared to 5.2% of the
placebo patients, suggesting a 37%
decrease in stroke risk with warfarin
(95% CI, - 63.5%-75%%, p = 0.17).

Safety outcomes:
*Severe bleeding was present in
2.5% of the warfarin subjects
compared to 0.5% in the placebo
subjects. *Minor bleeding occurred
in 16% of the warfarin subjects
compared to 9% of the placebo
subjects.

Conclusion: Warfarin is superior to a
placebo in preventing stroke and noncentral nervous system embolism in
patients with atrial fibrillation, yet
displays a high risk of minor and
severe bleeding compared to a
placebo.
EAFT
(European Atrial
Fibrillation Trial
Study Group,
1993)

Randomized, multicenter
study assessing the safety
and efficacy of
anticoagulation versus
aspirin in patients with
non-valvular atrial
fibrillation who have
suffered a minor stroke or
transient ischemic attack.
This study was completed
in 108 clinics in 13
countries, with an average
follow-up of 2.3 years.
The primary efficacy
outcomes measured
included the incidence of
stroke, myocardial
infarction, systemic
embolism, or death from

In group 1, 669 patients were
randomized to either open-label
anticoagulation or a double-blind
group receiving a placebo or 300
mg aspirin daily. In group 2, 2,338
patients were randomized to receive
aspirin or placebo if they had
contraindications to warfarin. The
average age was 73 years old, with
55-59% men per group.
Inclusion criteria: patients 25
years or older with non-valvular
atrial fibrillation and history of a
minor ischemic stroke or TIA
within the past 3 months.
Exclusion criteria for the study:
secondary causes of atrial
fibrillation such as
hyperthyroidism, coronary surgery

Efficacy outcomes:
*Annually, in group 1, primary
events occurred in 8% of the
anticoagulant group compared to
17% in the placebo group (hazard
ratio [HR] 0.53; 95% confidence
interval [CI] 0.36-0.79).
However, the rate of strokes
decreased annually in group 1 from
significantly from 12% to 4% (HR
0.34; 95% CI0.20-0.57).
*If the patient was on aspirin and in
group 1 or group 2, primary events
annually occurred in 15% of
subjects compared to 19% in the
placebo (HR 0.83; 95% CI 0.651.05).
*Anticoagulation was determined to
be superior to aspirin in preventing
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a vascular etiology. The
primary safety outcome
measured was bleeding
events.

scheduled within the next 3
months
Exclusion criteria for
randomization to a treatment
group: concurrent use of
medications with a high bleeding
risk (NSAIDS, anti-platelets, or
oral anticoagulants), mechanical
valves, cardiac aneurysm, atrial
myxoma, myocardial infarction
within the past 3 months, or
coagulation disorders. The
acceptable range for the INR for
the anticoagulant was 2.5-4, with a
goal of 3. The choice of
anticoagulant was selected by the
physician, predominantly
coumarin.
Exclusion criteria for
anticoagulation: high bleeding
risk, hypertension >180/100 mm
Hg, chronic alcoholism, prior
intracranial bleed, hemorrhagic
retinopathy, or poor adherence to
the treatment plan.

Trial
SPAF-II:
(Stroke
Prevention in
Atrial Fibrillation
II)
Halperin et al.,
1994)

primary events (HR 0.60; 95% CI 0.410.87).

Safety outcome: No intracranial bleeds
were observed in patients
anticoagulated, with minor bleeding
present annually in only 2.8% of
subjects in the warfarin group and 0.9%
of the aspirin group.

Conclusion: Anticoagulation is
superior to aspirin for both safety and
efficacy in patients with non-valvular
atrial fibrillation who have suffered
from a recent TIA or stroke. If
anticoagulation is contraindicated,
aspirin is a safe alternative for this
population to prevent stroke.

Design/Method

Sample

This study was a
continuation of SPAF-I to
better assess through two
parallel randomized trials
the efficacy of warfarin
compared to aspirin in
reducing stroke in patients
with atrial fibrillation. The
focus in this study was the
incidence of
thromboembolic events
with warfarin compared to
aspirin and to compare the
effectiveness of
anticoagulants based on
patient age.

The first randomized trial
contained 715 subjects less than
75 years old and the second
randomized trial contained 383
patients over 75 years of age.
Patients randomized to the
warfarin group had a goal INR of
2.0-4.5, while the aspirin group
was given 325 mg daily.

Patients less than 75 years old:

All 416 patients from SPAF-I were
who able to take anticoagulation
continued the therapy they were
given during this first study. Also
from SPAF-I, 265 of the patients in
the placebo group were randomized
to a group in SPAF-II. The other
419 patients were new patients who
did not participate in SPAF-I.

*In the absence of hypertension, new
onset heart failure, or a prior
thromboembolism, stroke or systemic
embolism occurred in 0.5% of these
patients annually (95% CI; 0.1-1.9).

The goal was to determine
if warfarin compared to
aspirin would decrease
systemic embolism or
stroke in patients less than
75 years old by 2%
decrease this risk by 4% in
patients older than 75
years old. The safety
outcome measured was
incidence of systemic
embolism or stroke.
This study took place
from 1985-1991 at 16

The same inclusion criteria as in
SPAF-I were utilized.
Additionally, patients were
excluded from the study if they
were less than 60 years old
without cardiovascular disease,
mitral stenosis, contraindications
to warfarin or aspirin, or
mechanical heart valves.
Confirmation of atrial fibrillation
through an electrocardiogram
within the past year was necessary
to participate in this study.

Findings and
Conclusions
*Warfarin decreased the rate or stroke
or systemic embolism by 7% per year
(95% CI; 0.4-1.7). In comparing
warfarin to aspirin, the rate of stroke or
systemic embolization was 1.3%
compared to 1.9% respectively (relative
risk [RR] 0.67, p = 0.24).

Patients older than 75 years old:
*Systemic embolism or stroke was
reduced by 0.5% per year (95% CI, 1.7-4.1). In comparing warfarin to
aspirin, the rate of stroke or systemic
embolization was 3.6% compared to
4.8% respectively (relative risk [RR]
0.73, p = 0.39).
*The overall rate of hemorrhagic or
ischemic stroke with deficits was 4.3%
per year in the aspirin group and 4.6%
per year in the warfarin group (RR 1.1).
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sites within the United
States.

Conclusions: To prevent ischemic
stroke in patients with atrial
fibrillation, warfarin is superior to
aspirin. In the absence of risk
factors, patients less than 75 years
old demonstrate a low stroke risk if
treated with aspirin. In patients older
than 75 years old, the hemorrhagic
and ischemic stroke risk is increased,
despite administration of warfarin or
aspirin. Selecting the type of
anticoagulation should be dependent
on patient age and stroke risk with
atrial fibrillation.

Trial

Design/Method

Sample

Findings and
Conclusions

SPAF-III:
(Stroke Prevention
in Atrial
Fibrillation III)

This randomized,
multicenter study was a
continuation of SPAF-I
and SPAF-II.

Patients were randomly assigned
to the adjusted-dose warfarin
(INR 2.0-3.0) group (523
subjects) or to the low intensity,
fixed-dose warfarin (INR 1.2-1.5)
with aspirin (325 mg daily) group
(521 subjects).

*In the warfarin patients, the
average INR in the aspirin with
warfarin group was 1.3 compared to
2.4 for the dose adjusted warfarin.

(Adjusted dose
warfarin, 1996).

The goal of this study was
to compare warfarin to the
combination of warfarin
and aspirin to assess
safety and efficacy of
anticoagulation in patients
with atrial fibrillation and
high risk of stroke.
This study was designed
to take place over 2 ½
years from 1993-1995 in
20 sites in both the United
States and Canada.
The primary efficacy
outcomes measured were
rates of ischemic stroke
and systemic embolism.

This study was comprised of 1044
patients with atrial fibrillation and a
minimum of one risk factor for
stroke (female sex over 75 years
old, congestive heart failure, left
ventricular ejection fraction
≤25%, prior thromboembolism, or
systolic blood pressure >160
mmHg).
The same inclusion and exclusion
criteria from SPAF-I and SPAF-II
applied except: subjects who
participated in the prior trials were
exempt. Inclusion criteria included
documented AF through an
electrocardiogram within 6 months,
no history of mitral stenosis,
mechanical heart valves or
pulmonary embolism, and no
contraindications to warfarin or
aspirin. Compared to prior trials,
patients who suffered from an
ischemic stroke or TIA within 30
days where included in SPAF-III.

*During the mean follow-up of 1.1
years, INRs in the aspirin with
warfarin group were therapeutic
(1.2-1.5 range) 54% of the time and
subtherapeutic (<1.2) 34% of the
time.
*The follow-up period was stopped
prematurely, as the risk of ischemic
stroke and systemic embolism was
significantly higher in the aspirin
with warfarin group (7.9% annually,
p = 0.0001), compared to the
adjusted-dose warfarin (1.9%
annually, 95% CI (3.4,
8.6).
*The warfarin with aspirin group
displayed higher annual rates of
stroke (5.6%, p = 0.0007) compared
to warfarin only (1.7%), as well as
higher rates of death from a vascular
cause (11.8% in the combination
group compared to 6.4% with
warfarin, p = 0.0002).
*Severe bleeding annually was
similar between the combination
group [2.4%, 95% CI 1.4, 4.1)]
and warfarin only group [1.4%, 95%
CI (1.2-3.7)].

Conclusions: Low-intensity, fixeddose warfarin with aspirin is not
recommended to prevent stroke in
patients with atrial fibrillation.
Adjusted-dose warfarin with a
target INR of 2.0-3.0 has
demonstrated safety and efficacy in
decreasing stroke in patients with
atrial fibrillation.
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Trial

Design/Method

Sample

AFASAK-II:
(Copenhagen Atrial
Fibrillation,
Aspirin, and
Anticoagulation II)

This randomized,
controlled study was a
continuation of AFASAKI to further assess safety
and efficacy of warfarin to
aspirin in preventing
stroke in patients with
non- valvular atrial
fibrillation.

A total of 677 subjects were
randomly assigned to one of four
groups: 1) minidose warfarin 1.25
mg/day, 2) warfarin sodium 1.25
mg/day plus aspirin 300 mg/day,
3) aspirin 300 mg/day, and 4)
adjusted dose warfarin with a target
INR of 2.0-3.0. The average age of
the subjects was 74 years old and
35-43% females per group.
Inclusion criteria: documentation
of atrial fibrillation through an
electrocardiogram by at least one
month, and age 18 or older.

(Gullov et al.,
1998)

Primary efficacy outcomes
measures included the
incidence of stroke or
systemic
thromboembolism.
Secondary efficacy
outcomes measured
included death, TIA, or
myocardial infraction.
The safety outcome
measured was bleeding
events.
The trial was designed to
run for six years starting in
1993, was but stopped
prematurely in 1996 when
another study (SPAF-II)
concluded low- intensity
(minidose) warfarin in
combination with aspirin is
less effective compared to
adjusted dose warfarin.

PATAF:
Prevention of
Arterial
Thromboembolis m
in non-valvular
Atrial Fibrillation)

Randomized control trial
comparing aspirin to
warfarin preventing
thromboembolism in
patients with nonvalvular atrial fibrillation.

(Hellemons et
al., 1999)

The average follow-up
time was 2.7 years.
Efficacy outcomes
measured included stroke
or systemic embolism.
Safety outcomes
measured included
vascular death or severe
bleed.

Exclusion criteria: less than age 60
with atrial fibrillation as a cause of
heart disease, heart failure,
hyperthyroidism, or chronic
obstructive pulmonary disease;
blood pressure >180/100 mmHg;
history of stroke or TIA within the
past 6 months; high bleeding risk;
patients already on warfarin
therapy; valvular atrial fibrillation;
or contraindication to warfarin or
aspirin.

Findings and
Conclusions
Efficacy outcomes:
*The incidence of stroke or
thromboembolism after one year
on therapy occurred in 5.8% of
the minidose warfarin group,
7.2% in the combination aspirin
and warfarin group, and 2.8% in
the adjusted-dose warfarin group
(p = .67).
*No significant differences were
noted when comparing treatment
of one to three years.

Safety Outcomes:
*Severe bleeding was not
evident in any of the groups
after three years.
*Minor bleeding was present in
24.7% of patients on minidose
warfarin, 24.4% on combination
warfarin and aspirin, group, 30.0%
on aspirin, and 41.1% on adjusted
dose warfarin.
*With the additional factors of
allergic reactions and dyspepsia,
the risk of bleeding with aspirin
increased to 46.2% after three
years.

729 atrial fibrillation patients in
Netherland age 60 years old or
older were randomly assigned to
standard coumarin therapy (target
INR of 2.5-3.5), low intensity
coumarin therapy (target INR of
1.1-1.6) or aspirin (150 mg daily).
The average age of patients was 75
years old, with 32-57% men per
group. Patients unable to be take
standard coumarin doses were
randomized to either the aspirin or
low intensity coumarin groups.
Inclusion criteria: patients age 60
or older with atrial fibrillation
diagnosed through an
electrocardiogram within the past
two years.
Exclusion criteria: prior stroke,
valvular atrial fibrillation,

Conclusion: Minidose warfarin did
not display statistically significance
in reducing stroke in patients with
atrial fibrillation, thus adjusteddose warfarin with a target INR of
2.0-3.0 continues to be
recommended.
Efficacy outcome: In comparing
low dose anticoagulation to
aspirin, the hazard ratio for
stroke or thromboembolism was
0.91 (0.t1 to 1.36) and 0.78 for
standard anticoagulation to
aspirin (0.34 to 1.81).

Safety Outcomes:
* Out of all three groups, 108
adverse events occurred (5.5%
per year), including 13 severe
bleeds (0.7% annually).
*Death from a non-vascular cause
was lower in the anticoagulation
group compared to aspirin [hazard
ratio 0.41 [0.20 to 0.82]).
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myocardial infarction or
cardiovascular surgery within the
prior year, cardiomyopathy, heart
failure, cardiac aneurysm,
reversible causes of AF,
pacemaker, contraindications to
aspirin or coumarin, history of
systemic embolism, renal
infarction, prior coumarin use
within 3 months, life expectancy of
less than 2 years.
Exclusion criteria for standard
coumarin doses: age older than 78
years old, duodenal or gastric ulcer,
retinopathy, history of a
genitourinary or gastrointestinal
bleed, hypertension (systolic blood
pressure >185 mm Hg and/or
diastolic blood pressure
>105 mm Hg).

BAFTA:
Birmingham Atrial
Fibrillation
Treatment of the
Aged Study
(Mant et al., 2007)

Prospective, randomized,
open-label, blind
assessment of end points,
controlled study
investigating the bleeding
versus stroke risk in
elderly patients on
warfarin versus aspirin.
Subjects were gathered
from 260 clinics within
England and Wales from
2001-2004.
Subjects were followedup between 2-7 years.
The primary efficacy and
safety outcomes measures
were incidence of ischemic
or hemorrhagic stroke,
arterial embolism,
intracranial hemorrhage
and extracranial
hemorrhage.

Findings and
Conclusions
*Severe
bleeding
was
nonsignificant when comparing the
three treatment groups.

Conclusion: Coumarin therapy (both
low-intensity and standard therapy)
has not demonstrating superiority to
aspirin in preventing
thromboembolism with no reduction in
bleeding risk in patients with nonvalvular atrial fibrillation, thus
aspirin is recommended as first line
treatment in this population.

A total of 937 subjects age 75
years age or older were randomly
assigned to the warfarin group
(target INR of 2.0-3.0) or aspirin
(75 mg daily). The average age
was 81.4 years old with 54-55%
men per group.

Safety and Efficacy outcomes:

Inclusion criteria: age 75 or older
with a confirmed diagnosis of atrial
fibrillation by EKG within the past
two years.

*In comparison, the aspirin group
had 44 strokes, 1 intracranial
hemorrhage, and 3 systemic
embolisms (annual risk of 3.5%;
relative risk 0.48, 95% CI
0.28-0.80, p = 0.003: absolute yearly
risk reduction 2%, 95% CI 0.7-3.2).

Exclusion criteria: rheumatic
(valvular) heart disease,
intracranial hemorrhage, nontraumatic bleed within the past 5
years, esophageal varices,
contraindications to warfarin or
aspirin, terminal illness, surgery
within the past 3 months, and
blood pressure >180/110 mm Hg.

*Throughout the study there was a
total of 21 strokes, 2 intracranial
hemorrhages, and 1 systemic
embolism in the warfarin group
(annual risk 1.8%).

*Regarding extracranial bleeds, 1.4%
occurred yearly in the warfarin group
compared to 1.6% in the aspirin
group (relative risk 0.97, 0.43-1.73;
absolute
risk reduction 0.2%-, -0.7 to 1.2).

Conclusion: Anticoagulation with
warfarin is safe and efficacious, thus it
is recommended over aspirin in
patients over age 75 years old with
atrial fibrillation to prevent stroke.
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REVERSAL
AGENTS

Open-label, randomized,
three-treatment, threeperiod, crossover study
examining a 50-gram
overdose of apixaban and
the results of subsequent
administration of activated
charcoal.

18 healthy subjects age 18-45 years
(mean age of 31.8 years), received
50 grams of activated charcoal 2
hours OR 6 hours after
administration of 20 mg apixaban
PO. The average age of subjects
was 31.8 years old with 10 males
and 8 females, 14 Caucasians and
4 Blacks.

Efficacy outcomes:
*Apixaban was evident in mean
plasma concentrations 72 hours
after ingestion and 48 hours after
activated charcoal administration, at
both the 2 and 6 hour intervals post
apixaban dose.
*Activated charcoal decreased the
apixaban exposure (AUC) by 50%
when administered 2 hours after
ingestion of 20 mg apixaban and 27%
when administered 6 hours after the
20 mg apixaban ingestion.
*The mean half-life of apixaban
(13.4 hours) decreased to ~5 hours
after administration of activated
charcoal at 2 or 6 hours post-dose.

Activated
Charcoal and
Apixaban
(Wang et.al., 2013)

This study was completed
from May 6th-17th, 2011.
Activated charcoal was
ingested at 2 hours or 6
hours after the overdose of
apixaban. Serum labs were
obtained up to 72 hours after
the administration of
activated charcoal.

Inclusion criteria: healthy males
and females age 18-45 years old
with a body mass index of 18-32
kg/m2.
Exclusion criteria: relevant acute or
chronic medical diagnoses,
pregnancy or breastfeeding,
gastrointestinal disorders, personal
history of coagulopathies, family
history of first degree relatives with
coagulopathies, or intracranial
hemorrhage, or smoking greater
than 10 cigarettes daily.
Five subjected were also excluded
with emesis 6 hours after
administration of apixaban or 30
minutes after ingestion of activated
charcoal.

RE-VERSE AD
Idarucizumab
(Praxbind®):
Reversal for
Dabigatran
(Pollack et. al.,
2015)

Prospective cohort study
examining safety and
efficacy of 5 g
idarucizumab IV to reverse
the anticoagulant effects of
dabigatran in the event of
significant bleeding or
necessity for an urgent
surgery.
Idarucizumab was
administered as two 50- mL
boluses containing 2.5 mg
of medication each.
The medications were
administered intravenously
less than 15 minutes apart.
Blood levels of
idarucizumab were obtained
at baseline, after
the first administration of

A total of 90 subjects group A had
51 with significant bleeding; group
B had 39 requiring an urgent
procedure). Over 68 subjects had an
elevated dilute thrombin at baseline
and 81 had an elevated ecarin
clotting time. The median age of the
subjects was 76.5 years and 56%
males, with a median creatinine
clearance of 58 mL/min. Over 90%
of subjects were receiving
dabigatran to prevent stroke related
to atrial fibrillation.
In group A, the necessity for a
reversal agent were as follows: 18
intracranial hemorrhages, 20
gastrointestinal bleeds, 9 traumarelated bleeding, and 11 other
etiologies of bleeding.

Safety outcomes:
*Adverse effects in patients who
received activated charcoal after
apixaban overdose included:
diarrhea, nausea, abdominal pain,
vomiting, flatulence, and abdominal
distention (11%).
*Adverse effects were higher in
patients who received apixaban
followed by activated charcoal 2
hours later (72.2%) and 6 hours later
(77.8%), compared to patients who
received only apixaban (16.7%).
* Adverse effects were mild
(38.9%) or moderate (44.4%) in
patients and resolved by the end of
the study.
*These adverse effects are
comparable to known adverse effects
or activated charcoal.
Conclusion: Activated charcoal can
help eliminate a 20 mg apixaban
overdose up to 6 hours postdose.
Efficacy outcomes:
*The median maximum percentage
reversal of anticoagulant effects of
dabigatran was 100% [(CI: 95%:
100
(100, 100)].
*Test results reached normal levels
within minutes, in 88-98% of
subjects. 24 hours later, results of
unbound dabigatran were <20 ng/mL
in 79% of subjects. *Hemostasis in
group A was obtained at a median
rate of 11.4 hours in 35 patients.
*Hemostasis in group B was obtained
intraoperatively in 33 patients, mildly
abnormal hemostasis in 2 patients,
and moderately abnormal hemostasis
in 1 patient.
*Thrombosis occurred 72 hours
after idarucizumab in 1 patient
whom anticoagulation was not restarted.
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idarucizumab, between 10
to 30 minutes, and at 1, 2,
4, 12, and 24 hours after the
second administration.

In Group B, the most common
indications for requiring a reversal
agent included bone fractures, acute
cholecystitis, acute renal
insufficiency with catheter
This study was completed at placement, acute appendicitis,
400 sites in 38 countries
joint/wound infection, and acute
from 2014-2015. Patient
mesenteric ischemia.
follow-up was for 1 month
after the study.
Inclusion criteria: Group A
subjects required a reversal agent
Outcomes measured
for uncontrollable or serious
included the dilute
bleeding. Group B subjects needed
thrombin time (dTT) or
surgery or invasive procedures
ecarin clotting time
which could not be delayed for 8
(ECT)lab 4 hours after
hours, the normal time for
administration of
hemostasis.
idarucizumab, and
hemostasis.
Exclusion criteria: none.

Conclusion: Idarucizumab can
safely and fully reverse the
anticoagulation effects of
dabigatran.
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ANNEXA-A and
ANNEXA-R:
Reversal agents for
Factor Xa
Inhibitors

Randomized, double-blind
two-part, placebocontrolled study examining
reversal of apixaban and
rivaroxaban with andexanet
alpha in healthy, elderly
subjects.

A total of 101 subjects were
administered apixaban 5 mg twice
daily for 3.5 days (ANNEXA-A, 48
subjects) or rivaroxaban 20 mg
daily for 4 days (ANNEXA-R, 53
subjects), until therapeutic drug
levels were achieved. In
ANNEXA-A, subjects were
randomized in a 3:1 ratio of
andexanet to placebo (17 subjects
received placebo), while in
ANNEXA-R, subjects were
randomized in a 2:1 ratio of
andexanet or placebo (27 subjects).

Apixaban:
*Anti-factor Xa activity of apixaban
was inhibited by 94% (24 subjects)
with the andexanet bolus compared
to 21% (9 subjects) with the placebo
(p<0.001).
*The amount of unbound apixaban
was decreased 9.3 ng/mL compared
to
1.9 ng/mL with the placebo (p<0.001).
*Thrombin was returned to normal
levels within 2-5 minutes in 100%
of the apixaban subjects compared
to 11% of the placebo (p<0.001).

Subjects also were randomized to a
part 1 or part 2 portion of the study.
In part 1 of the study, on day 4,
andexanet was given as a 400-mg
bolus in ANNEXA-A and an 800mg bolus in ANNEXA-R. In part 2
of the study, andexanet was given
as bolus with a 2-hour infusion.

Rivaroxaban:
*Anti-factor Xa activity or
rivaroxaban was inhibited by 92%
(27 subjects) compared to 18% (14
subjects) with the placebo (p<0.001).
*The amount of unbound
rivaroxaban was decreased 23.4
ng/mL compared to 4.2 ng/mL with
the placebo (p<0.001).
*With both rivaroxaban and
apixaban, the same results were
evident with the 2-hour infusion with
bolus compared to only the bolus.

(Siegal et al., 2015)

The outcome measured was
the average change in antifactor Xa activity
(inhibition), measured as a
percentage.
This study was completed
from 2014-2015:
ANNEXA-A was
completed in Arizona and
ANNEXA-R was
completed in California.
ANNEXA-A: Andexanet
alpha antidote administered
to reverse the anticoagulant
effects of apixaban
ANNEXA-R: Andexanet
alpha antidote administered
to reverse the anticoagulant
effects of rivaroxaban
Subjects were observed
for 8 days after
administration of the
antidotes, with safety
outcomes monitored for
up to 43 days after
administration.

The mean age of the subjects was
57.9 years old with 39% women.
Inclusion criteria: Subjects were
healthy and age 50-75 years old.
Exclusion criteria: none

D-dimer and prothrombin increased
in 1-2 subjects, yet results
normalized within 1-3 days. No
subjects reported any adverse events.
No thrombotic events occurred.
Conclusion: andexant alpha can
safely, quickly, and effectively
reduce the effects of apixaban and
rivaroxaban in the healthy elderly
population.
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OTHER KEY
TRIALS

Randomized controlled
trial comparing the
combination of clopidogrel
ACTIVE W:
and aspirin to
Atrial Fibrillation
anticoagulation in
Clopidogrel
preventing vascular events
(Plavix©)Trial with in patients with atrial
Irbesartan for
fibrillation.
Prevention of
Vascular Events W Subjects were assigned to
one of three ACTIVE trials
(ACTIVE
based on eligibility criteria:
Investigators,
ACTIVE W was for
2006)
patients who could take
oral anticoagulation,
ACTIVE A was for
patients unable to take oral
anticoagulation, and
ACTIVE I included
patients from ACTIVE A
or ACTIVE W who were
candidates for irbesartan.
Primary outcomes
measured included the
incidence of stroke, noncentral nervous system
systemic embolus,
vascular death, or
myocardial infarction.

ACTIVE A:
Atrial Fibrillation
Clopidogrel Trial
with Irbesartan for
Prevention of
Vascular Events A
(ACTIVE
Investigators,
2009)

Randomized, doubleblind, multicenter study
examining if the
combination of clopidogrel
and aspirin would decrease
the risk of vascular events
in patients with atrial
fibrillation unable to take
warfarin for
anticoagulation.
This study was completed
at 580 sites within 33
countries.
The primary outcomes
measured were the
incidence of myocardial
infarction, non-central
nervous system embolism,
stroke or death from a
vascular etiology.

Sample

Findings and
Conclusions

Subjects were randomly assigned
to either the oral anticoagulation
group with a therapeutic INR of
2.0-3.0 (3,371 subjects), or the
combination clopidogrel with
aspirin group (3,335 subjects). The
daily dose of clopidogrel was 75
mg and the daily dose of aspirin
was 75-100 mg.
The average age of patients was
70.2 years with 66-67% males per
group. The average CHADS2 score
was 2.0

*This study was terminated
prematurely as oral anticoagulation
displayed superiority to the clopidogrel
plus aspirin treatment in decreasing
vascular events (165 events or 3.93%
annually with anticoagulation
compared to 234 events or 5.6%
annually with clopidogrel plus aspirin;
relative risk 1.44 (1.17-1.76), p =
0.0003).

Inclusion criteria: AF confirmed
by an ECG plus at least one of the
following stroke risk factors: age
>75 years old, hypertension, prior
stroke/TIA/non-central nervous
system embolism, peripheral
vascular disease, left ventricular
ejection fraction <45%, age 55-74
years old with either diabetes or
coronary artery disease.

*The risk of bleeding was reduced in
patients who were taking oral
anticoagulation prior to starting this
study (1.30, 0.94-1.79) compared to
patients newly initiating oral
anticoagulation (1.27, 0.85-1.89), plus
displayed a larger reduction in
vascular events (relative risk 1.50,
95% CI 1.191.80, p = 0.03).

Exclusion criteria:
contraindications to warfarin or
clopidogrel, mechanical heart
valves, peptic ulcer disease within
the past 6 months, prior
intracerebral bleed, mitral stenosis,
or severe
thrombocytopenia.

Conclusion: in patients with atrial
fibrillation with a high risk of stroke,
oral anticoagulation is superior in
preventing vascular events compared
to the combination of clopidogrel with
aspirin.

Out of 7,554 subjects, 3,772 were
randomly assigned to a clopidogrel
group (75 mg) and 3,782 were
randomly assigned to a placebo
group. The average follow-up time
was 3.6 years.
Patients in both groups received
daily aspirin (75-100 mg). The
average age of subjects was 70.971.1 years old and 57-58% males
per group with an average
CHADS2 score of 2.0.

*Total vascular events arose in 832
(6.8% annually) of the clopidogrel
subjects, compared to 942 placebo
subjects (relative risk 0.89, 95% CI,
0.81 to 0.98, p = 0.01).

Inclusion criteria: the patient was
currently in AF at the beginning of
the trial or at least two episodes of
AF within the past 6 months. At
least one of the same stroke risk
factors highlighted in ACTIVE W.
Exclusion criteria: concurrent use
of warfarin or clopidogrel or high
bleeding risk factors (peptic ulcer
disease within the last 6 months,
history of an intracerebral bleed,
severe thrombocytopenia, or
alcoholism).

*Clopidogrel was associated with a
reduced risk of stroke (296 subjects,
2.4% annually) compared to the
placebo (408 subjects, 3.3% annually;
relative risk 0.72, 95% CI 0.62 to 0.83,
p <0.001).
*Myocardial infarction presented in
90 subjects (0.7% annually) of the
clopidogrel patients compared to 116
placebo subjects (0.9% per year;
relative risk 0.78, 95% CI 0.59 to
1.03, p = 0.08).
*Severe bleeding developed in 251
clopidogrel subjects (2.0% annually)
compared to 162 placebo subjects
(1.3% annually; relative risk 1.57,
95% CI 1.29 to 1.92, p <0.001).
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Conclusion: clopidogrel with aspirin
is a suitable alternative to decrease
the risk of vascular events, especially
stroke, in patients with atrial
fibrillation who are unable to take
warfarin, yet this combination
augments major bleeding risk.
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PROTECT-AF

Multicenter, randomized,
non-inferiority trial
examining safety and
efficacy of WATCHMAN
(percutaneous closure of
the left atrial appendage)
to warfarin in preventing
embolic stroke in patients
with non-valvular atrial
fibrillation.

707 subjects were randomly
assigned in a 2:1 ratio of
WATCHMAN (473 subjects) or
dose controlled warfarin with a
goal INR of 2.0-3.0 (244 subjects).
Subjects were an average age of
71.7-72.7 years, 70% males, over
91% Caucasian, and with a means
CHADS2 score of 1-2.

Efficacy outcome: WATCHMAN was
implanted in 88% (408 out of 463)
patients. At 1065 patient years of
follow-up, with an average follow-up
of 18 months, stroke, systemic emboli,
or cardiovascular death occurred in 3
out of 100 patient years (95% credible
interval [CrI] 1·9–4·5) in the
WATCHMAN group and 4·9 per 100
patient-years (2·8–7·1) in the warfarin
group (rate ratio [RR] 0·62, 95% CrI
0·35–1·25). Non-inferiority in the
WATCHMAN group compared to
warfarin was >99.9%.

WATCHMAN©
vs Warfarin
(Holmes et al.,
2009)

For 45 days after implantation of
the WATCHMAN device, patients
in this group received warfarin and
aspirin 81 mg daily for 45 days to
prevent the formation of a thrombus
while the device endothelializes in
The efficacy outcome
the heart. Warfarin was
measured was the incidence discontinued once the
of death from a
transesophageal echocardiogram
cardiovascular cause,
(completed at 45 days, 6 months,
stroke (ischemic or
and 12 months post procedure)
hemorrhagic), or systemic
demonstrated complete closure
embolism.
(seal) of the left atrial appendage, or
peri-device blood flow of <5 mm
The safety outcomes
width was present in the left atrial
measured included severe
appendage with no thrombus
bleeding, embolization from
present on the device. After 45 days
implantation of the
and discontinuation of warfarin,
WATCHMAN device, and
clopidogrel and aspirin were
pericardial effusion.
continued for 6 months postimplant, followed by aspirin
administration for life.
The study was completed
at 59 sites within the
United States and Europe
from 2005 to 2008.

Inclusion criteria: adults 18 years
or older with atrial fibrillation with
a minimum of one of the following
factors based on a CHADS2 risk
score of ≥1: congestive heart
failure, hypertension, diabetes, ≥75
years old, or prior stroke or TIA
Exclusion criteria: necessity of
chronic warfarin use to treat a
condition other than atrial
fibrillation, contraindication to
warfarin, thrombus in the left
atrial appendage, symptomatic
carotid artery disease, mobile
aortic atheroma, and patent
foramen ovale with atrial septal
aneurysm and right-to-left shun

Safety outcome: Severe bleeding,
embolization from implantation and
pericardial effusion were more
common in the WATCHMAN group
compared to the warfarin group (7·4
per 100 patient years,
95% CrI 5·5–9·7, vs 4·4 per 100
patient-years, 95% CrI 2·5–6·7;
RR 1·69, 1·01–3·19).

Conclusion: Efficacy of
WATCHMAN is non-inferior to
warfarin in patients with nonvalvular
atrial fibrillation to prevent stroke.
Adverse safety events were more
common in the WATCHMAN group;
however, the events were
predominantly related to the
procedure itself. The study concluded
closure of left atrial appendage
through WATCHMAN is an
efficacious alternative to long-term
anticoagulation in patients with nonvalvular atrial fibrillation, as the
safety concerns are related to surgery
with minimal long-term negative
effects identified.
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PREVAIL

This randomized, doubleblind study is a
continuation of PROTECT
AF to further assess the
safety and efficacy of
WATCHAN© versus
warfarin in patients with
non- valvular atrial
fibrillation, as early safety
concerns were discovered
with WATCHMAN© in
the prior study.

407 patients were randomly
assigned in a 2:1 ratio to either the
WATCHMAN© group (269
patients) or long-term warfarin
group (138 patients). The target
INR for warfarin patients was 2.03.0. The average age of subjects
was 74 years old, 67-74% males,
94% Caucasian, and 45-50% with a
CHADS2 score of 2.

Efficacy outcomes: The incidence of
stroke, systemic embolism or
cardiovascular death occurred in
0.064 patients in the
WATCHMAN© group compared to
0.063 patients in the warfarin group
p (rate ratio 1.07 [95% credible
interval (CrI): 0.57 to 1.89]; noninferiority was not discovered for
WATCHMAN© compared to
warfarin (95% CrI ≥1.75). Stroke or
systemic embolization greater than
7 days after randomization to a
group occurred in 0.0253 of the
WATCHMAN© group, compared
to 0.0200 in the warfarin group
[95% CrI: –0.0190 to 0.0273]),
displaying noninferiority
for WATCHMAN© to
warfarin.

WATCHMAN©
versus Warfarin
(Holmes et al.,
2014)

The efficacy endpoints
measured were 1) the
incidence of stroke,
systemic embolism and
cardiovascular death and
2) stroke or systemic
embolization >7 days after
randomization to study
group.
The safety endpoint
measured was ischemic
stroke, systemic
embolization, all-cause
death, or an adverse event
related to the procedure or
device, requiring
intervention within 7 days
of the implantation of the
WATCHMAN© device.
Complications excluded
from this safety endpoint
included pericardial
effusions drained through
percutaneous catheter
drainage, snaring of the
embolized device, and
treating access
complications through nonsurgical means.

Transesophageal echocardiograms
were completed at 45 days, 6
months, and 12 months, the same as
in the PROTECT-AF trial.
Continuing or discontinuing
warfarin followed the same
parameters as the PROTECT-AF
trial.
Inclusion criteria: Adult patients
with nonvalvular atrial fibrillation
and a CHADS2 score of ≥2
(congestive heart failure,
hypertension, age >75 years old,
diabetes, or prior stroke/TIA) or 1
with other risk factors present.
These high-risk factors include:
female sex and ≥75 years old,
baseline ejection fraction ≥30%,
baseline ejection fraction <35% if
age 65-74 years old with diabetes
or coronary artery disease, or age
≥65 years old and congestive heart
failure).
Exclusion criteria: necessity of
chronic warfarin use to treat a
condition other than atrial
fibrillation, contraindication to
warfarin or aspirin, thrombus in the
left atrial appendage, symptomatic
carotid artery disease, prior stroke
or TIA within 90 days of the study,
patent foramen ovale or atrial septal
defect necessitating surgery, or
patients requiring clopidogrel
therapy.

Safety outcome: Early safety
events were discovered less in in
the WATCHMAN© group in
PREVAIL compared to
PROTECT-AF (2.2% of subjects).
Compared to warfarin (8.7%),
safety events were less with
WATCHMAN© (4.2%, p =
0.004).
Less pericardial effusions requiring
surgery were noted in
WATCHMAN© patients in the
PREVAIL trial (0.4%) compared to
the PROTECT-AF trial (1.6%, p =
0.027), as well as reduced rates of
pericardiocentesis (1.5% compared
to 2.9%, p = 0.36 respectively)

Conclusions: the study concluded
improved procedural safety of
WATCHMAN© implantation in
patients with nonvalvular atrial
fibrillation to prevent stroke, as long
at the patient does not have a
contraindication to using warfarin
short-term post- procedure.
WATCHMAN© is non- inferior to
warfarin to prevent ischemic stroke
in patients with non-valvular atrial
fibrillation, as well as preventing
systemic embolization greater than 7
days post-implantation.
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ACTIVE I:
Atrial Fibrillation
Clopidogrel Trial
with Irbesartan for
Prevention of
Vascular Events I

Randomized, double blind
study investigating whether
the addition of irbesartan
to either anticoagulation
or aspirin with clopidogrel
would decrease the risk of
cardiovascular sequelae in
patients with atrial
fibrillation.

Subjects for this trial were
currently partaking in either
ACTIVE A or ACTIVE W,
depending on their ability to take
oral anticoagulation. Subjects
randomly were administered
irbesartan 300 mg daily (4,518
subjects) or a placebo (4,498
subjects). The average age of
subjects was 69.5 years old, 60%
male and with a CHADS2 score of
2.

*Average systolic blood pressure was
decreased by 2.9 mmHg more in the
irbesartan group compared to the
placebo, in addition to a systolic
blood pressure reduction of 1.9
mmHg more.

(ACTIVE
Investigators,
2011)

Primary outcomes
measures included the
incidence of stroke,
myocardial infarction, or
death from a vascular
etiology. Secondary
outcomes measures
included hospitalization
related to heart failure.
The average follow-up
period was 4.1 years.

Inclusion criteria: risk factors for
stroke described in ACTIVE A and
ACTIVE W plus systolic blood
pressure >110 mmHg.
Exclusion criteria: The same as
ACTIVE A and ACTIVE W.
Patients could not be taking any
other angiotensin receptor
blockers.

*Primary vascular events occurred
in 5.4% per 100 person years in the
irbesartan and placebo groups (HR
0.99, 95% CI 0.91-1.09, p = 0.85).
*The secondary outcome of
hospitalization related to heart failure
occurred at 7.3% per 100 person
years in the irbesartan group and
7.7% per 100 person years in the
placebo group (HR 0.94%, 95% CI,
0.87-1.02, p =
0.12).
*Irbesartan did not prevent any
hospitalizations for a diagnosis
of solely atrial fibrillation.
*Renal impairment (43 subjects) and
hypotension (127 subjects) were more
common adverse effects with
irbesartan than the placebo (24
subjects and 64 subjects, respectively)

WOEST:
(What is the
Optimal
Antiplatelet
Therapy in Patients
with Oral
Anticoagulation
and Coronary
Stenting?
(Dewilde et al.,
2013).

Randomized, controlled,
open-label study assessing
the safety and efficacy of
clopidogrel in comparison
to clopidogrel with aspirin
in patients who have
undergone percutaneous
coronary intervention
(PCI) for ischemic heart
disease. Patients with
mechanical valves and
atrial fibrillation require
chronic anticoagulation.
This study was completed
at 15 clinics within the
Belgium and the
Netherlands over a threeyear period.
The primary safety
outcome measured
bleeding within one year
after the PCI.

Patients were randomly assigned to
either double therapy (clopidogrel
with anticoagulation, 279 subjects)
or triple therapy (clopidogrel with
anticoagulation and aspirin, 284
subjects). The average age of
patients in the double therapy
group was 70.3 years and 69.5
years in the triple therapy group.
The subjects were 77-82% males
with an average CHADS2 score of
1-2.
Inclusion criteria: age 18-80 years
old, necessity of anticoagulation for
at least one year, a minimum of
75% stenosis on angiography or a
fractional flow reserve lower than
0.80 and the need for a PCI.
Exclusion criteria: cardiogenic
shock, history of intracranial
hemorrhage, peptic ulcer within
the past 6 months, severe
thrombocytopenia (platelet count
<50x109/L), severe bleeding
within the past year, and
pregnancy.

Conclusion: In patients with atrial
fibrillation, irbesartan did not
statistically decrease
cardiovascular sequelae.
Safety outcomes:
*Bleeding occurred in 54 (19.4%) of
subjects in the double therapy group
compared to 126 (44.4%) of subjects
in the triple therapy group; HR 0.36,
95% CI, 0.26-0.60, p <0.0001).
*Recurrent bleeding occurred
more often in the triple therapy
group (34 subjects or 12%)
compared to the double therapy
group (6 subjects or 2.2%).
*Bleeding was severe enough to
warrant a transfusion in 27 (9.5%) of
patients in the triple therapy group,
compared to 11 (3.9%) in the double
therapy group (odds ratio 0.39, 95%
CI 0.17-0.84, p = 0.011).
Conclusion: in patients post PCI who
require anticoagulation, clopidogrel
without aspirin is recommended due
to the decrease in bleeding without a
corresponding increase in
thromboembolism.
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APPENDIX D
2016 EUROPEAN SOCIETY OF CARDIOLOGY
GUIDELINES FOR THE MANAGEMENT OF
ATRIAL FIBRILLATION DEVELOPED IN
COLLABORATION WITH EUROPEAN
ASSOCIATION FOR CARDIOTHORACIC SURGERY
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Recommendations
Recommendations for diagnosis and screening of AF
ECG documentation is required to establish the diagnosis of AF.
Opportunistic screening for AF is recommended by pulse taking or ECG rhythm strip in patients >65 years of age.
In patients with TIA or ischaemic stroke, screening for AF is recommended by short-term ECG recording followed by continuous ECG monitoring
for at least 72 hours.
It is recommended to interrogate pacemakers and ICDs on a regular basis for atrial high rate episodes (AHRE). Patients with AHRE should undergo
further ECG monitoring to document AF before initiating AF therapy.
Recommendations for general management of AF
Tailored patient education is recommended in all phases of AF management to support patients’ perception of AF and to improve management.
A full cardiovascular evaluation, including an accurate history, careful clinical examination, and assessment of concomitant conditions, is recommended in
all AF patients.
Use of the modified EHRA symptom scale is recommended in clinical practice and research studies to quantify AF-related symptoms.
Transthoracic echocardiography is recommended in all AF patients to guide management.
The assessment of kidney function by serum creatinine or creatinine clearance is recommended in all AF patients to detect kidney disease and to support
correct dosing of AF therapy.
Recommendations for stroke prevention in AF
The CHA2DS2-VASc score is recommended for stroke risk prediction in patients with AF.
Oral anticoagulation therapy to prevent thromboembolism is recommended for all male AF patients with a CHA2DS2-VASc score of 2 or more.
Oral anticoagulation therapy to prevent thromboembolism is recommended in all female AF patients with a CHA2DS2-VASc score of 3 or more.
When oral anticoagulation is initiated in a patient with AF who is eligible for a non vitamin-K-antagonist oral anticoagulant (apixaban, dabigatran,
edoxaban, or rivaroxaban), a NOAC is recommended in preference to a Vitamin K antagonist.
Vitamin K antagonist therapy (INR 2.0–3.0 or higher) is recommended for stroke prevention in AF patients with moderate-to- severe mitral
stenosis or mechanical heart valves.
NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) are not recommended in patients with mechanical heart valves (Level of evidence B) or
moderate-to-severe mitral stenosis (Level of evidence C).
When patients are treated with a vitamin K antagonist, time in therapeutic range (TTR) should be kept as high as possible and closely monitored.
Combinations of oral anticoagulants and platelet inhibitors increase bleeding risk and should be avoided in AF patients without another indication for
platelet inhibition.
In male or female AF patients without additional stroke risk factors, anticoagulant or antiplatelet therapy is not recommended for stroke prevention.
Antiplatelet monotherapy is not recommended for stroke prevention in AF patients, regardless of stroke risk.
After surgical occlusion or exclusion of the left atrial appendage, it is recommended to continue anticoagulation in at-risk patients with AF for stroke
prevention.

Levelb

I
I

B
B

I

B

I

B

I

C

I

C

I
I

C
C

I

A

I

A

I

A

I

A

I

A

I

B

III
(harm)

B

C

I

A

III
(harm)
III
(harm)
III
(harm)

B
B
A

I

B

III
(no
benefit)

B
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Genetic testing before the initiation of vitamin K antagonist therapy is not recommended.

Classa

249

In AF patients with severe active bleeding events, it is recommended to interrupt oral anticoagulation therapy until the underlying cause is resolved.
NOACs should be avoided in pregnancy and in women planning a pregnancy.
For patients with atrial flutter, antithrombotic therapy is recommended according to the same risk profile used for AF.
Management of typical atrial flutter with ablation of the cavotricuspid isthmus is recommended for patients failing antiarrhythmic drug therapy or as
first-line treatment considering patient preference.
Lifelong oral anticoagulation to prevent stroke is recommended in hypertrophic cardiomyopathy patients who develop AF.
Anticoagulation with heparin or low-molecular-weight heparin immediately after ischaemic stroke is not recommended in AF patients.
Systemic thrombolysis with a recombinant tissue plasminogen activator is not recommended if the INR is above 1.7 (or, for patients on dabigatran, if
activated partial thromboplastin time is outside the normal range).
After TIA or stroke, combination therapy of OAC and an antiplatelet is not recommended.

I

C

III
(harm)
I

C

I

B

I
III
(harm)
III
(harm)
III
(harm)

B

B
A
C
B
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Classa

Levelb

Beta-blockers, digoxin, diltiazem, or verapamil are recommended to control heart rate in AF patients with LVEF 40%.

I

B

Beta-blockers and/or digoxin are recommended to control heart rate in AF patients with LVEF <40%.

I

B

III

A

Recommendations
Recommendations for rate control of AF

In patients with permanent AF (i.e. where no attempt to restore sinus rhythm is planned), antiarrhythmic drugs should not routinely be used for rate control.

(harm)

Recommendations for rhythm control of AF
I

B

I

B

I

A

In patients with ischaemic and/or structural heart disease, amiodarone is recommended for cardioversion of AF.

I

A

For cardioversion of AF/atrial flutter, effective anticoagulation is recommended for a minimum of 3 weeks before cardioversion.

I

B

I

B

The choice of antiarrhythmic drug needs to be carefully evaluated, taking into account the presence of comorbidities, cardiovascular risk and potential for serious proarrhythmia, extracardiac
toxic effects, patient preferences, and symptom burden.

I

A

Dronedarone, flecainide, propafenone, or sotalol are recommended for prevention of recurrent symptomatic AF in patients with normal left ventricular function and without pathological left
ventricular hypertrophy.

I

A

I

A

I

B

III

C

Rhythm control therapy is indicated for symptom improvement in patients with AF.
Cardioversion of AF (either electrical or pharmacological) is recommended in symptomatic patients with persistent or long-standing persistent AF as part of rhythm control therapy.
In patients with no history of ischaemic or structural heart disease, flecainide, propafenone, or vernakalant are recommended for pharmacological cardioversion of new-onset AF.

Transoesophageal echocardiography (TOE) is recommended to exclude cardiac thrombus as an alternative to preprocedural anticoagulation when early cardioversion is planned.

Dronedarone is recommended for prevention of recurrent symptomatic AF in patients with stable coronary artery disease, and without heart failure.
Amiodarone is recommended for prevention of recurrent symptomatic AF in patients with heart failure.
Antiarrhythmic drug therapy is not recommended in patients with prolonged QT interval (> 0.5 s) or with significant sinoatrial node disease or atrioventricular node dysfunction who do not
have a functioning permanent pacemaker.
Catheter ablation of symptomatic paroxysmal AF is recommended to improve AF symptoms in patients who have symptomatic recurrences of AF on antiarrhythmic drug therapy
(amiodarone, dronedarone, flecainide, propafenone, sotalol) and who prefer further rhythm control therapy, when performed by an electrophysiologist who has received appropriate training
and is performing the procedure in an experienced centre.
ACE-Is or ARBs are not recommended for the secondary prevention of paroxysmal AF in patients with little or no underlying heart disease.

(harm)

I

A

III

B

(no benefit)

Moderate regular physical activity is recommended to prevent AF, while athletes should be counselled that long-lasting, more intense sports participation can promote AF.

I

A

Note: Adapted from Kirchhof et al. (2016). Copyright 2016 by the European Society of Cardiology.
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APPENDIX E
AMERICAN HEART ASSOCIATION, AMERICAN COLLEGE
OF CARDIOLOGY, AND HEART RHYTHM SOCIETY’S
SUMMARY OF RECOMMENDATIONS FOR SPECIFIC
PATIENT GROUPS AND ATRIAL FIBRILLATION
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Recommendations

COR

LOE

References

Hypertrophic cardiomyopathy
Anticoagulation is indicated in HCM with AF independent of the CHA 2DS2-VASc score

I

B

(169,170)

Antiarrhythmic drugs can be useful to prevent recurrent AF in HCM. Amiodarone or disopyramide
combined with a beta blocker or nondihydropyridine calcium channel antagonist are reasonable

IIa

C

N/A

AF catheter ablation can be beneﬁcial for HCM to facilitate a rhythm-control strategy when
antiarrhythmics fail or are not tolerated

IIa

B

(171–174)

Sotalol, dofetilide, and dronedarone may be considered for a rhythm-control strategy in HCM

IIb

C

(12)

Urgent cardioversion of new-onset AF in the setting of ACS is recommended for patients with
hemodynamic compromise, ongoing ischemia, or inadequate rate control

I

C

N/A

IV beta blockers are recommended to slow RVR with ACS and no HF, hemodynamic
instability, or bronchospasm

I

C

N/A

With ACS and AF with CHA2DS2-VASc score $2, anticoagulation with warfarin is recommended
unless contraindicated

I

C

N/A

Amiodarone or digoxin may be considered to slow RVR with ACS and AF and severe LV
dysfunction and HF or hemodynamic instability

IIb

C

N/A

Nondihydropyridine calcium antagonists might be considered to slow RVR with ACS and AF only
in the absence of signiﬁcant HF or hemodynamic instability

IIb

C

N/A

Beta blockers are recommended to control ventricular rate with AF complicating thyrotoxicosis
unless contraindicated

I

C

N/A

When beta blockers cannot be used, a nondihydropyridine calcium channel antagonist is
recommended to control ventricular rate

I

C

N/A

A nondihydropyridine calcium channel antagonist is recommended to control ventricular rate with
AF and COPD

I

C

N/A

Cardioversion should be attempted for patients with pulmonary disease who become
hemodynamically unstable with new-onset AF

I

C

N/A

Cardioversion is recommended for patients with AF, WPW syndrome, and RVR who are
hemodynamically compromised

I

C

(175)

IV procainamide or ibutilide to restore sinus rhythm or slow ventricular rate is recommended for patients
with pre-excited AF and RVR who are not hemodynamically compromised

I

C

(175)

Catheter ablation of the accessory pathway is recommended in symptomatic patients with
pre-excited AF, especially if the accessory pathway has a short refractory period

I

C

(175)

AF complicating ACS

Hyperthyroidism

Pulmonary diseases

WPW and pre-excitation syndromes
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IV amiodarone, adenosine, digoxin, or nondihydropyridine calcium channel antagonists in patients
with WPW syndrome who have pre-excited AF is potentially harmful

III: Harm

B

(176–178)

A beta blocker or nondihydropyridine calcium channel antagonist is recommended for persistent
or permanent AF in patients with HFpEF

I

B

(95)

In the absence of preexcitation, an IV beta blocker (or a nondihydropyridine calcium channel
antagonist with HFpEF) is recommended to slow ventricular response to AF in the acute
setting, with caution in patients with overt congestion, hypotension, or HFrEF

I

B

(179–182)

In the absence of pre-excitation, IV digoxin or amiodarone is recommended to control heart
rate acutely

I

B

(103,180,183,184)

Assess heart rate during exercise and adjust pharmacological treatment in symptomatic patients
during activity

I

C

N/A

Heart failure

I

C

N/A

A combination of digoxin and beta blocker (or a nondihydropyridine calcium channel antagonist
with HFpEF) is reasonable to control resting and exercise heart rate with AF

Digoxin is effective to control resting heart rate with HFrEF

IIa

B

(93,180)

It is reasonable to perform AV node ablation with ventricular pacing to control heart rate when
pharmacological therapy is insufﬁcient or not tolerated

IIa

B

(95,185,186)

IV amiodarone can be useful to control heart rate with AF when other measures are unsuccessful
or contraindicated

IIa

C

N/A

With AF and RVR causing or suspected of causing tachycardia-induced cardiomyopathy, it is
reasonable to achieve rate control by AV nodal blockade or a rhythm-control strategy

IIa

B

(187–189)

Recommendations

COR

LOE

References

In patients with chronic HF who remain symptomatic from AF despite a rate-control strategy, it is
reasonable to use a rhythm-control strategy

IIa

C

N/A

Amiodarone may be considered when resting and exercise heart rate cannot be controlled with a beta blocker (or
a nondihydropyridine calcium channel antagonist with HFpEF) or digoxin, alone or in combination

IIb

C

N/A

AV node ablation may be considered when rate cannot be controlled and tachycardia-mediated cardiomyopathy
is suspected

IIb

C

N/A

III: Harm

C

N/A

III:
Harm

C

N/A

IIb

C

N/A

I

A

(190–193)

AV node ablation should not be performed without a pharmacological trial to control ventricular rate
For rate control, IV nondihydropyridine calcium channel antagonists, IV beta blockers,
and dronedarone should not be given with decompensated HF

Familial (genetic) AF
For patients with AF and multigenerational family members with AF, referral to a tertiary
care center for genetic counseling and testing may be considered
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Postoperative cardiac and thoracic surgery
A beta blocker is recommended to treat postoperative AF unless contraindicated
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A nondihydropyridine calcium channel blocker is recommended when a beta blocker is inadequate to
achieve rate control with postoperative AF

I

B

(194)

Preoperative amiodarone reduces AF with cardiac surgery and is reasonable as prophylactic therapy for
patients at high risk of postoperative AF

IIa

A

(195–197)

It is reasonable to restore sinus rhythm pharmacologically with ibutilide or direct-current
cardioversion with postoperative AF

IIa

B

(198)

It is reasonable to administer antiarrhythmic medications to maintain sinus rhythm with recurrent or
refractory postoperative AF

IIa

B

(194)

It is reasonable to administer antithrombotic medications for postoperative AF

IIa

B

(199)

It is reasonable to manage new-onset postoperative AF with rate control and anticoagulation
with cardioversion if AF does not revert spontaneously to sinus rhythm during follow-up

IIa

C

N/A

Prophylactic sotalol may be considered for patients with AF risk after cardiac surgery

IIb

B

(193,200)

Colchicine may be considered postoperatively to reduce AF after cardiac surgery

IIb

B

(201)

ACS indicates acute coronary syndromes; AF, atrial ﬁbrillation; AV, atrioventricular; CHA2 DS2-VASc, Congestive heart failure, Hypertension, Age $75 years (doubled), Diabetes mellitus, Prior Stroke or TIA or thromboembolism (doubled),
Vascular disease, Age 65 to 74 years, Sex category; COPD, chronic obstructive pulmonary disease; COR, Class of Recommendation; HCM, hypertrophic cardiomyopathy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction;
HFrEF, heart failure with reduced ejection fraction; IV, intravenous; LOE, Level of Evidence; LV, left ventricular; N/A, not applicable; RVR, rapid ventricular response; and WPW, Wolff-Parkinson-White.

Note: Adapted from “2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive summary,” C.T. January, L.S.
Wann, J.S. Alpert, H. Calkins, J.E. Ciagarroa, J.C. Cleveland, . . . C.W. Yancy, 2014, p. 2261-2262. Copyright, 2015 by Elsevier.
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APPENDIX F
ANTITHROMBOTIC THERAPY FOR ATRIAL FIBRILLATION:
ANTITHROMBOTIC THERAPY AND PREVENTION
OF THROMBOSIS
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•

Nonrheumatic atrial fibrillation (including paroxysmal) with a CHADS 2 score of 0 (low risk of stroke), no treatment is recommended but if
a patient selects treatment, aspirin is preferred. With a CHADS2 score of 1 (intermediate risk of stroke) or with a CHADS2 score of ≥2 (high
risk of stroke), oral anticoagulation is recommended. Assessment of stroke risk is assessed through CHADS 2 scoring which has been
validated through research and is easy to use.

•

When selecting oral anticoagulation, dabigatran 150 mg BID is preferred to warfarin (vitamin K antagonist).

•

With a high risk of stroke, oral anticoagulation is the recommended treatment, yet with a low risk of stroke, managed is based on the
individual patient.
Recommendation 2.1.8. For patients with AF, including those with paroxysmal AF, who are at low risk of stroke (eg, CHADS 2 [congestive
heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient attack] score = 0), we suggest no therapy rather than
antithrombotic therapy (Grade 2B). For patients who do choose antithrombotic therapy, we suggest aspirin (75 mg to 326 mg once daily)
rather than oral anticoagulation (Grade 2B) or combination therapy with aspirin and clopidogrel (Grade 2B; American College of Chest
Physicians, 2012, p. e532S).

•

•

Recommendation 2.1.8. For patients with AF, including those with paroxysmal AF, who are at low risk of stroke (eg,
CHADS2 [congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient attack] score = 0), we suggest no
therapy rather than antithrombotic therapy (Grade 2B). For patients who do choose antithrombotic therapy, we suggest aspirin (75 mg to
326 mg once daily) rather than oral anticoagulation (Grade 2B) or combination therapy with aspirin and clopidogrel (Grade 2B; American
College of Chest Physicians, 2012, p. e532S).

•

Recommendation 2.1.9. For patients with AF, including those with paroxysmal AF, who are at intermediate risk of stroke (eg,
CHADS2 score = 1), we recommend oral anticoagulation rather than no therapy (Grade 1B). We suggest oral anticoagulation rather than
aspirin (75 mg to 325 mg once daily) (Grade 2B) or combination therapy with aspirin and clopidogrel (Grade 2B). For patients who are
unsuitable for to choose not to take an oral anticoagulant (for reasons other than concerns about major), we suggest combination therapy
with aspirin and clopidogrel rather than aspirin (75 mg to 325 mg once daily) (Grade 2B; American College of Chest Physicians, 2012, p.
e532S).

•

Recommendation 2.1.10. For patients with AF, including whose with AF, including those with paroxysmal AF, who are at high risk of
stroke (ex. CHADS2 score = 2), we recommend oral anticoagulation rather than no therapy (Grade 1A), aspirin (75 mg to 325 mg once
daily) (Grade 1B), or combination therapy with aspirin and clopidogrel (Grade 1B). For patients who are unsuitable for or chose not to take
an oral anticoagulant (for reasons other than concerns about major bleeding), we recommend combination therapy with aspiring and
clopidogrel rather than aspirin (75 mg to 325 mg once daily) (Grade 1B; American College of Chest Physicians, 2012, pp. e532S-e533S).
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•

Recommendation 2.1.11. For patients with AF, including those with paroxysmal AF, for recommendations in favor of oral anticoagulation
(including 2.1.9, 2.1.10, and excluding 2.2, 3.1, 3.2, and 3.3, we suggest dabigatran 150 mg twice daily rather than adjusted-dose vitamin K
antagonist (VKA) therapy (target INR range, 2.0-3.0) (Grade 2B; American College of Chest Physicians, 2012, p e533S).

•

Recommendation 2.2. For patients with AF and mitral stenosis, we recommend adjusted dose VKA therapy (target INR range, 2.0-3.0)
rather than no therapy, aspirin (75 mg to 325 mg once daily), or combination therapy with aspirin and clopidogrel (all Grade 1B). For
patients with AF and mitral stenosis who are unsuitable for or choose not to take adjusted-dose VKA therapy (for reasons other than
concerns about major bleeding), we recommend combination therapy with aspirin and clopidogrel rather than aspirin (75 mg to 325 mg
once daily alone (Grade 1B; American College of Chest Physicians, 2012, p e533S).

•

Recommendation 3.1. For patients with AF and stable coronary artery disease (eg, no acute coronary syndrome within the previous year)
and who choose oral anticoagulation, we suggest adjusted-dose VKA therapy alone (target internationalized normalized ratio [INR] range,
2.0-3.0) rather than the combination of adjusted-dose VKA therapy and aspirin (Grade 2C; American College of Chest Physicians, 2012, p
e533S).

•

Recommendation 3.2. For patients with AF at high risk of stroke (eg, CHADS2 score of 2 or greater) during the first month after placement
of a bare-metal stent or the first 3 to 6 months after placement of a drug-eluting stent, we suggest triple therapy (eg, VKA therapy, aspirin,
and clopidogrel) rather than dual antiplatelet therapy (eg, aspirin and clopidogrel) (Grade 2C). After this initial period of triple therapy, we
suggest a VKA (INR 2.0-3.0) plus a single antiplatelet drug rather than VKA alone (Grade 2C). At 12 months after intracoronary stent
placement, antithrombotic therapy is suggested as for patients with AF and stable coronary artery disease (see section 3.1). For patients with
AF at low to intermediate risk of stroke (eg, CHADS2 score of 0 or 1 during the first 12 months after placement of an intracoronary stent
(bare metal or drug eluting), we suggest dual antiplatelet therapy rather than triple therapy (Grade 2C). At 12 months after intracoronary
stent placement, antithrombotic therapy is suggested as for patients with AF and stable coronary artery disease (see section 3.1; American
College of Chest Physicians, 2012, p e533S).

•

Recommendation 3.3. For patients with AF at intermediate to high risk of stroke (eg, CHADS 2 score of 1 or greater) who experience an
acute coronary syndrome and do not undergo intracoronary stent placement, we suggest for the first 12 months, adjusted-dose VKA therapy
(INR 2.0-3.0) plus single antiplatelet therapy rather than dual antiplatelet therapy (eg, aspirin and clopidogrel) or triple therapy (eg,
warfarin, aspirin, and clopidogrel) (Grade 2C). After the first 12 months, antithrombotic therapy is suggested as for patients with AF and
stable coronary artery disease (see section 3.1).
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For patients with AF at low risk of stroke (eg, CHADS2 score of 0), we suggest dual antiplatelet therapy (eg, aspirin and clopidogrel) rather
than adjusted-dose VKA therapy (INR 2.0-3.0) plus single antiplatelet therapy or triple therapy (eg, warfarin, aspirin, and clopidogrel)
(Grade 2C). After the first 12 months, antithrombotic therapy is suggested as for patients with AF and stable coronary artery disease (see
section 3.1; American College of Chest Physicians, 2012, p e533S).
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Recommendation 3.4. For patients with AF being managed with a rhythm control strategy (pharmacologic or catheter ablation), we suggest
that antithrombotic therapy decisions follow the general risk-based recommendations for patients with AF in section 2.1, regardless of the
apparent persistence of normal sinus rhythm (Grade 2C; American College of Cardiology, 2012, p. e534S).

•

Recommendation 3.5: For patients with atrial flutter, we suggest that antithrombotic therapy decisions follow the same risk-based
recommendations as for AF (American College of Chest Physicians, 2012, p. e534S).

•

Recommendation 4.1.1. For patients with AF of greater than 48 hours or unknown duration undergoing elective electrical or
pharmacologic conversion, we recommend therapeutic anticoagulation (adjusted-dose VKA therapy, target UBR range 2.0-3.0, low
molecular weight heparin at full venous thromboembolism treatment doses, or dabigatran) for at least 3 weeks before cardioversion or a
transesophageal echocardiography (TEE)- guided approach with abbreviated anticoagulation before cardioversion rather than no
anticoagulation (Grade 1B). We recommend therapeutic anticoagulation for at least 4 weeks after successful cardioversion to sinus rhythm
rather than no anticoagulation, regardless of the baseline risk of stroke (Grade 1B). Decisions about anticoagulation beyond 4 weeks should
be made in accordance with our risk-based recommendations for long-term antithrombotic therapy in section 2.1 (American College of
Chest Physicians, 2012, p. e534S).

•

Recommendation 4.1.2. For patients with AF of documented duration of 48 h or less undergoing elective cardioversion (electrical or
pharmacologic), we suggest starting anticoagulation at presentation (low-molecular-weight heparin or unfractionated heparin at full venous
thromboembolism treatment doses) and proceeding to cardioversion for 3 weeks of therapeutic anticoagulation or a TEE-guided approach
(Grade 2C). After successful cardioversion to sinus rhythm, we recommend therapeutic anticoagulation for at least 4 weeks rather than no
anticoagulation, regardless of baseline stroke risk (Grade 2C). Decisions about long-term anticoagulation after cardioversion should be
made in accordance with our risk-based recommendations for long-term antithrombotic therapy in section 2.1 (American College of Chest
Physicians, 2012, pp. e533S-e534S).

•

Recommendation 4.2. For patients with AF and hemodynamic instability undergoing cardioversion (electrical or pharmacologic), we
suggest that therapeutic-dose parenteral anticoagulation be started before cardioversion, if possible (Grade 2C), but that initiation of
anticoagulation must not delay any emergency intervention (Grade 2C). After successful cardioversion to sinus rhythm, we suggest
therapeutic anticoagulation for at least 4 weeks after successful cardioversion to sinus rhythm rather than no anticoagulation, regardless of
baseline stroke risk (Grade 2C). Decisions about anticoagulation beyond 4 weeks should be made in accordance with our risk-based
recommendations for long-term antithrombotic therapy in section 2.1 (American College of Chest Physicians, 2012, p. e534S).
Recommendation 4.3: “For patients with atrial flutter undergoing elective or urgent pharmacologic or electrical cardioversion, we suggest
that the same approach to thromboprophylaxis be used as for patients with atrial fibrillation undergoing cardioversion (American College of
Chest Physicians, 2012, p. e534S).

•

258

•
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Note: Adapted from “Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines,” J. J. You, D.E., Singer, P.A. Howard, D.A. Lane, M.H. Eckman, M. C., Fang … G.Y. H. Lip, 2012,
Chest, 368(8), pp. e531S-e534S. Copyright 2012 by the American College of Chest Physicians.
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2014 NEW RECOMMENDATIONS FOR PREVENTING
STROKE IN PATIENTS WITH ATRIAL
FIBRILLATION
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•
•
•

For patients with valvular atrial fibrillation at high risk for stroke, defined as a CHA2DS2- VASc score of
≥2, and acceptably low risk for hemorrhagic complications, chronic oral anticoagulant therapy with
warfarin at a target INR of 2.0 to 3.0 is recommended (Class I; Level of Evidence A).
For patients with nonvalvular atrial fibrillation, a CHA2DS2-VASc score of ≥2, and acceptably low risk for
hemorrhagic complications, oral anticoagulants are recommended (Class I).

Options include warfarin (INR, 2.0 to 3.0) (Level of Evidence A), dabigatran (Level of Evidence B), apixaban
(Level of Evidence B), and rivaroxaban (Level of Evidence B). The selection of antithrombotic agent should
be individualized on the basis of patient risk factors (particularly risk for intracranial hemorrhage), cost,
tolerability, patient preference, potential for drug interactions, and other clinical characteristics,
including time INR is in therapeutic range for patients taking warfarin.
• For patients with nonvalvular atrial fibrillation and CHA2DS2-VASc score of 0, it is reasonable to omit
antithrombotic therapy (Class IIa; Level of Evidence B).
• For patients with nonvalvular atrial fibrillation, a CHA 2DS2-VASc score of 1, and acceptably low risk
for hemorrhagic complication, no antithrombotic therapy, anticoagulant therapy, or aspirin therapy may
be considered (Class IIb; Level of Evidence C). The selection of antithrombotic agent should be
individualized on the basis of patient risk factors (particularly risk for intracranial hemorrhage), cost,
tolerability, patient preference, potential for drug interactions, and other clinical characteristics,
including time INR is in therapeutic range for patients taking warfarin.
• Closure of the left atrial appendage may be considered for high-risk patients with atrial fibrillation
who are deemed unsuitable for anticoagulation if performed at a center with low rates of periprocedural
complications and the patient can tolerate the risk of at least 45 d of postprocedural anticoagulation (Class
IIb; Level of Evidence B; Meschia et al., 2014, p. 3802).
Note: Adapted from “Guidelines for the primary prevention of stroke: A statement for healthcare
professionals from the American Heart Association/American Stroke Association,” J.F. Meschia, C.
Bushnell, B. Boden-Albala, L.T. Braun, D.M. Bravata, M.A. Creager, . . . J.A. Wilson, 2014, p. 3802.
Copyright, 2014 by the American Heart Association.
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CONSENT FORM FOR HUMAN PARTICIPATION IN RESEARCH
UNIVERSITY OF NORTHERN COLORADO
FAMILY PHYSICIANS OF GREELEY
INFORMED CONSENT – NO SIGNATURE DOCUMENT
Project Title: Stroke Reduction in Elderly Patients with Atrial Fibrillation
Through Utilization of an Anticoagulation Toolkit in the Primary Care Setting
Student Researcher: Rachel J. Mommer, BSN, BS, RN-BC, DNP-S
Research Advisor: Kathleen N. Dunemn, PhD, APRN, CNM, School of Nursing
Expert Consensus: A Delphi Study
The purpose of the following Doctor of Nursing Practice Capstone Project is to develop
an evidence-based anticoagulation toolkit comprised of an algorithm and guideline to
assist primary care providers on improved diagnosis of atrial fibrillation and enhanced
initiation and maintenance of oral anticoagulation to reduce the incidence of stroke in
elderly patients with atrial fibrillation (AF). A summary of the rationale for selecting this
topic and background information on AF can be forwarded by request. A chart review
will be completed at Family Physicians of Greeley- Central to evaluate current practice,
collecting demographics on patients with AF, in addition to diagnosis and treatment of
AF in the primary care setting. All subjects’ initials within the chart review will be
assigned a unique numerical value to maintain confidentiality. In addition, providers
within various primary care and cardiology clinics throughout Northern Colorado will be
requested to participate in this research.
The evidence-based anticoagulation toolkit for this capstone project will be formulated
from an extensive and current literature review, including the recommendations from
national and international guidelines on anticoagulation with AF. Expert consensus will
be obtained through a series of two surveys in alignment with the Delphi technique,
striving for group consensus to create and evaluate the anticoagulation guideline with
algorithm. Since the 1950’s, the Delphi technique has been used as a group
communication tool to attain controlled, expert consensus for program structuring, needs
evaluations, policy writing, and resource management.
For the first round of the Delphi technique, a short survey will discuss expert experience
and comfort level with diagnosing atrial fibrillation and prescribing anticoagulation for
this high-risk population. For the second round of the Delphi method an anonymous
summary of the 70% group consensus from the first round will be attached to a second
survey assessing the benefits and challenges of this toolkit. In concordance with the
Delphi technique, feedback to improve this anticoagulation toolkit is essential to improve
its applicability and relevance to practice. For each round of the Delphi technique, the
DNP student researcher is requesting the electronic survey be completed and returned to
her private e-mail account within two weeks. Approximately 10 minutes will be required
to complete the first round of the Delphi technique and 15-20 minutes for the second
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round. After completion of the two rounds of the Delphi technique, the data and
demographics from the surveys and chart review will be statistically analyzed to compare
and identify any gaps between evidence and practice.
The purpose of this e-mail is to invite your participation in this research study.
Participation is voluntary and all responses and subject identifiers will remain
confidential and anonymous, including the aggregated group consensus obtained in
Round 1 and summarized in Round 2. There are no foreseeable risks to the participants.
All data collected from the chart reviews and Delphi surveys will be statistically analyzed
and secured on a password protected zip drive, only accessible by the DNP student and
her advisor. This is a quality improvement project to improve the diagnosis and
management of atrial fibrillation within the primary are setting. If you have any
questions, please contact one of the undersigned.
Participation is voluntary. You may decide not to participate in this study and if you
begin
participation you may still decide to stop and withdraw at any time. Your decision will be
respected and will not result in loss of benefits to which you are otherwise entitled.
Having read
the above and having had an opportunity to ask any questions, please electronically sign
below if you would like to participate in this research. A copy of this form will be given
to you to retain for future reference. If you have any concerns about your selection or
treatment as a research participant, please contact Sherry May, IRB Administrator, Office
of Research, 25 Kepner Hall, University of Northern Colorado Greeley, CO 80639; 970351-1910.
If you wish to participate in this study, please access and complete the attached document
“Phase 1: Delphi Study Round One Survey” and return the completed survey to
rachel.j.mommer@gmail.com. If you know any colleagues who would be interested in
participating in this study, please forward this consent form and Delphi survey via e-mail.
Thank you for your time and consideration.
Student Researcher: Rachel J. Mommer, BSN, BA, RN-BC, DNP-S
E-mail: Rachel.j.mommer@gmail.com
Phone: (970) 481-5523
Research Advisor: Kathleen N. Dunemn, PhD, APRN, CNM
E-mail: Kathleen.Dunemn@unco.edu
Phone: (970) 351-3081/ (303) 649-5581

Participation Signature ___________________________________
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1)

Please fill in the following demographics.
Title: MD DO
NP
PA
Specialty: ________________________
Number of years in practice: _______

2)

What patient presentation (symptoms and risk factors) warrants a work-up for
atrial fibrillation (AF)?

3)

Do you screen for atrial fibrillation in all your elderly patients older than 65 years
old?
Yes
No

4)

Explain your work-up for diagnosing atrial fibrillation.

5)

How do you typically treat patients with atrial fibrillation?

6)

Which factors influence your decision to initiate anticoagulation in a patient with
atrial fibrillation, including selection of a particular agent?

7)

What is your comfort level with prescribing and managing anticoagulation for
atrial fibrillation (scale of 0 very uncomfortable to 5 very comfortable).

8)

Do you use any screening tools to assess for stroke and bleeding risk with
anticoagulation and AF (ex. CHADS2, CHA2DS2-VASc, HAS-BLED, etc.)?

9)

This question addresses AF guidelines and algoirthms.

10)

a.

What guidelines, algorithms, and resources do you reference for
anticoagulating and treating atrial fibrillation?

b.

What would you find most helpful in an AF algorithm or guideline?

c.

What would you find least helpful in an AF algorithm or guideline?

What would help you improve your management of anticoagulation for patients
with atrial fibrillation (ex. algorithms, community resources, specialists, shared
decision-making tools, websites, phone apps, more anticoagulation clinics, etc.)?
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1)

Was the anticoagulation tool kit straightforward and user friendly?
Yes
No

2)

Do you think this toolkit would improve safety and efficacy of anticoagulation
therapy?
Yes
No

3)

Would this toolkit influence your future practice?
Yes
No

4)

Was this toolkit applicable to your practice and the patients you provide care for?
Yes
No

5)

Was this toolkit inclusive of current evidence-based practice and guidelines on
anticoagulation for atrial fibrillation?
Yes
No

6)

What are the benefits of this toolkit?

7)

What are the challenges of this toolkit?

8)

Any other feedback, questions or concerns?
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